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ABSTRACT 
 
Pharmacogenomics is the study of how genes affect a individual response to drugs to 
develop medications tailored to a person’s genetic makeup because the efficacy/safety 
profile have not be the same way for everyone. 
Mitochondria are characterized by a unique milieu, with an alkaline and negatively 
charged interior (pH value 8) due to the proton pumping associated with OXPHOS and 
a series of specific channels and carrier proteins. As a consequence, mitochondria can 
easily accumulate lipophilic compounds of cationic character and weak acids in their 
anionic form, particularly amphiphilic xenobiotics including ethidium bromide, 1-
methyl-4 phenylpyridinium (MPP+), paraquat (1,1’-dimethyl-4,4’-bipyridinium 
dichloride; PQ) and others that can penetrate the inner mitochondrial membrane 
(IMM) freely since in their undissociated forms. Indeed, it is well understood that many 
drugs and chemicals can cause mitochondrial dysfunction (mitotoxicity) by interacting 
with mitochondrial DNA (mtDNA), protein synthesis, respiratory chain, other metabolic 
processes, channels and transporters Moreover, due to its peculiar uniparental 
maternal inheritance and high mutation rate, mtDNA presents different clusters of 
population-specific-polymorphism (SNPs) that characterize different maternal lineages 
(mitochondrial haplogroups). It has been demonstrated that many non-synonymous 
SNPs, cause amino acid variations in the mitochondrial-encoded proteins, potentially 
modifying OXPHOS activity and ROS production. Some of these haplotypes may confer 
vulnerability to, or protection from, various common diseases. Well-documented 
examples are the role of mtDNA haplotype in Parkinson’s disease (PD) and Leber’s 
hereditary optic neuropathy (LHON). It has been proposed that European haplogroups 
J and K are protective for PD. On the other hand the haplogroups J and T may influence 
mitochondrial dysfunction, resulting in an increased risk of PD. In addition the 
11778/ND4, 14484/ND6 and 3460/ND1 LHON mutations are associated respectively 
with mitochondrial subhaplogroup J2b, J1c and K, as these mtDNA backgrounds may 
increase penetrance of LHON mutations. 
Several reports suggest that environmental factors such as pesticides (e.g. rotenone), 
herbicides (e.g. paraquat) and MPTP or 1-methyl 4-phenyl 1,2,3,6-tetrahydro-pyridine 
(contaminant in the illicit synthesis of opiates) increase the risk of PD due to a 
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reduction in ATP synthesis and increase of reactive oxygen species (ROS). Furthermore, 
tobacco smoking has been proposed as an environmental trigger of visual loss in 
LHON, due to the presence of substances, contained in the tobacco that can directly 
act inhibiting CI.  
Researchers have also associated non synonymous variants in mtDNA with the 
development of side effects of drugs. Effectively the analysis of mtDNA haplogroup in 
patients with cancer treated with chemioterapic agent cisplatin (cisPt) revealed an 
increased incidence of hearing loss in haplogroup J, due to inhibition of mtDNA 
replication. It has also been shown that patients treated with the antibiotic Linezolid 
may develop LHON-like optic neuropathy, myelosuppression and lactic acidosis. This is 
possibly due to the inhibition of mitochondrial protein synthesis, which is modulated 
by the SNPs at positions 2706 and 3010, in the 16S gene of mtDNA. This sequence 
region is predicted to be very close to the Peptidyl Transferase Center (PTC) that is the 
binding site of several antibiotics.  
To demonstrate that mitochondrial genetic variability may influence individual 
susceptibility to drugs toxicity (Linezolid and CisPt) or to toxic environmental factors 
(rotenone, MPP+, paraquat and cigarette smoking) we assessed in vitro cell viability, 
mitochondrial functions including ATP synthesis, activity of OXPHOS complexes and 
ROS generation, and biogenesis (mtDNA copy number) in a collection of 
transmitochondrial cytoplasmic hybrids (cybrids) carrying divergent human mtDNA 
haplogroups (N1b, H, J, T, U, and K) or LHON mutations, that have been defined by 
sequencing of D-loop region and then of the entire mtDNA. Cybrids were constructed 
from fibroblasts obtained, after informed consent, from skin biopsies of unrelated 
healthy subjects and LHON patients. 
The results of this study demonstrated that mitochondrial genetic variability may 
influence individual susceptibility to drugs or environmental factors toxicity, 
highlighting interesting associations between specific haplogroups, mitochondrial 
functional alterations, and toxic agent. More in details: 1) haplogroup K1 was found to 
play a protective role against rotenone toxicity, whereas haplogroup J1 seem to be 
more susceptible to the action of both rotenone and MPP+; 2) haplogroup T seems to 
be more susceptible to the action of paraquat; 3) haplogroups H12 and T1 in 
association with the LHON mutation 3460/ND1, and haplogroups J1c and J2A all 
Abstract 
6 
increase the susceptibility to mitochondrial damage after smoke exposure. Moreover 
haplogroup H1, characterized by SNPs 2706A/3010A in 16SrRNA is the most sensitive 
to Linezolid toxicity and haplogroup J appears to act as risk factor in CisPt toxicity. 
Even though future studies will be necessary to better understand the mechanism of 
action of some of these molecules, studying the association between mitochondrial 
haplogroup and toxicity of drugs and chemicals is extremely useful to prevent toxicity 
in predisposed subjects. This may avoid the occurrence of adverse reactions leading to 
the withdrawal of drugs from the market or Black Box warnings by FDA. For these 
reasons, pharmaceutical companies have introduced early in the drug-development 
process stringent in vitro studies to evaluate mitochondrial function (respiratory chain, 
ROS, membrane potential and mtDNA).  
 
RIASSUNTO 
La farmacogenomica si occupa di indagare gli effetti di un determinato farmaco o 
sostanza chimica in base al genotipo dell’individuo con lo scopo di personalizzare le 
cure e fornire le terapie adeguate.  
I mitocondri presentano un potenziale di membrana (Δψ) di 180mV, una matrice 
alcalina (pH 8) con carica negativa e possono accumulare al loro interno sia sostanze 
cariche positivamente sia acidi deboli in forma anionica, rendendosi bersaglio primario 
o secondario dell’azione di farmaci e agenti tossici. I mitocondri sono dotati di un 
proprio corredo genomico (mtDNA) che si caratterizza per un’ereditarietà uniparentale 
materna un elevato tasso di mutazione e numerose varianti genetiche, distinte in 
aplogruppi. È noto che variazioni non sinonime nel mtDNA causano alterazioni 
funzionali di proteine implicate nel processo OXPHOS, tali da supportare studi per 
comprendere se la variabilità mitocondriale possa svolgere un’azione protettiva o 
rappresentare un fattore di rischio per l’insorgenza di patologie. In particolare è stato 
dimostrato che soggetti appartenenti agli aplogruppi J e K e con polimorfismo 10398G 
nel gene ND3 (CI) si correlano a minore rischio di sviluppare il Morbo di Parkinson (PD). 
Al contrario la variante 4216C nel gene ND1 (CI), comune al sottogruppo JT, parrebbe 
correlata a un aumentato rischio di malattia. Inoltre è stato dimostrato un maggiore 
rischio di Neuropatia Ottica di Leber (LHON) se le mutazioni 11778/ND4 (CI), 
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14484/ND6 (ND1) e 3460/ND1 (CI) si associano agli aplogruppi J2b, J1c e K 
rispettivamente. 
Ulteriormente studi ipotizzano che agenti inquinanti ambientali quali pesticidi (es. 
rotenone), erbicidi (es. paraquat) e MPTP o 1-metil 4-fenil 1,2,3,6-tetraidro-piridina 
(composto secondario contaminante nella sintesi illecita di oppiacei) siano causa di un 
maggiore rischio di PD per un’alterata funzionalità mitocondriale con riduzione della 
sintesi di ATP e aumento di specie reattive dell’ossigeno (ROS). In altri studi s’ipotizza 
che il rischio di perdita della vista in carrier di mutazioni LHON, aumenta se il soggetto 
è fumatore, per azione sul CI della catena respiratoria. 
Infine ancora dati di letteratura associano numerose variazioni mitocondriali non 
sinonime allo sviluppo di patologie collaterali a trattamenti farmacologici. E’ stato 
dimostrato che soggetti appartenenti all’aplogruppo J, presentano un aumento del 
rischio di sviluppare ototossicità dopo trattamento con l’antitumorale Cisplatino (CisPt) 
per inibizione della replicazione del mtDNA mentre pazienti con SNPs nella regione 
16SrRNA in posizione 2706A e 3010A trattati con l’antibiotico Linezolid, sviluppano 
mielosoppressione, neuropatia e acidosi lattica in seguito a inibizione della sintesi 
proteica mitocondriale. 
L’attività di ricerca ha avuto come oggetto di studio il ruolo della variabilità del genoma 
mitocondriale (mtDNA) nella suscettibilità individuale alla tossicità da farmaci 
(Linezolid e Cisplatino) o da agenti tossici inquinanti ambientali (rotenone, MPP+, 
paraquat ed estratto di fumo) in un modello in vitro costituito, da ibridi 
transcitoplasmatici (cibridi) creati mediante fusione di fibroblasti da donatore, dopo 
enucleazione, con cellule di osteosarcoma private di mtDNA (rho0). Sono così stati 
originati cloni di cibridi appartenenti ai principali aplogruppi mitocondriali europei 
(N1b, H, J, T, U, K) o portatori di diverse mutazioni LHON, e caratterizzati mediante 
analisi di sequenza della regione non codificante di 1122 bp o“Displacement loop” 
(Dloop) e dell’intero genoma mitocondriale. Gli studi sono stati eseguiti valutando la 
vitalità cellulare, la funzionalità (sintesi di ATP, produzione di ROS) e la biogenesi 
mitocondriale (numero di copie di mtDNA). 
I risultati ottenuti da queste analisi hanno dimostrato che una variabilità genetica 
mitocondriale può influenzare la suscettibilità individuale alla tossicità da agenti tossici 
inquinanti ambientali e farmaci. In particolare sono state evidenziate alcune 
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interessanti associazioni tra specifici aplogruppi mitocondriali, alterazioni mitocondriali 
e agente tossico: 1) l’aplogruppo K1 sembra svolgere un’azione protettiva rispetto al 
rotenone mentre l’aplogruppo J1 sembra più sensibile all’azione del pesticida e del 
MPP+ anche se quest’ultimo è meno specifico e affine al CI.; 2) l’aplogruppo T sembra 
più suscettibile all’azione del paraquat.; 3) gli aplogruppi H12 e T1 quando associati a 
mutazione LHON 3460/ND1 e gli aplogruppi J1c e J2a aumentano la suscettibilità al 
danno mitocondriale da fumo. Successive evidenze hanno dimostrato che l’aplogroup 
H1, caratterizzato dai polimorfismi 2706A e 3010A nel gene 16SrRNA, sembra essere il 
più sensibile all’azione tossica del Linezolid così come l’aplogruppo J è risultato più 
sensibile alla citotossicità da Cisplatino. 
Questi dati suggeriscono che procedere nello studio di associazioni tra aplogruppo 
mitocondriale e tossicità da farmaci e agenti chimici potrebbe consentire di individuare 
precocemente il rischio tossicologico individuale. Queste conoscenze potrebbero 
essere di particolare impatto per prevenire reazioni avverse a farmaci in alcuni casi 
causa di ritiro dal commercio o black box. Con questo scopo di recente le aziende 
farmaceutiche hanno introdotto nelle fasi iniziali dello sviluppo di un farmaco studi in 
vitro per valutare eventuali effetti sulla funzionalità mitocondriale (catena respiratoria, 
ROS, potenziale di membrana e mtDNA). 
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INTRODUCTION 
 
1. PHARMACOGENOMICS 
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This 
relatively new field combines pharmacology and genomics to develop effective and 
safe medications tailored to a person’s genetic make up. Many drugs that are currently 
available are “one size fits all,” but they don’t work the same way for everyone. It can 
be difficult to predict which person will benefit from a medication, which person will 
not respond at all, and which person will experience negative side effects (adverse 
drug reactions). With the knowledge gained from the Human Genome Project, 
researchers are learning how inherited differences in genes affect the individual 
response to medications. Many studies describe the role of nuclear genome (nDNA) 
variability in toxicity/pharmacological efficacy using single nucleotide polymorphisms 
(SNPs) [http://ghr.nlm.nih.gov/handbook/genomicresearch/pharmacogenomics]. 
Interestingly the mitochondrial genome (mtDNA), present in multiple copies within the 
cell, may also play a role in the toxicity/pharmacological efficacy. Medically applied 
substances that interact with mitochondria can be specifically designed to affect 
mitochondrial structures and functions as primary or secondary targets facilitating a 
better understanding of their mechanism of action and opening new perspectives to 
their application [Szewczyk A. et al., 2002; Don A.S et al., 2004; Duchen M.R, 2004]. 
Mitochondria are not merely the center for energy metabolism, but are also the 
headquarters for various catabolic and anabolic processes, calcium fluxes, and various 
signaling pathways. In this context, the interaction of pharmacological agents with 
mitochondria is an aspect of molecular pharmacology that is recently considered of 
interest not only in terms of toxicology but also from a therapeutic point of view 
[Scatena .R, 2012; Scatena R. et al., 2007]. 
 
2. MITOCHONDRIA 
Mitochondria firstly discovered in 1890 were defined “bioblast” and were described as 
“elementary organism” living inside the cells with “vital functions” [Altmann R., 1890]. 
Mitochondria [from the Greek mitos (thread-like) and khondros (grain or granule)] are 
bacterium-sized organelles found in all nucleated cells [Schon E.A. et al., 2012]. Their 
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origin is explained by the endo-symbiont theory, which proposes that more than a 
billion years ago these subcellular organelles originate from aerobic bacteria, 
incorporated into an oxidative proto-eukaryote host cell and maintained during 
evolution [Sagal L., 1967; Margulis L.,1981]. Mitochondria are the ‘powerhouses of the 
cell because they are responsible for producing the most of cellular ATP through the 
process of oxidative phosphorylation (OXPHOS) [Schon E.A. et al., 2012]. Moreover 
they host numerous biochemical pathways, including pyruvate oxidation and 
tricarboxylic acid cycle (TCA), fatty acid oxidation and metabolism of amino acids (urea 
cycle) [Greaves L.C. et al., 2012]. Mitochondria are also important regulators of several 
other physiological processes that include buffering of cytoplasmic calcium [Pozzan T. 
et al., 2000], controlling of cellular redox status, generating and releasing of reactive 
oxygen species (ROS) [Murphy M.P., 2009; Galluzzi L. et al., 2012], and are central to 
iron–sulphur cluster biogenesis [van der Giezen M. et al., 2005]. Overall, mitochondria 
maintained over the evolution their own multicopy circular bacter-like DNA, reduced in 
size, which is packaged with proteins in structures called nucleoids [Miyakawa I et al., 
1987; Bogenhagen D.F., 2012]. 
 
2.1 Mitochondrial Architecture 
Mitochondria are very small organelles about 0.5–1µm in diameter and up to 7µm 
long. Their shape and number (about 100-1000/cell) depends on the energy 
requirements. They have two membranes, each composed of a phospholipid bilayer, 
distinct in appearance and in physic-chemical properties, thus determining the 
biochemical function of each one [Krauss S. et al., 2001] (Figure 1). 
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Figure 1. Mitochondrial structure 
 
The outer mitochondrial membrane (OMM), delimitating and containing the organelle, 
is a relatively simple phospholipid bilayer identical to plasma membrane containing 
many copies of integral protein called porins. Porins are aqueous channels that render 
OMM free permeable to molecules of about 5000 Dalton or less such as ions, nutrient 
molecules, ATP, ADP, etc. [Bruce A. et al., 1994; Subhashini B. et al., 2013]. The OMM 
contains also a large multisubunit complex called translocase of the outer membrane 
(TOM), which actively translocates proteins with a specific signalling sequence into the 
mitochondrion [Kulawiak B. et al., 2013]. OMM interacts physically with endoplasmic 
reticulum (ER) membrane forming inter-organellar membrane micro domains MAMs 
(mitochondria-associated ER-membrane). Recently, it has been demonstrated that 
MAMs are crucial for highly efficient transmission of Ca(2+) from the ER to 
mitochondria, enhancing the importance of the relationships between the two cellular 
compartments in controlling fundamental processes involved in energy production and 
also determining cell fate by triggering or preventing apoptosis [Hayashi T. et al, 2009]. 
The inner mitochondrial membrane (IMM) is folded to form invaginations called 
cristae, which protrude into the mitochondria defining two spaces: the intermembrane 
space between the OMM and IMM and the matrix, the space limited by the internal 
membrane. The IMM has a unique structure, which invaginations that form narrow 
tubular structures that connect the cristae to the periphery of the IMM. The cristae 
form an intracristal and intermembrane space that might produce a 
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microcompartmentation within the IMM space with implication for the formation of 
the membrane potential [Mannella C.A. et al., 2013]. Also the composition of proteins 
and phospholipids of IMM is very peculiar and crucial for mitochondrial function. In 
particular this membrane is highly enriched in proteins specific for OXPHOS and 
transport and contains an unusual lipid cardiolipin in addition to the major classes of 
phospholipids found in all cell membranes. Cardiolipin is located predominantly but 
not exclusively in the mitochondria membrane, it contains four fatty acids and plays an 
important role in maintaining the mitochondrial membrane potential (Δψ) contributing 
to make the IMM strongly impermeable to polar molecules, in particular ions [Bruce A. 
et al., 1994; Herrmann J.M. et al., 2000; McMillin J.B. et al., 2002]. Nevertheless the 
IMM is freely permeable to oxygen (O2), carbon dioxide (CO2), and water (H2O). 
The internal compartment enclosed by IMM is called matrix and contains the enzymes 
for the TCA cycle and the other metabolic pathways, mitochondrial ribosomes transfer 
RNAs and several copies of the mtDNA [Bruce A. et al., 1994]. 
Mitochondria are highly dynamic organelles that response to cellular stress through 
changes in overall mass, interconnectedness, and sub-cellular localization. Changes in 
overall mitochondrial mass reflects and altered balance between mitochondrial 
biogenesis (increased mitochondrial genome duplication combined with increased 
protein mass added to mitochondria) and rate mitophagy (degradation of 
mitochondria at the autophagosome) [Boland M.L et al., 2013]. In addition 
mitochondria continually undergo a process of fusion and fission depending on the 
functional state of the cell and the balance between these opposing events determines 
the morphology of the organelle [Bereiter-Hahn J.et al., 1994; Westermann B., 2010; 
Kanamuru Y et al., 2012]. Mitochondria fusion occurs when mitofusin proteins (MFN) 
link the OMM of two separated mitochondria, and the protein OPA1, which resides in 
the IMM, facilitate the lengthening and tethering of adjacent mitochondria to form a 
connected tubular network [Martinez T.N et al., 2012]. It is thought to allow the 
exchange of contents between intact and dysfunctional mitochondria consenting the 
replacement of damage material. Therefore fusion contributes to the suppression of 
further damage and mitochondrial homogeneity [Kanamaru Y. et al., 2012]. On the 
contrary, mitochondria fission involves division of mitochondria in punctuate 
structures and it is mediated by fission-1 (FIS1) and dynamin-related protein 1 (Drp-1) 
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[Subhashini B. et al., 2013]. Fission is thought to allow the segregation of severely 
damaged mitochondria from healthy mitochondrial networks. These segregated 
damaged mitochondria are delivered to autophagosomes and ultimately degraded 
(mitophagy) [Kanamaru Y. et al., 2012] (Figure 2). 
 
 
Figure 2. Pool of viable mitochondria: Fusion and Fission [Kanamaru Y et al., 2012] 
 
2.2 Mitochondrial Functions 
 Oxidative phosphorilation system  
Mitochondrial reaction chain (MRC) is classically defined as an electron-transfer chain 
driven by a sequence of prosthetic groups (flavins and cytochromes) localized in the 
IMM and that catalyzes redox reaction from nicotinamide adenine dinucleotide 
(NADH) or flavin adenine dinucleotide (FADH2) originating in different metabolic 
pathways (glycolysis, fatty acid oxidation or the TCA cycle) to oxygen (O2) [Chance B. et 
al., 1955]. Subsequently, the MRC has been depicted as the functional sequence of 
four multi-subunit complexes (CI-IV), randomly dispersed in the IMM where reducing 
equivalents enter the MRC through CI (NADH-coenzyme Q reductase) or several 
FADH2 dehydrogenases (e.g. succinate-coenzyme Q reductase or CII, glycerol-3-
phosphate dehydrogenase, electron-transfer flavoprotein (ETF)-ubiquinone 
oxidoreductase, dihydroorotate dehydrogenase, etc) to reduce coenzyme Q (CoQ10). 
CoQ10 is a lipophilic mobile redox-active molecule that transports electrons to 
ubiquinone: cytochrome c reductase (CIII) for reducing cytochrome c (cyt c), that in 
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turn is oxidized by cytochrome c oxidase (CIV) to reduce O2 as the final acceptor. The 
oxidation of NADH and FADH2 is coupled to the pumping of protons (ΔpH+) into the 
IMM space, and the resulting proton gradient (ΔμH) is used by the ATPase to generate 
ATP [Lenaz G. et al., 2010] (Figure 3). 
 
 
Figure3. OXPHOS complexes. CI, III, IV and ATPase contain both mtDNA and nuclear DNA (nDNA)-
encoded subunits, whereas CII, which is also part of the TCA cycle, has only nDNA-encoded. 
Polypeptides encoded by nDNA are in blue (except for Dihydroorotate dehydrogenase (DHOD), which is 
in pink); those encoded by mtDNA are in colours [Schon E.A. et al., 2012] 
 
 NADH-coenzyme Q reductase or Complex I 
Although it has not been possible to crystallize the human CI due to the difficult to 
preserve the enzyme, excellent progression has been made in revealing the structure 
[Gabaldón T. et al., 2005]. CI has an L-shaped structure consisting of 2 arms: a 
hydrophobic membrane region which is embedded in the IMM and a hydrophilic 
peripheral or matrix region which protrudes into the matrix [Leonard K. et al., 1987; 
Efremov R.G et al., 2011]. It is composed of 45 subunits, seven of which are 
mitochondrially encoded [Carroll J. et al., 2002] and constitute the hydrophobic arm of 
the complex. The remaining 38, encoded by nDNA, are present in both the hydrophilic 
and hydrophobic arms of the complex [Iommarini L et al. 2013]. It also includes a 
flavine mononucleotide (FMN)-containing flavoprotein and six iron-sulfur (Fe-S) center. 
The latter are one of the three types of electron-carryng molecules function in the 
MRC in which the iron (Fe ion) is surrounded by sufur (S) atoms of four Cys residues.  
Nevertheless the function and the molecular mechanism involved in CI assembly are 
still poorly understood. Three functional modules can be distinguished for bovine CI i) 
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the NADH dehydrogenase part, responsible for the oxidation of NADH, consisting of at 
least the NDUFV1, NDUFV2, NDUFV3 and NDUFS1 subunits; ii) hydrogenase module, 
which guides the released electrons to CoQ10, consisting of at least the NDUFS2, 
NDUFS3, NDUFS7 and NDUFS8 subunits and iii) proton traslocating unit or membrane 
arm, which consist of at least the ND1, ND2, ND3, ND4, ND4L, ND5 and ND6 subunits 
[Galkin A. et al., 2006; Ragan C.I. et al., 1986] (Figure 4). 
 
 
Figura 4. CI structure and function [modified from Iommarini L. et. Al,. 2013] 
 
CI is the first and crucial component of MRC. Electrons derived from NADH, generated 
by Krebs Cycles, are transferred to FMN bound to NDUFV1 subunit (51 kDa) that then 
transferred them to a series of Fe-S clusters. Thus electrons would flow to N3 in the 
same subunit and to N4 and N5 in the NDUFS1 subunit (75 kDa), and then to N6a and 
N6b in the NDUFS8 subunit (TYKY) and to N2 in the NDUFS7 subunit (PSST). Finally, the 
electrons are transferred from N2 Fe-S cluster, that is likely located between the 
hydrophobic membrane and hydrophilic arm to CoQ10, in the Q-pocket (ND1) where it 
initiates a cascade of conformational changes (Figure 5) [Lenaz G. et al., 2010]. 
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Figure 5.A schematic representation of the electron pathway from NADH to physiologic acceptor CoQ10 
through FMN and the Fe-S clusters [modified from Iommarini L. et. Al., 2013] 
 
Effectively a suitable conformational change occurs after the first electron delivery to 
CoQ10 to provide a gating mechanism for the second electron to semiquinone to 
produce ubiquinol (CoQH2). Reduction of CoQ10 to CoQH2 also contributes to the 
generation of ΔpH at ND2, ND4 and ND5 subunits across the IMM from the matrix side 
to the intermembrane space [Lenaz G. et al., 2007]. The ND2, ND4 and ND5 subunits 
known as Nqo14, Nqo13 and Nqo12 respectively in T. thermophilus are homologous to 
Na+/H+ antiporter complex subunits and contain a putative proton-translocation 
channel [Baradaran R. et al., 2013]. Three mechanisms of ΔpH have been 
hypothesized: 1) a revised direct model for coupling the transport of H+ to electron 
transfer [Ohnishi, T. et al., 2005; 2012]; 2) an indirect coupling, which involves a 
conformational change of the enzyme [Belogrudov G. et al, 1994; Euro L. et al., 2008], 
and 3) a chimera models of having both direct and indirect mechanism [Friedrich T. et 
al., 2004; Sazanov et al.,2000; Baranova, E.A., 2007]. The revise direct model 
simultaneously involves 2H+/2e- stoichiometry via conformation-coupled indirect 
proton (H+)-pumping plus (2H+/2e-) stoichiometry by CoQ10 redox-coupled direct H
+-
pump [Ohnishi, T.et al., 2012]. As regards the chimera model, it has been discovered 
that ND5 subunit extends a long amphipathic α-helix (called HL) aligned with the 
membranes close to the end of the electron transfer chain. HL links most subunits 
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together (ND 3, 4L, 6), separating antiporter homologs from the putative Q site in ND1 
subunit. Therefore a “piston-like rod” metod has been proposed in which HL will 
simultaneously open and close three antiporter pumps (ND2, ND4 and ND5) subunits 
for the total (3H+/2e−) stoichiometry. And by the reduction of the CoQ10 likely in ND1 
subunit, conducts the remaining one H+ pumping with the (1 H+/2e−) stoichiometry, 
by an unknown mechanism [Mathiesen C. et al., 2002] 
CI is also considered one of the main site of ROS production having two sites, NADH-
binding and the CoQ10-binding sites, accessible to O2 where formation of superoxide 
anion (O2
•−) may occur [Murphy M.P., 2009; Iommarini L et al. 2013]. Effectively the 
Fe-S cluster (N2-N6) in the hydrophilic arm is reasonably well shielded from O2 thus O2 
is more likely to access electron carriers at FMN and CoQ10 sites. Nonetheless the 
involvement of the N2 Fe-S cluster is not excluded. The other mechanism by witch CI 
produced O2
•− is during reverse electron transport (RET) even though the site of ROS 
production is not known. RET occurs when electron supply reduces the CoQ pool, 
which in the presence of a significant ΔpH , forces electrons back from CoQH2 into CI 
reducing NAD+ to NADH at the FMN site [Murphy M.P., 2009]. 
In conclusion, CI is inhibited by more than 60 different families of natural and 
commercial compounds from rotenone to a number of synthetic neurotoxins including 
1-methyl-4-phenyl-1,2,3,4,-tetrahydropyridine (MPTP) and its active metabolite 1-
methyl-4 phenylpyridinium (MPP+). They have been grouped into three classes: 1a) 
antagonistits of CoQ10 substrate including rolliniastatin-2, piercidin A and idebenone, 
1b) antagonists of semiquininone intermediate including pesticide rotenone, pieridin A 
and B, aureothin, amytal, phenoxan and MPP+ analogue and 1c) antagonists of CoQH2 
includin stigmatellin, reduced Q-2, myxothiazol and meperidine [Lenaz G. et al., 2010]. 
Both rotenone and MPP+ displace the ubiquinone intermediate and they might act at 
the hydrophobic pocket where CoQ10 access to the catalytic site of the enzyme [Degli 
Esposti M. et al., 1994a; Vinogradov A.D., 1993]. Their specific interactions with CI 
where demonstrated by replacing the endogenous subunit in human neuroblastoma 
cells with the single-subunit NADH dehydrogenase from Saccharomyces Cerevisiae. 
The substitution of this neurotoxic-insensitive CI attenuated rotenone and MPP+ toxic 
effect [Shere T.B. et al., 2003; Richardson J.R. et al., 2007]. 
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 Succinate-coenzyme Q reductase or Complex II 
Besides its functional role in the Krebs cycle, CII is involved in the respiratory chain 
because it can couple the two-electron oxidation of succinate to fumarate with the 
electron transfer from FADH2 to CoQ10. It is the only respiratory enzyme completely 
encoded by nDNA. [Rustin P. et al., 2002]. Mammalian CII contains a single b heme, a 
binding site for CoQ10 and it has anchored to the IMM by two hydrophobic subunits, 
SdhC (14.2 kDa) and SdhD (12.8 kDa). Moreover the primary sequence of the soluble 
domain consists of a flavoprotein subunit (SdhA, 79 kDa) containing covalently linked 
FAD and a Fe-S protein subunit (SdhB, 31 kDa) both located on the matrix side of the 
membrane. Electrons derived from oxidation of succinate to fumarate are transferred 
to Fe-S redox co-transport chain that extends from FAD to the CoQ10 site. Heme b does 
not seem to be directly involved in the transfer of electrons within the enzyme but it 
may serve to reduce the frequency with which electrons “leak” out the system, moving 
from succinate to O2 to produce ROS (Figure 6). 
 
 
Figure 6. CII structure [Gottlieb E. et al., 2005] 
 
CII is the only enzyme that does not pump protons from the matrix to the 
intermembrane space and it has inhibited by malonate [Lenaz G. et al., 2010]. 
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 Coenzime Q 
In addiction to NAD and flavoproteins, CoQ10 is another type of electron-carrying 
molecule in the MRC. It is a lipid-soluble benzoquinone with a long isopropenil side 
chain formed by ten unitis. The quinone chemical group allows the CoQ10 to function 
as electron transporter. Effectively this molecule exists in three different oxidation 
states: the completely oxidized CoQ10 can accept one electron to become the 
semiquinone radical or two electrons to form the completely reduced CoQH2 (Figure 
7). 
 
 
Figure 7. Three different oxidation states of CoQ10 
 
The isoprenoid hydrophobic tail allows to freely diffuse within the lipid bilayer of the 
IMM where CoQ10 tranfers electrons from CI and CII to CIII. It receives electrons both 
from MRC, and glycerol 3-phosphate and ETF dehydrogenase, etc. 
 
 Ubiquinone:cytochrome c reductase or Complex III 
CIII catalyze the transfer of electrons from CoQH2 to cyt c and it can, concomitantly, 
link this redox reaction to translocation of H+ across the membrane. [Lenaz G. et al., 
2010]. It is a symmetrical, oligomeric dimer of identical monomers, each with 11 
subunits. Only one is mtDNA-encoded, cytochrome b, whereas the other 10 are nDNA-
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encoded, and at least one of the nDNA-encoded subunits has been reported to be 
essential for the enzyme assembly [Berry E.A. et al., 2000; Zeviani M. et al., 2003]. Each 
monomer presents three protein subunits with redox prosthetic groups: i) a di-heme 
cytochrome b containing two hemes bH (or b566) and bL (or b562), ii) cytochrome c1 and 
iii) a Fe-S protein (Rieske protein) with a 2Fe-2S cluster (figure 8). The other seven non-
redox subunits are also present but not required for electron-transfer and proton 
translocation activities of the enzyme so their possible functions include structural 
stability and regulation of coordinated activity of the dimeric enzyme [Lenaz G. et al., 
2010]. These structural details provide a confirmatory evidence of the the 
protonmotive Q-cycle mechanism of the enzyme proposed by Mitchell (Q cycle), with 
protons being carried across the IMM, whereas electrons from CoQH2 are transferred 
through the bc1 complex. According to Mitchell, CoQH2 delivers the first electron at 
the outer positive site called site Qo of the IMM to the Rieske Fe-S protein and hence 
to cytochrome c1 that then reduces cyt c. The result is the release of two protons in 
the intermembrane space and the formation of semiquinone anion at the Qo site, 
which is immediately oxidized to CoQ10 by cytochrome bL. The electron is then 
delivered to the cytochrome bH at the internal negative site (site Qi), and then bH is 
reoxidized by CoQ10 at the Qi site, forming another semiquinone. The cycle is 
completed by oxidation of a second molecule of CoQH2. The Q-cycle cycle determines 
the oxidation of the two CoQH2 molecules resulting in the release of four H
+ in the 
intermembrane space, the reduction of two molecules of cyt c and the traslocation of 
two H+ from the matrix to the intermembrane space (Figure 8) [Mitchell P.,1975; Lenaz 
G. et al., 2010] 
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Figure 8 The Q cycle. 
 
The formation of O2
•− in CIII depends on this peculiar mechanism of electron transfer. 
It is possible that both center Qo and semiquinone are the main responsible for ROS 
production. Effectively Mulleret al. suggested that oxidation of CoQH2 at center Qo is 
characterized by the delivery of the first electron to the Rieske Fe-S cluster, producing 
a semiquinone that, in the absence of further oxidation by cytochrome bL, would 
interact with oxygen, forming O2
•−. It is directed toward intermembrane space due to 
the position of the Qo site [Muller F.L. et al, 2003]. Antimycin A (AA) is known to blocks 
CoQ10 reduction by cytochrome bH at center Qi enhancing the production of O2
•− 
[Lenaz G. et al., 2010]  
CIII inhibitors have been grouped into two classes: i) class I inhibitors that target the 
Qo center and were further divided into three subclasses (Ia, Ib and Ic) and ii) class II 
inhibitors that act on center Qi.  
 
 Cytocrome c 
The third type of electron-carryng molecules function in MRC is an iron-conteining 
protein as cytocromes. Mitochondria contains three classe of cytocromes, designed a, 
b and c. The heme factors of a and b cytocromes are not covalently bound to their 
associated proteins, whereas the hemes of c-type cytocromes are covalently attached 
through Cys residues.The latter is a small soluble protein of the intermembrane space. 
It is responsible for the transfer of electron from CIII to CIV. After its single heme 
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accepts an electron from CIII, cyt c move to CIV to donate electron to a binuclear 
copper center 
 
 Cytochrome c oxidase or Complex IV 
In the final step of the respiratory chain, CIV carries electrons from cyt c to O2, 
reducing it to H20. CIV is a large enzyme composed of 13 subunits that belongs to the 
heme-copper oxygen reductase superfamily. Tree (subunit I,II and III) of the 13 
subunits are encoded by mtDNA and represent the the catalytic center of the enzyme, 
whereas the remaining ten subunits are encoded by nDNA and they have been 
identified as essential to the enzyme assembly [Zeviani M et al., 2003; Shoubridge E.A, 
2001b]. Mitochondrial subunit I contains two heme group, designed a and a3, and an 
other copper ion (CuB). Heme a3 and CuB form a second binuclear center that accept 
electrons from heme a and transfer them to O2 bound to heme a3. Subunit II contains 
two Cu ions complexed with the –SH group of two Cys residues in a binuclear center 
(CuA) that resembles the 2Fe-S center of Fe-S proteins (Figure 9). 
 
 
Figure 9. Path of electrons through CIV  
 
Electron transfer through CIV occurs from cyt c to the CuA center which acts as a single-
electron receptor, then to heme a3-CuB center, and finally to 02 bound to heme a3 For 
every four electrons passing throught this complex, the enzyme consumes four 
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“substrate “H+ from the matrix in converting O2 to 2H20. It also uses the energy of this 
redox reaction to pump one H+ outward into the intermembrane space for each 
electron that passes through, adding to ΔμH produced by redox-driven proton 
transport through CI and CIII [Lenaz G. et al., 2010]. This four-electron reduction of O2 
must occur without release of incompletely reduced intermediates such as hydrogen 
peroxide (H2O2) or hydroxyl free radicals (OH
•) that remains bound to the complex 
until completely converted to H20. 
CIV is potently inhibited by potassium cyanide (KCN), azide (N3), nitric oxide (NO) and 
carbon monoxide (CO), which bind at the O2 binding site (heme a3). 
 
In other words CI, III and IV are considered the core proton translocating complexes 
because are involved in the ΔpH coupled to the ATP synthesis. The organization of 
respiratory complexes in the IMM is an object of intense debate. For many years, the 
most accepted model for the MRC organization was the fluid or random collision 
model [Hackenbrock C.R. et al., 1986] opposite to the original model that proposed the 
respiratory components closely packed to guarantee high efficiency in electron 
transport [Chance B. et al., 1955]. At the beginning of 2000 years, some evidences for a 
supermolecular organization of respiratory complexes were obtained by introducing a 
sensitive analytical approach as the BN-PAGE in digitonin-solubilized mitochondria 
[SchäggerH. et al., 2000]. With this tecnique, it was demonstrated in different 
organisms that respiratory CI, III and IV are involved in supramolecular association to 
form the “respirasome” leading to a reformulation of the solid model proposed by 
Chance [SchäggerH. E t al., 2000]. However, none of the two models satisfactory 
explain the functional studies on mitochondrial respiratory chain. In a very recent 
work, Lapeunte-Brun and colleagues [Lapuente-Brun E. et al., 2013] showed that in 
vivo, the MRC should be able to work both when supercomplexes are present and 
when the formation of supercomplexes is prevented. This work confirm the previously 
proposed model, “the plasticity model” in which the respiratory chain is a very 
dynamic organization that can move from respirasome to dispersed respiratory 
complexes allowing the cell to adapt to different carbon sources and varying 
physiological conditions [Acin Perez R. et al., 2008; Lapuente-Brun E. et al., 2013; Acin-
Perez R. et al., 2013]. 
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 F1Fo ATPase or Comple V 
According to the chemiosomotic model proposed by Mitchell, the electron flow 
through thr MRC is coupled with a proton transfer across the membrane, producing 
both a chemical gradient (ΔpH) and an electrical gradient (Δψ). The energy associated 
to electrochemical gradient ΔμH drives the synthesis of ATP by the molecular motor 
ATP synthase (F1-FoATPase or CV) [Mitchell P., 1961; Sgarbi G. et al., 2006]. CV is a 
ubiquitous enzyme that catalyses the terminal step in OXPHOS. The enzyme consists of 
two structurally and functionally distinct sectors termed F1, the proper catalytic 
domain, where ATP synthesis or hydrolysis takes place, and Fo (oligomycin-sensible), 
the membrane bound-portion that sustains H+ transport. ATPase has two subunits 
encoded by mtDNA (ATPase6 and ATPase8), that take part to the Fo portion, and 
about 13 other subunits encoded by nDNA [Abrahams J.P et al., 1994]. F1 has nine 
subunits of five different types with the composition α3β3γδε. Each of the three β 
subunits has a nucleotide-binding site critical to the catalytic activity and together with 
three α subunits are arranged like the segment of an orange with alterating α and β 
subunits around a central shaft, the γ subunit. The γ subunit is associated with one of 
the three αβ pairs forcing each β subunit into slightly difference conformations, with 
different nucleotide-binding sites: one subunit has ADP (β-ADP) in its binding site, the 
next has ATP (β-ATP), and the third has no bound nucleotide (β-empty). The Fo 
complex is composed of three subunits a, b and c in the proportion ab2c10-12. Subunit c 
is a small, very hydrophobic peptide consisting of two transmembrane helices with a 
loop extending from the matrix side of the membrane. It is attached to the shaft 
(subunits γ). The two b subunits of Fo associate firmly with α and β subunits of F1, 
holding them fixed relative to the membrane (Figure 10). [Baker L.A. et al., 2012]. 
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Figure 10. Structure of F1Fo ATPsynthase  
 
As protons flow through Fo, the cylinder of c subunits and shaft (γ subunit) rotate 
forcing each β subunit into slightly difference conformations in which the β-ATP site is 
converted to the β-empty conformation and dissociate ATP; the β-ADP site is 
converted to the β-ATP conformation, which promotes condensation of bound ADP+Pi 
to form ATP; and the β-empty site becomes a β-ADP sites. ATP can not be release from 
one site unless and until ADP and Pi are bound at the other. Therefore one complete 
rotation of the γ subunit causes each β subunit to cycle through all three of its possible 
conformations, and for each rotation, three ATP are synthesized and released from the 
enzyme surface [Gresser M.J. et al., 1982]. 
Oligomycin and Dicyclohexylcarbodiimide (DCDD) are ATPase inhitors that blocks the 
transfer of electrons through the Fo portion and then ATP synthesis. 
Chemiosmotic theory explains the dependence of electron transfer on ATP synthesis. 
Nonetheless certain chemical compounds including 2,4-dinitrophenon (DNP) and 
carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP) cause uncoupling without 
disrupting mitochondrial structure. They are weak acid with hydrophobic properties 
that permit them to diffuse across the IMM. After entering the matrix in the 
protonated form they can release H+ thus dissipating the ΔpH allowing respiration to 
continue without ATP synthesis. On the other hand ionofores such as valinomycin 
allow inorganic ions (K+) to pass through membrane dissipating the Δψ across the 
IMM. 
The ATP synthesized in the matrix is transported across the IMM with an exchange 
mechanism, importing cytosolic ADP and phosphate (Pi) by the adenine nucleotide and 
phosphate translocase system. Adenine nucleotide translocase (ANT) is an antiporter 
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thus the same protein moves ADP into the matrix and ATP out. The effect is the net 
flux of one negative charge which is favorited by Δψ. The phosphate translocate is 
specif for H2PO4
-. There is not a net flux of charge during symport of H2PO4
- and H+. 
Therefore ΔμH is also responsible for transporting substrates (ADP and Pi) in and 
product (ATP) out of the matrix. 
 
 Reactive Oxygen Species and Antioxidant Agent 
During NADH oxidation or CoQ10 reduction by CI and CoQ10 oxidation by CIII, electrons 
may escape leading to Reactive Oxygen Species (ROS) generation. ROS are dangerous 
for the cell since they can damage mtDNA, proteins and lipids [Adam-Vizi V. et al., 
2006; Murphy M.P., 2009] but also function as molecular signaling molecules 
[D’Autreaux B. et al., 2007]. 
Free radicals were described as “any species capable of independent existence that 
contains one or more unpaired electrons” [Halliwell B. et al., 1984]. The term ROS 
refers to a variety of reactive molecules that are derived from oxygen (O2) and can be 
free radicals such as superoxide (O2
•−), hydroxyl radical (OH•) and non-radicals 
(hydrogen peroxide (H2O2)). It was demonstrated that ROS are generated by loose 
electron spilling from CI and CIII, and reacting with O2 to form O2
•− in IMS through the 
transfer of electrons from NADH to CoQ10, which is accompanied by translocation of 
protons from the matrix to the IMM. Similarly, CII is responsible for the reduction of 
CoQ10 generating low levels of O2
•− [McLennan H.R. et al., 2000; Fato R. et al., 2008; 
Murphy M.P., 2009; Yankovskaya V. et al., 2003] 
Given that low levels of O2
•− are constantly generated, evolution has selected 
antioxidant system enable to detoxify this anion. Basically manganese superoxide 
dismutase (MnSOD, SOD2), that is a mitochondrial matrix enzyme, rapidly converts 
O2
•− to H2O2 which is subsequently converted to H20 by glutathione peroxide (GPx) and 
catalase in the mitochondria or follows diffusion into the cytosol. GPx oxidizes reduced 
glutathione (GSH) to oxidized glutathione (GSSG) that is reproduced by glutathione 
reductase starting from GSH (Figure 11). O2
•− can be also converted to H2O2 by copper-
zinc superoxide dismutase (CuZnSOD) in the IMS. Nevertheless, in the presence of iron, 
H2O2 is rapidly converted to the highly reactive OH
• via the Fenton reaction. OH• may 
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further react with bicarbonate to yield the very reactive carbonate radical anion (CO3
•¯) 
[Szeto H.H., 2006] (Figure 11). 
 
 
Figure 11. Generation of mitochondrial reactive species [Bellance N. et al.2009] 
 
On the other hand, reactive nitrogen species (RNS) refers to reactive species derived 
from nitrogen (NO) and can be broadly classified as ions (peroxynitrite (ONOO−)) or 
non-ions (Nitric Oxide (NO•)) [Subhashini B. et al., 2013]. ROS are formed at low levels 
during normal respiration by healthy mitochondria. In fact, O2
•−, generated during the 
electron transport chain through partial reduction of O2, can react with NO
• to form 
ONOO− (Figure 11). 
In conclusion, ROS are formed at different rates in a cell and differ in their activity. In 
terms of activity, OH• is the most reactive species known and is by in large responsible 
for the cytotoxic effects of ROS. In contrast, reactive species such as NO• and H2O2 are 
less reactive and have shown to play an important role in several cellular activities. 
[Subhashini B. et al., 2013]. However, damaged and dysregulated mitochondria 
generate excessive amounts of O2
•−, which can damage several mitochondrial 
components and functions and ultimately lead to cell death via apoptosis and necrosis 
[Subhashini B. et al., 2013; Szeto H.H., 2006].  
 
 Apoptosis 
Apoptosis is a major pathway of programmed cell death and is extremely important 
both in several physiological conditions and pathological events, including 
neurodegenerative, cardiovascular and immunological disorders [Zimmermann K.C. et 
al., 2001]. It is characterized by a cascade of controlled events that leads to specific 
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morphological changes in the cell: loss of adhesion, cell shrinkage, plasmatic 
membrane blebbing, chromatine, and DNA fragmentation, proteolytic cut of specific 
substrates and exposure of phosphatidylserine on the external surface of the cell [Kerr 
J.F. et al., 1972]. The final event of this cascade is the phagocytosis of the apoptotic 
cell, without any release of cytoplasmic content into the extracellular matrix or 
inflammatory response induction. Apart the granzyme B pathway, there are two other 
apoptotic cascades: the “extrinsic” or death receptor pathway, and the “intrinsic” or 
mitochondrial pathway. The mitochondrial pathway is a complex signaling cascade, 
regulated by the Bcl-2 family proteins, that needs the release of apoptogenic factors 
(cyt c, AIF, Apoptotic protease activating factor-1 (Apaf 1), endonuclease G, 
Smac/DIABLO and Omi/HtrA2) from mitochondria for the caspase activation. It can be 
divided in three well-defined phases: induction, mitochondrial and execution phases. 
During the induction phase external and internal stimuli activate different signals 
which are transduced to mitochondria by the Bcl2-family proteins [Adams J.M. et al., 
1998]. The second apoptotic step is the mitochondrial phase characterized by an 
alteration of the IMM/OMM permeability and the release of apoptogenic factors to 
the cytosol. Two mechanisms are hypothesized to explain this phenomenon, involving 
two distinct channels, which are the permeability transition pore (PTP) in the IMM and 
the mitochondrial apoptosis-induced channel (MAC) in OMM. The last step in 
apoptosis is the executive phase. Cyt c, released from the mitochondria into the 
cytosol, binds to APAF-1 and to pro-caspase-9 to create a protein complex called 
apoptosome. Caspases (cysteine aspartyl-specific protease) are specific protease that 
can be activated by proteolytic cleavage at conserved Aspartic Acid (Asp) residues. 
Effectively procaspase-9 binds Apaf-1 at a conserved amino acid sequence called the 
caspase recruitment domain or CARD, leading to the activation of procaspase-9. 
Caspases collaborate in a proteolytic cascades, where caspases activate themselves 
and each other, and finally cleave their substrate at conserved Asp residues 
[Thornberry N. et al, 1998; Cryns V. et al. 1999] (Figure 12). 
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Figure 12.Mitochondrial pathway of apoptosis. It is regulated by the Bcl-2 family proteins with pro-
apoptotic functions: the Bax type proteins (Bax, Bak and Bok) that cause the release of apoptogenic 
factors (cytochrome c, AIF, Apaf 1, endonuclease G, Smac/DIABLO and Omi/HtrA2) to the cytosol for the 
caspase activation [Feldstein A.E. et al., 2005] 
 
3. MITOCHONDRIAL DNA 
The human mtDNA is a double-stranded, circular molecule of 16,569 bp, now 
completely decoded [Anderson S. et al., 1981], containing 37 genes. Of these 24 genes 
- consisting of 2 ribosomal RNAs (rRNAs) and 22 tRNAs — are used for translation of 13 
polypeptides [Wallace D.C., 1995] that encode subunits of the OXPHOS multimeric 
enzymes located in the IMM: 7 subunits of CI (ND1, 2, 3, 4, 4L, 5, and 6), 1 subunit of 
CIII (cyt b), 3 subunits of CIV (COX I, II, and III), and 2 subunits of ATP synthase (A6 and 
A8) [DiMauro S. et al., 2003]. More than 99% of mitochondrial proteins are encoded by 
nDNA, translated on cytoplasmic ribosomes, and selectively imported into the 
appropriate mitochondrial compartment [Johns D. R., 1995]. The mtDNA is composed 
of 2 strains: the guanosine (G)-rich heavy (H)-strand (OH) and the cytosine (C)-rich light 
(L)-strand (OL) [Schon E.A. et al., 2012]. All of the mtDNA mRNAs, except for ND6, are 
encoded by OH and are derived from one long polycistronic transcript. ND6, by 
contrast, is transcribed from OL using an independent L-strand promoter (Figure13) 
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Figure 13. The mtDNA [Schon E.A. et al., 2012] 
 
Almost the entire genome sequence is coding because there are no introns or 
intergenic regions. Some respiratory protein genes overlap and protein coding and 
rRNA genes are interspersed with tRNA genes that represent the signal for cleavage 
sites of RNA processing. However, there are two non-coding regions. One of 1122bp 
called Displacement Loop (Dloop), characterized by the presence of a triple strand 
structure due to the association of the new H-strand in this region. It contains the 
origin of H-strand DNA replication and is also the site of transcription from opposing 
heavy and light strand promoters [Clayton D.A., 2000; Scarpulla R.C., 2008]. The other 
of 30bp represents the replication origin for the L-strand (Figure 13). 
 
3.1 Mitochondrial replication, transcription and translation 
Mitochondrial DNA replication is independent from the cell cycle (relaxed replication) 
[Bogenhagen D.F. et al., 2003; Clayton D.A., 2003]. Originally it has been described as a 
strand-asymmetric and asynchronous replication, in which the primers for the H-
strand replication are provided by the transcription mechanism. When H-strand 
synthesis has reached 3/4 of the DNA molecule, it exposes the origin of L-strand DNA 
replication (OL) and lagging-strand DNA synthesis initiates in the opposite direction. 
New complete mtDNA molecules are finally ligated [Clayton D.A., 1991; Falkenberg M. 
et al., 2007] (Figure 14). 
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Figure 14. Strand-asymmetric and asynchronous replication of mtDNA [Clayton D.A et al., 1991] 
 
More recently another model has been more proposed in which mtDNA replicates 
symmetrically, with leading and lagging strands synthesis progressing from multiple, 
bidirectional replication forks [Holt I.J.et al., 2000] (Figure 15). 
 
  
Figure 15. Symmetrically and synchronous replication of mtDNA [Holt I.J. et al., 2000] 
 
The enzyme responsible for mtDNA replication is DNA polymerase γ (POLγ), an RNA 
dependent DNA polymerase, discovered in human HeLa cells [Fridlender B. et al., 
1972], composed by a catalytic subunit (POLγA, 140kDa), with polymerase 3’-5’ 
exonuclease, and 5’-deoxyribose phosphate lyase activities, and 2 smaller accessory 
subunits (POLγB, 55kDa), able to increase the catalytic activity of POLγA [Gray H. et al., 
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1992; Kaguni L.S., 2004; Pinz K.G. et al., 2000]. Other 2 proteins are necessary for 
mtDNA replication: the helicase TWINKLE and the mitochondrial single-stranded DNA-
binding protein (mtSSB). Together with POLγ, they form a processive replisome, able to 
replicate the entire mtDNA [Falkenberg M. et al., 2007]. Moreover, mtDNA replication 
requires a RNA primer synthesized by the action of the mitochondrial transcription 
factor A (TFAM) and the mitochondrial RNA polymerase (mtRPOL). TFAM is able to 
wrap, bend and unwind DNA by HMG-boxes (High Mobility Group) inducing a 
structural change in the promoter region of mtDNA that allows the mtRPOL to initiate 
transcription of the RNA primer necessary for the replication of mtDNA. The 
synthesized RNA fragment is stably hybridized to parental L-strand of mtDNA to form a 
triple helix causing the displacement of the parental H-strand. The hybrid RNA-DNA 
starts the H-strand replication following the binding of the POLγ [Shadel G.S. et al., 
1997]. 
 
Mitochondrial transcription starts from 3 different transcription origins, one for the L-
strand (OL) and 2 for the H-strand (H1 and H2), producing 3 polycistronic molecules 
[Montoya J. et al., 2006]. The machinery required for mtDNA transcription includes the 
mtRPOL, the initiations factors TFAM, TFB1M and TFB2M and the termination factor 
mTERF. ORI H1 (nucleotide 561) is responsible for the synthesis of the 2 rRNAs (12S and 
16S), tRNAPhe and tRNAVal. This short transcript is terminated thanks to the binding of 
mTERF protein to a specific sequence within the tRNALeu gene, and is needed to 
produce the appropriate amount of ribosome for translation. ORI H2 (position 646) 
produces a polycistronic molecule that is subsequently processed in 12 mRNAs and 14 
tRNA [Clayton D.A. 1991]. ORIL generates a single polycistron starting at position 407, 
from which 8 tRNAs and the ND6 mRNA are derived [Montoya J. et al., 2006]. The 
primary transcripts are processed, according to the “tRNA punctuation” model, to 
generate the mature RNAs after an endonucleolytic cleavage, triggered by the 
maturation of tRNAs secondary structure [Montoya J. et al., 1983; Ojala D. et al., 1981] 
(Figure 16). 
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Figure 16. Mitochondrial transcription. The 2 internal circles represent both mtDNA strands with the 
encoded genes in yellow (rRNAs), red dots (tRNAs) and blue (protein coding genes). External circles 
represent the RNAs transcribed from the H- strand (in orange or in blue for the RNAs derived from the 
H1 or H2 transcription units) and L- strand (in pink). Arrows at the OH and OL, and in the outside part of 
the figure, indicate the direction of replication and transcription of both strands. [Montoya J. et al., 
2006]. 
 
Mitochondrial encoded mRNAs are translated in the matrix with specific translational 
machinery represented by the mitoribosomes composed by 2 mitochondrial rRNAs 
(12s and 16s) and nuclear encoded proteins.  
The genetic code of mtDNA is also slightly different. Thus, UGA in mitochondrial 
translation does not specify for a tryptophan amino acid, but a stop codon; moreover 
AUA represent an isoleucine and not a methionine and AGA/AGG are not stop codons 
but specify for arginine [Attardi G. et al., 1988]. 
 
3.2 Mitochondrial genetics 
Mitochondrial genetics follows its specific rules and encompasses the rules of both 
Mendelian and non-Mendelian genes [Coskun P. et al., 2012]. The mtDNA is maternally 
inherited [Wallace D.C. 2005] so every mitochondrion and every mtDNA, in the zygote 
derives from the oocyte, because after the fecundation process all mitochondria from 
the spermatocytes are degraded in a ubiquitin-dependent fashion [Sutovsky P. et al., 
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1999; 2000]. Thus, mtDNA molecules and, if present, mtDNA mutations are 
transmitted in the progeny, along the maternal lineage. However it has been reported 
a case of paternal transmission of a pathogenic microdeletion of 3bp in the context of 
a mitochondrial diseases affecting the skeletal muscle [Schwartz M., 2002]. Each 
mitochondrion contains several hundred to several thousand copies of mtDNA 
molecules packaged in nucleoids that are anchored to the IMM [Scheffler I.E., 2001; 
Meyer J.N. et al., 2013]; the number varies according to the bioenergetic needs of each 
particular tissue [Schon E.A. et al., 2012]. Whether all mtDNA molecules are identical 
(wild type (wt) or mutant), this condition is called homoplasmy. When a mutation 
occurs, wt and mutant mtDNA can coexist within the same cell, a condition known as 
heteroplasmy [Wallace D.C, 1999]. The proportions of mutant and wt mtDNAs are 
distributed to the daughter cells stochastically during both mitosis and meiosis 
according to the distribution of mutant mtDNAs at cytokinesis. Therefore, the 
percentage of mutant mtDNAs can drift during cell division toward either more or less 
mutant. As the percentage of mutant mtDNAs increases, the energy output of the cell 
declines until it crosses the minimum energy threshold for that tissue to function, the 
bioenergetic threshold, at which point symptoms appear [Coskun P., 2012]. 
A heteroplasmic mutation can be transmitted with different mutation load because 
during the oogenesis there is a preferential amplification of only few mtDNA molecules 
(bottleneck) (Figure 17) [Marchington D.R. et al., 1998].  
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Figure 17. The mitochondrial genetic bottleneck. During fertilization, a selected number of mtDNA 
molecules are transferred into each oocyte which maturation is associated with the rapid replication of 
this mtDNA population. This restriction-amplification event can lead to a random shift of mtDNA 
mutational load between generations and is responsible for the variable levels of mutated mtDNA 
observed in offspring (heteroplasmy) [Taylor R.W. et al., 2005] 
 
The bottleneck phenomenon explains the rapid shift of some heteroplasmic mutation 
to homoplasmy, in a few generations. In the majority of cases, mutations do not cause 
a biochemical phenotype until they reach a threshold level, which has been shown to 
vary for different types of mutation, in the range of 50–60% [Shoubridge E.A., 1994; 
Moraes C.T. et al., 1992; Mita S. et al., 1990; Hayashi J. et al.; 1991], for deleted 
mtDNA molecules, and up to >90% for some tRNA point mutations [Boulet L. et al., 
1992; Chomyn A. et al., 1992]. However, there has been one recent report of a 
dominant mutation, m.5545C → T, in the MT-TW gene, which showed tissues to be 
clinically affected with a mutation level of <25% [Sacconi S. et al., 2008; Greaves L.C. et 
al., 2012] 
 
The mtDNA has a very high mutation rate, presumably due to its chronic exposure to 
mitochondrial ROS [DiMauro S. et al., 2008] because it is hypomethylated, employs a 
relatively inefficient repair mechanism, and is proximal to the ETC in the IMM 
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[Martinez N.T. et al., 2012]. The absence of protective histones, the lack of effective 
repair mechanism, and the high mtDNA replication rate are alla factors increasing the 
likelihood of errors [Yu-Wai-Man P. et al., 2011]. 
 
3.3 Mitochondrial-nucleus communications: mitochondrial biogenesis 
Mitochondrial biogenesis is a complex and regulated process that involves the 
coordinated expression of mitochondrial and nuclear genes. As a matter of fact 
mitochondria only have limited autonomy and they rely heavily on the nDNA for the 
majority of their structural and functional subunits [Yu-Wai-Man P. et al., 2011]. 
Mitochondrial biogenesis is finely tuned by different signaling cascades that involve 
transcription factors and co-activators that regulate the expression of genes coding for 
mitochondrial components, which include nuclear encoded mitochondrial proteins 
participating in OXPHOS, heme biosynthesis, mitochondrial protein import, and mtDNA 
transcription and replication. The most important transcription factors activating 
promoters of mitochondrial genes are transcription factor A mitochondrial (TFAM), 
NRF (nuclear respiratory factor)-1, NRF-2, PPARs (peroxisome proliferator associated 
receptors) and ERRα (estrogen related receptor), together with transcriptional co-
activators belonging to the peroxisome proliferator-activated receptor γ-coactivator-1 
(PGC-1) family [Diaz F. et al., 2008]. Many other nuclear factors have been implicated 
in the expression of respiratory genes and in the control of mitochondrial biogenesis. 
For example, the cyt c promoter contains cis-elements that recognize transcription 
factors ATF/CREB, c-Myc and Sp1, while muscle-specific CIV subunits are regulated by 
MEF-2 and/or YY1 (YingYang1) [Alaynick W.A. 2008] 
 
3.4 Mitochondrial DNA variability 
Due to its peculiar uniparental maternal inheritance and high mutation rate, mtDNA 
has been extensively used to study population genetics by phylogenetic analysis since 
a great number of mtDNA variants have been fixed and accumulated sequentially 
characterizing different maternal lineages. These mtDNA lineages have diverged from 
the first “Eve” and colonized different geographic regions. Based on different clusters 
of population-specific polymorphism, present both in coding and control regions, it is 
possible to define the mitochondrial haplogroups clusters of mitochondrial genomes, 
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which are continent-specific and defined by the presence of ancestral polymorphisms 
in the maternal line [Torroni A. et al., 1993; Graven L. et al., 1995; Torroni A. et al., 
1994; 1994b]. The origin of modern humans dates back to about 70,000 years ago 
when some sapiens (haplogroup L3) left the Horn of Africa (“out of Africa” model) to 
direct toward the coasts of Arabia, Iran, India, arriving in East Asia (haplogroups N, M). 
Macrohaplogroup N moved along north into the Middle East and radiated to create 
submacrohaplogroup R. Both R and N lineage spread into Europe to generate the 
European-specific haplogroups (H, I, J, K, T, U, V, W, X) It also moved along Southeast 
Asia to Australia and from southern Asia north into central Asia to form haplogroups A 
and Y, whereas the N-derived R lineage generated haplogroup B and F. 
Macrohaplogroup M moved along tropical Southeast Asia, ultimately reaching 
Australia, and later moved north out of Southeast Asia to form Asian-specifi mtDNA 
haplogroup (C,D,G and M1-M40). Ultimately, haplogroups A, B, C, and D migrated into 
the American to found the Native American populations. [Maca-Meyer et al., 2001; 
Olivieri A. et al., 2006; Wallace D.C., 2013a]. Thus haplogroups, designated by a capital 
letter followed by a number that represents the subcluster of haplogroups [Torroni A. 
et al., 1996], tend to be limited to specific geographic areas and population groups 
(Figure 18). 
 
 
Figure 18. The migration history of human mtDNA haplogroups [Wallace D.C. 2013a] 
 
The mtDNA polymorphisms might produce important mtDNA evolutionary changes 
that coincide with the major human geographical transitions facilitating the human 
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adaptation to different regional environments. Indeed the macroohaplogroup N 
migration from Sub-Saharan Africans into Eurasia have not been facilitated by the cold 
of the northern latitudes. Thus to survive, early humans would have needed to 
produce more core body heat to increase resistance to cold. It has been achieved by 
the mtDNA mutations that decreased the “coupling efficiency” of OXPHOS. 
Macrohaplogroup M, in contrast, stayed in the semi-tropic Southeast Asia, so cold-
adaptative variants were not fixed in this lineage [Wallace D.C. 2013a; 2013b]. 
It has also been hypothesized that many non-synonymous polymorphisms in mtDNA 
(SNPs), causing aminoacid variations in the mitochondrial-encoded proteins, have the 
potential to modify OXPHOS activity and ROS production [Wallace D.C., 2005]. 
Therefore some of these haplogroups may confer vulnerability to, or protection from, 
a wide range of metabolic and degenerative disease, cancer and longevity [Schon E.A., 
2012; Wallace D.C. 2013b]. 
 
 Mitochondrial Medicine 
The term “mitochondial medicine” was introduced for the first time by Rolf Luft in 
1994 and now is commonly used to indicate the branch of medicine dedicated to study 
mitochondrial dysfunctions [Luft R., 1994]. Mitochondrial disorders can be divided in 
two classes: the first comprise Mendelian diseases associated with nDNA mutations or 
rearrangments in genes encoding mitochondrial proteins, whereas the second is due 
to mtDNA mutations or rearrangments [DiMauro S. et al., 2008]. 
Major rearrangements of mtDNA usually come as deletions that are caused by defects 
in nuclear genes encoding for enzymes involved in mtDNA maintainance and 
nucleotide metabolism, whereas single deletions are usually sporadic [DiMauro S. et 
al., 2008]. The main syndromes associated with single sporadic deletions are Kearns-
Sayre Syndrome (KSS), Pearson marrow-pancreas Syndrome (PS) and some forms of 
Chronic ProgressiveExternal Opthalmoplegia (CPEO). CPEO is clinically defined by 
palpebral ptosis, generalized weakness and progressive limitation of ocular 
movements [Spinazzola A. et al., 2005; 2007]. Sporadic forms are reported but there 
are also inherited CPEO, that can be autosomal dominant (adCPEO), autosomal 
recessive (arCPEO) and maternally inherited [DiMauro S. et al., 2008]. The latter is 
caused by point mutations in mitochondrial tRNA genes specifying for leucine, 
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isoleucine and alanine, whereas autosomal forms are caused by mutations in POLG1, 
POLG2, Twinkle and ANT-1 and others. The large majority of these genes is involved in 
mtDNA replication or nucleotide metabolism and lead to the accumulation of multiple 
deletions in postmitotic tissue, mainly skeletal muscle and CNS [Kaukonen J. et al., 
2000; Spelbrink J.N. et al., 2001; Longley M.J. et al., 2006]. 
Moreover it has been recently described a syndrome, characterized by dominant optic 
atrophy, sensorineural deafness, ataxia, axonal sensory-motor polyneuropathy, CPEO 
and mitochondrial myopathy with cytochrome c oxidase negative and ragged-red 
fibres (RRFs), in which patients harbour missense mutations in the OPA1 GTPase 
domain and accumulated multiple deletions of mtDNA in skeletal muscle [Ferraris S. et 
al., 2008; Amati-Bonneau P. et al., 2008; Hudson G. et al., 2008]. 
A more complex syndrome is MNGIE (Mitochondrial NeuroGastroIntestinal 
Encephalomyopathy), an autosomal recessive disorder affecting young adults. It is 
characterized by CPEO, peripheral neuropathy, leukoencephalopathy and 
gastrointestinal dysmotility [Hirano M. et al., 2004]. MNGIE is caused by different 
mutations in the gene TP, encoding the enzyme thymidine phosphorylase [Nishino I. et 
al., 1999] that is necessary in the thymine metabolism, and acting in the thymine 
recycle pathway. 
Other recessive disorders leading to mtDNA depletion and multiple deletions are 
Sensory-Ataxia Neuropathy, Dysarthria and Opthalmoplegia (SANDO), spinocerebellar 
ataxia epilepsy syndrome and Alpers’ syndrome, all associated with recessive 
mutations in the POLG1 gene [Spinazzola A. et al., 2007]. 
Mitochondrial DNA depletion syndromes are also recessive traits with various 
phenotypical expressions, which are caused by mutations in several genes. The two 
major syndromes are (1) hepatocerebral syndrome, caused by mutations in POLG1 
(Alpers’ syndrome), DGUOK (deoxyguanosine kinase, involved in nucleotide 
metabolism) and MPV17 (an IMM protein with unknown function) [DiMauro S. et al., 
2008; Spinazzola A. et al., 2006; 2007] and (2) pure myopathic syndromes, due to 
mutations in TK2, SUCLA2 (encoding the β-subunit of succinylCoA synthetase) and 
RRM2B (p53 inducible ribonucleotide reductase small subunit) [DiMauro S. et al., 
2008; Elpeleg O. et al., 2005; Bourdon A. et al., 2007]. 
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The mtDNA is also a hot spot for pathogenic point mutations accumulation, causing 
MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like episodes) a 
multisystem disorder characterized by stroke-like episodes in young age, 
encephalopathy with seizures and/or dementia and mitochondrial myopathy with 
lactic acidosis and RRFs [Di Mauro S. et al., 2008; Zeviani M. et al., 2007; Hirano M. et 
al., 2006]. More than 80% of the patients harbor the common mutation A3243G in the 
tRNALeu gene resulting in biochemical dysfunction affecting CI, III, IV and ATP synthase 
[Yasukawa T et al., 2000]. Mutations in structural genes, such as COIII, ND1, ND5 and 
ND6, have been also reported in association with the MELAS phenotype 
[http://www.mitomap.org/MITOMAP]. 
Furthermore, Leigh syndrome is a complex, early-onset, disease with a heterogeous 
clinical manifestation, due to different mutations in several genes (nuclear and 
mitochondrial) [Hirano M et al., 2006]. Mutations in structural genes ND1-ND6, with 
the only exception of ND4L have been reported [Santorelli F.M. et al., 1993; Ugalde C. 
et al., 2004]. 
Another syndrome characterized by the presence of mitochondrial tRNAs point 
mutations is MERRF (Myoclonus, Epilepsy and Ragged-Red Fibers). In literature are 
described at least 6 different mutations, especially in tRNALys (A8344G, T8356C, 
G8361A) [Mancuso M. et al., 2004]. Mutations can also occur in structural 
mitochondrial genes and the major disorders associated with these mutations are 
NARP (Neuropathy, ataxia, retinitis pigmentosa), MILS (Maternally Inherited Leigh 
Syndrome) and Leber’s hereditary optic neuropathy (LHON). NARP is a multisystem 
disorder affecting young adults characterized by a single heteroplasmic point mutation 
in the ATPase6 gene (T8993G/C) [Hirano M. et al., 2006; Hirano M. et al., 1994; Holt I.J. 
et al. 1990]. The same mutations, at high levels of mutational load may lead to MILS 
[Santorelli F.M. et al., 1993].  
Disorders caused by CI deficiency such as MELAS, Leigh Syndrome and LHON, are 
usually progressive, multi-systemic, have a poor prognosis and lead to early death or 
permanent disabilities of the patients [Shoubridge E.A. et al., 2001; Janssen R.J. et al., 
2006; Koene S. et al., 2012]. They result in a broad spectrum of clinical signs and 
symptoms involving energy demanding tissue, like brain and muscle, but also other 
organ system can be affected.  
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There is growing evidence that mitochondrial dysfunctions play a key pathogenic 
mechanism in many neurodegenerative disorders including LHON and Dominant Optic 
Atrophy (DOA), even in those without a primary mitochondrial etiology such as 
Parkinson’s disease (PD) and Alzheimer’s disease (AD). Both LHON and DOA are 
associated with a CI defect [Carelli V. et al., 1999; 2007; 2009; Zanna C. et al., 2008] 
which is also recognized as a key feature in the pathogenesis of PD, both in the 
sporadic cases as well as in the genetic forms [Schapira A.H., 2008]. 
 
 Leber’s Hereditary Optic Neuropathy 
LHON is a maternally inherited blinding disease characterized by the degeneration of 
retinal ganglion cells and their axsons causing an acute or sub-acute loss of central 
vision and affecting predominantly young males [Wallace D.C. et al., 1988; Carelli V. et 
al.,2004; Sadun A.A. et al., 2011; Leber T. 1871]. This usually monosymptomatic 
disease was clinically defined by Leber and is now recognized as the most frequent 
mitochondrial disease [Man P.Y. et al., 2003]. Clinically it is characterized by 
degeneration of retinal ganglion cells (RGCs) leading to optic nerve atrophy and 
bilateral loss of central vision explained by selective damage to the papillomacular 
bundle (PMB) associated with dyschromatopsia. Fundus examination during the 
acute/subacute stage reveals circumpapillary telangiectatic microangiopathy, swelling 
of the nerve fiber layer around the disc (pseudoedema) and, absence of leakage on 
fluorescein angiography [Nikoskelainen E. et al., 1983; 1984].  
About 95% of LHON cases carry mtDNA point mutations that affect subunits of the 
respiratory chain CI subunits genes: m.3460G>A in ND1 (3460/ND1) [Howell N. et al., 
1991; Huoponen K. et al., 1991], m.11778G>A in ND4 (11778/ND4) [Wallace D.C. et al., 
1988], and m.14484T>C in ND6 (14484/ND6) [Johns D.R et al., 1992; Mackey D. et al., 
1992; Rizzo G. et al., 2012; Pello R. et al., 2008]. Several studies showed that CI 
dysfunction leads at least to two main pathogenic mechanisms: a bioenergetic defect 
of oxidative phosphorylation and a cronically production of ROS [Carelli V. et al 2007].  
The mutation G3460A results in the substitution of threonine for alanine at position 52 
of the ND1 protein. The threonine substitution is adjacent to an invariant aspartic acid 
residue and the additional electronegativity of the threonine hydroxyl group -and/or 
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its greater side chain volume might distort or weaken the electrostatic interactions 
among the charged residues, thereby altering the tertiary structure of this loop and/or 
its dielectric environment [Howell N. et al., 1991].  
The mutation G11778A induces changes an evolutionarily conserved arginine with a 
histidine at position 340 in subunit ND4 of CI involved in CoQ10 binding site. It alters 
the affinity of CI for CoQ10 reflecting a substantial loss in the energy conserving 
function of CI and thus explain the pathological effect of the mutation [Degli Esposti M. 
et al., 1994b].  
The mutation T14484C, on ND6 subunit gene, converts the amino acid methionine in 
position 64, with a valine in the C strand that damage the conformation of CI [Carelli V. 
et al., 1999]. 
However, two unresolved questions in the understanding of LHON remain 
unexplained: the variability of intra and interfamiliar penetrance (percent affect of 
total number of mutation carriers), especially when the pathogenic mutation is 
homoplasmic in all maternally related individuals and the male prevalence, with only 
50% of male and 10% of female carriers eventually losing vision in their life time [Pello 
R. et al., 2008; Howell N. 1998; Chalmers R.M. et al., 1999]. Factors proposed as 
possible contributors to LHON penetrance, may include heteroplasmy, environmental 
factors, like tobacco smoking [Howell N. 1998b; Chalmers R.M. et al., 1999; Tsao K et 
al., 1999; Sadun A.A. et al., 2003; Newman N.J. 2009] and mtDNA background as well 
as nuclear modyfing gene [Carelli, V. et al., 2006; Hudson G. et al., 2007; Sadun A.A. et 
al.. 2011]. Haplogroup analyses of LHON mutations have revealed an increased risk of 
vision loss with suhaplogroup J1, J2 and K, increasing the expressivity and penetrance 
of different primary LHON mutations. Basically 11778/ND4 and 14484/ND6 mutations 
are associated respectively with mitochondrial subhaplogroup J2b and J1c, and that 
the 3460/ND1 mutation is associated with haplogroup K. Probably, accumulation of 
non-synonymous polymorphisms in ND subunits can increase the penetrance of LHON 
[Carelli, V. et al., 2006; Hudson G. et al., 2007]. To further complicate the scenario for 
LHON mutations environmental factors such as tobacco smoking have been proposed 
as further contributors for developing visual loss in LHON due to the presence of 
substances, contained in the tobacco, that can directly act on CI [Yu-Wai-Man P. et al., 
2011]. Moreover the rare esposure to toxic vapors from solvents such as n-exane and 
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toluene has also been associated with LHON as triggering factors for the disease. 
Interestingly, haplogroup J was shown to be more sensitive to these chemicals, thus 
highlighting a potentially very complex interplay among a pathogenic mtDNA mutation 
and the interactive role played by both mtDNA haplogroup and environmental factors 
[Ghelli A. et al., 2009]. Other studies provide new insights for LHON unexplained male 
prevalence. These observations suggest that oestrogens may influence mitochondrial 
functions by acting on the mitochondrial respiratory chain, oxidative stress and 
mitochondrial biogenesis and they might be responsible for female longevity. Thus the 
different exposure to oestrogens between males and females is sufficient to modify 
the severity of mitochondrial dysfunction induced by mitochondrial DNA mutations 
affecting complex I in LHON [Giordano C. et al., 2011] 
 
 Parkinson’s disease 
PD is the second most common neurodegenerative disease after Alzheimer disease, 
affecting over 4 million people with pronounced degeneration of the dopaminergic 
neurons of the substantia nigra and formation of fibrillar cytoplasmic inclusions, 
known as Lewy bodies, which contain ubiquitin and α-synuclein [Ghezzi D. et al., 2005 ; 
Martin I., 2011; Giordano S., 2012]. It is characterized by bradykinesia, tremor, rigidity 
and impaired postural reflexes. In addition mental disorders like depression of 
psychosis and autonomic and gastrointestinal dysfunction may occur [Lopez-Gallardo 
E. et al., 2011]. Roughly 10% of total cases are thought to stem from mutations in 
several nuclear genes including α-synuclein, Parkin, PINK1, DJ-1, LRRK2 and 
Omi/HTRA2, which play a prominent role in mitochondrial dysfunction in familiar PD 
[Cannon J.R. et al., 2011; Lopez-Gallardo E. et al., 2011; Winklhofer K.F et al., 2010; 
Banerjee R. et al., 2009; Schapira A.H. et al., 2008; Bueler H. 2009]. However, the most 
frequent form arises from unknown causes (idiopathic PD) [Cannon J.R. et al., 2011]. In 
these regards, a number of toxicants present in the environmental are capable of 
selectively damaging dopaminergic neurons, contributing to PD by inducing 
mitochondrial dysfunction due to their major role in the production of cellular ROS 
[Drechsel D.A. et al., 2008]. CI and CIV activities has been reported to be reduced in 
mitochondria isolated from central nervous system (CNS), skeletal muscle, and 
platelets of PD patients [Parker W.D. Jr, 1989; Bindoff L.A., 1989; Parker W.D. Jr., 1998; 
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Trimmer P.A., 2000; Smigrodzki R., 2004; Trimmer P.A., 2004; Parker W.D. Jr.,2008; 
Lopez-Gallardo E. et al., 2011]. Furthermore cybrid cell lines with mitochondria from 
sporadic PD patients also exhibit decreased CI activity, increased levels of ROS, 
increased expression of antioxidative proteins (bcl-2 and bcl-XL), the accumulation of 
protein inclusion bodies and enhanced susceptibility to cell death [Trimmer P.A., 2004; 
Esteves A.R., 2008; 2010; Swerdlow R.H., 2012]. 
Although parkinsonian features have occasionally been reported in mtDNA related 
encephalomyopathies, neither maternal transmission nor specific mtDNA mutations 
have been associated with idiopathic PD. Nevertheless, the analysis of mtDNA 
haplogroups in idiopathic PD suggested that European mtDNA haplogroups J and K, 
and their common SNP 10398G in ND3 gene, exert a protective effect from the risk of 
PD [Ghezzi D. et al, 2005]. On the contrary the root for haplogroups J and T, defined by 
4216C in the ND1 gene, seems to be more frequent among PD patients [Ross O.A. et 
al., 2003]. 
To further complicate this scenario, genetic susceptibility factors may interact with 
environmental toxins such as the pesticide rotenone, MPP+, and the herbicide 
paraquat (1,1’-dimethyl-4,4’-bipyridinium dichloride; PQ) increasing the risk of PD due 
to a reduction in ATP synthesis and increase of reactive oxygen species (ROS) 
[Swerdlow R.H. et al., 2012]. 
 
4. DRUG INDUCED MITOCHONDRIAL DYSFUNCTION  
Why mitochondria are so special for pharmacogenomics? Because of the special 
properties of these organelles which are characterized by a unique milieu, with an 
alkaline and negatively charged interior (pH value 8) due to the proton pumping 
associated with OXPHOS and a series of specific channels and carrier proteins. As a 
consequence, mitochondria can easily accumulate lipophilic compounds of cationic 
character and weak acids in their anionic form, particularly amphiphilic xenobiotics 
including ethidium bromide, MPP+, paraquat and others that can penetrate the IMM 
freely since in their undissociated form [MeyerJ.N et al., 2013]. When inside the 
alkaline matrix, their protons dissociate rendering the molecules much less permeable 
and trapping them inside the organelle [Blaikie F.H. et al., 2006; Olszewska A. et al., 
2013]. The high lipid content of mitochondrial membrane facilitates accumulation of 
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lipophilic compounds such as polycyclic aromatic hydrocarbons (PAHs) and some 
alkylating agents. Cationic metals, such as lead, cadmium, mercury and manganese, 
have also been shown to accumulate in mitochondria due to both calcium transporters 
and mitochondrial pH and charge. Cytocrome P450 in mitochondrial can activate 
chemicals that are relatively nonreactive prior to metabolism, such as PAHs and 
mycotoxins [Meyer J.N. et al., 2013] (Figure 19). 
 
 
Figure 19. Drud-induced mitotoxicity [Meyer J.N et al., 2013] 
 
Thus the progressive accumulation of these compounds inside mitochondria damage 
their function and permeability properties. Depending on the level and number of 
mitochondria, the cell could go toward a severe denergization state that in turn can 
lead to necrosis or more localized damage of a few mitochondria with a collapse of 
their Δψ. The resultant pH modification could reprotonate the substance, rendering it 
freely permeant in the cell and capable of entering other mitochondria [Scatena R et 
al., 2003; 2004; 2007]. 
Mitochondrial dysfunction (mitotoxicity) has been demonstrated in the etiology of 
drug-induced toxicities, causing withdrawn from the market, or Black Box warnings. 
Thus to increase the drugs safety, pharmaceutical companies have started to assay the 
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mitochondrial toxicity early in the drug-development process because severe in vitro 
mitochondrial impairment might be sufficient to abandon the development process of 
a new drug, whereas mild impairment may be acceptable. Early identification of 
mitochondrial liabilities during compound series selection and lead selection using in 
vitro screens allows for structure–activity relationship (SAR) studies to avoid it. General 
cytotoxicity is identified by cell-based screening. If a mitochondrial etiology is 
suspected, assessment of isolated mitochondrial function can be performed. If 
positive, additional in vitro mechanistic studies can examine effects on OXPHOS, 
permeability transition, ROS production, ΔΨm, and mtDNA status. Therefore 
mitochondrial assessment should be completed before a compound moves into 
further development and is elevated to drug candidate level (Figure 20) [Dykens J.A. et 
al., 2007]. 
 
 
Figure 20.Mitochondrial toxicity screening [Dykens K.A. et al., 2007] 
 
All in all, mitochondria seem to be a potential primary or secondary target of 
xenobiotics and drugs even though the interaction with mitochondria or mitochondrial 
components should not always be considered negative. These substances can act on 
mtDNA, mitochondrial protein synthesis, mitochondrial respiratory chain (MRC), 
mitochondrial metabolic processes and mitochondrial channels and transporters, 
leading to mitotoxicity [Figure 18] [Meyer J.N et al., 2013; Dykens K.A et al., 2007]. 
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4.1 Drugs targeting mitochondrial transporters and channels. 
The integrity of mitochondrial membrane is crucial for mitochondrial function. Not 
only IMM and OMM, but proteins, ion channels and transporters embedded within 
lipid membrane are also target by drugs [Olszewska A. et al., 2013] disrupting ion 
homeostasis or affecting the mPTP. [Scatena R. 2012; 2007].  
IMM potassium channel openers (e.g. nicorandil, diazoxide, antidiabetic and antitumor 
sulfonylureas) modify the activity of different mitochondrial channels, which have a 
fundamental role in maintaining the electrolyte homeostasis.  
Valproic acid, t-butyl-hydroperoxide, diclofenac and other NSAIDs are responsible for 
the opening of mPTP provoking cell death. It is a high-conductance; nonspecific pore in 
the IMM composed of proteins that link the IMM and OMM. When it is opened, low 
molecular weight substrates can freely penetrate the MM, carrying along with them 
H20 resulting in mitochondrial swelling and the release of cyt c into the cytosol that 
triggers a cascade of events that will lead to either apoptosis or necrosis [Scatena R. et 
al., 2007]. The mPTP represents the best targets for many drugs producing mitotoxicity 
[Bouchier-Hayes L. et al., 2005; Renner K. et al., 2003]. 
 
4.2 Drugs targeting mitochondrial metabolism 
Xenobiotics and drugs can interfere with catabolic and anabolic pathways in 
mitochondria, including pyruvate oxidation, TCA, and fatty acid β-oxidation [Di Mauro 
S. et al., 2008; Greaves L.C. et al., 2012]. Isoniazid inhibits the conversion of pyruvate 
to lactate and interferences with NADH synthesis in the TCA contributing to the lactic 
acidosis [Scatena R et al., 2007]. Cyclosporin reduces the concentration of TCA 
intermediates and inhibites OXPHOS at the level of ATP synthesis (CV) [Christians U. et 
al., 2004]. The inhibition of fatty acid β-oxidation can result in the accumulation of free 
fatty acids and triglycerides in the cytoplasm that can have toxic effects on 
mitochondrial respiration, ATP synthesis, ketone body production and gluconeogenesis 
[Rial E. et al., 2010]. Valproate, tetracycline derivates, NSAIDs such as ibuprofen and 
irprofen, glucocorticoids, antidepressants such as amineptine and tianeptine, statins, 
fibrtes, estrogens, antiarrhythmics and antianginal drugs such as amiodarone and 
perhexiline, can directly and/or indirectly interference with mitochondrial fatty acid 
oxidation [Scatena R et al., 2007]. Valproate enters the mitochondrial where it 
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activated to valproyl-CoA that sequesters CoA preventing the oxidation of fatty acids 
and resulting in failure of energy generation. Valproyl-CoA also inhibits carnitine 
palmitoyltrasferase I (CPTI), a critical enzyme for acylcarnitine transport into 
mitochondria [Cohen B.H. et al., 2010].  
 
4.3 Drugs targeting mitochondrial DNA 
Several drugs interfere with mtDNA and mtDNA processes, such as replication and 
transcription through interaction with mitochondrial topoisomerase (e.g. amsacrine, 
etoposide, teniposide and tamoxifen), mitochondrial rRNA (e.g. chloramphenicol and 
thiamphenicol) and mitochondrial POLγ (e.g. menadione and antiviral drugs) that is the 
unique enzyme responsible for mtDNA replication, required for normal mitochondrial 
maintenance and duplication [Neuzil J. et al., 2013; Olszewska A. et al., 2013]. 
Although POLγ is a nuclear protein, it has no known function other than mtDNA 
replication, and thus any mutation or inhibition of this enzyme will be manifested only 
in mtDNA. Drugs may damage POLγ through different mechanisms. Antiviral drugs 
used in the treatment of human immunodeficiency virus or hepatitis B infections have 
shown mitochondrial toxicity through the inhibition of POLγ [Scatena R. 2012; 2007; 
Cohen B.H, 2010; Apostolova N. et al., 2011; Olszewska A. et al., 2013]. 
The nucleotide reverse transcriptase inhibitors (NRTIs) (e.g. zidovudine, didanosine, 
zalcibatine, lamivudine, stavudine and abacavir) are nucleoside analogs that are taken 
up by cells and sequentially phosphorylated to the active triphosphate form [Collins 
M.L. et al., 2004; Lewis W. et al., 2006; Apostolova N. et al., 2011; Meyer J.N. et al., 
2013]. After phosphorylation they can be used as substrates by retroviral reverse 
transcriptase competing with natural nucleosides and they can be incorporate into the 
nascent DNA chain resulting in chain termination [Collins M.L. et al., 2004; Cohen B.H, 
2010; Olszewska A. et al., 2013]. Because the analog does not have a second hydroxyl 
group to support the lengthening of the chain, the nascent strand can no longer grow, 
resulting in a DNA pol-γ dysfunction and reduction of mtDNA copy number. This 
interferes with the synthesis of essential proteins of MRC [McComsey G. et al., 2005] 
resulting in reduced ATP synthesis, electron leakage and increased ROS production 
[Scatena R et al., 2007; Cohen B.H, 2010]. 
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Protonated tacrine, that is a reversible cholinesterase inhibitor approved for the 
treatment of Alzheimer’s disease, intercalates between mtDNA bases inhibiting 
mtDNA replication both directly and by inhibition of topoisomerases [Olszewska A. et 
al., 2013]. 
Finally recent studies revealed that a variety of chemotherapeutic agents, such as Cis-
diaminedichloroplatinum (II) (cisplatin), induce cell death generating a significant 
amount of ROS and impairing MRC after interaction with mtDNA [Qian W. et al., 2005]. 
Cisplatin (cisPt) is used to treat solid tumor including ovarian, testicular, cervical, lung, 
head, and neck and bladder cancer in adult patient [Podratz J.L et al., 2011; Mukherjea 
D. et al., 2011]. However side effects such as ototoxicity, nephrotoxicity and 
neurotoxicity are limiting factors in clinic [Pasetto L.M. et al., 2006; Cepeda V et al., 
2007]. Although nephrotoxicity may be prevented by saline hydration or mannitol 
diuresis, there are no known preventive treatments available for ototoxicity and 
neurotoxicity [Mukherjea D. et al., 2011]. CysPt, that is hydrolyzed to a positive 
charged metabolite, becomes activated intracellularly though the aquation to 
monoaqua species (in which one of the two chlorine groups is replaced by H20) [Wang 
D. et al., 2005] and accumulates inside mitochondrion because the membrane 
potential is negative inside (~180mV), being its uptake increasing proportionally to 
both the membrane potential and mitochondrial density. Consequently cells with 
higher density of mitochondria seem to accumulate a larger amount of cisPt and 
exhibit mitochondrial dysfunction due to enhanced mtDNA injury [Qian W. et al., 
2005]. As a result mtDNA appears to serve as one of the primary targets for cisPt 
because of: i) it is more susceptible to oxidative stress than nDNA since it does not 
contain histone-like proteins and it has a less efficient repair mechanism for injured 
DNA [Sawyer D.E et al., 1999], ii) preferential formation of cisPt-mtDNA adduct, and iii) 
a low activity of decomposing them [Reedii JK J et al., 1985; Olivero O.A. et al., 1997]. 
cisPt forms a preferential covalent binding to the nitrogen on position 7 of guanine. 
The major covalent bis-adduct that is formed involves adjacent guanines on the same 
strand of DNA (the intrastrand crosslink); a minor adduct involves binding to guanines 
on opposite DNA strands (the interstrand crosslink) [Wang D. et al, 2005] (Figure 21). 
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Figure 21. Formation and effects of cisplatin - DNA adducts [Wang D. et al, 2005] 
 
The mtDNA-cisPt adduct inhibits mtDNA replication, disrupt mtDNA transcription, 
generate ROS production, impair mitochondrial respiratory chain causing 
morphological changes within mitochondria that induce apoptosis. These findings are 
important because they provide a theoretical target for interventions to help prevent 
cisPt-induced neuropathy [Qian W. et al., 2005; Podratz J.L et al., 2011]. Furthermore 
analysis of mtDNA haplogroup revealed an increased incidence of cisPt-induced 
hearing loss in mitochondrial haplogroup J, which, however, did not reach statistical 
significance [Peter U. et al., 2003].  
 
4.4 Drudg targeting mitochondrial transduction 
During evolution, the mtDNA from the endosymbiont decrease its size because 
redundant genes were lost, many other genes of the primitive bacteria were 
transferred to the nDNA and the remaining ones were reduced in size [Schneider A. et 
al., 2004]. Therefore the mtDNA presents 2 genes of rRNAs – 12S and 16S – contained 
in the 55S mitochondrial ribosome (mitoribosome) that consists of 2 subunits of 28S 
and 39S. The 28S comprises 12S and 28 proteins, and the large subunit contains the 
16S rRNA and 48 proteins [Pacheu-Grau D et al., 2010]. Because of the bacterial origin 
of mitochondria, mitochondrial rRNAs (rRNAs 12S and 16S) resemble eubacterial 
rRNAs (16S and 23S) thus several bacterial antibiotics such as chloramphenicol, 
aminoglycosides, tetracycline, erythromycin and the oxolidozones also act on 
mitochondrial protein synthesis and, therefore, this mechanism is involved in side 
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effects for humans [Scatena R et al., 2007; Olszewska A. et al., 2013; Cohen B.H, 2010; 
Pacheu-Grau D. et al., 2010]. Aminoglycosides may induce hearing loss, especially 
when in the 12S rRNA gene, sequence is present the A>G transition at nucleotide 1555, 
where the codon-anticodon interaction occurs and aminoglycosides bind the bacterial 
ribosome [Cohen B.H, 2010]. This SNP has arisen in different mtDNA haplogroups, 
suggesting that there is no common haplogroup susceptibility [Tang H-Y et al., 2002]. 
Moreover chloramphenicol bind the bacterial 23S rRNA, which is the homolog of 
human mitochondrial 12S rRNA [Burk A. et al., 2002].  
Oxazolidinones antibiotics (e.g. linezolid (Zyvox)) inhibit bacterial protein synthesis 
binding the domain V of 23S rRNA, which constitutes the A site of ribosomal peptidyl 
transferase center (PTC), thus stopping the growth of bacteria. The PTC is in the middle 
of the 23S rRNA subunit in the bottom of the cleft where the 3’ ends of aminoacyl-
tRNA (A-site) and peptidyl-tRNA (P-site) are positioned for peptide transfer [Long S. K. 
et al., 2012; Leach K.L et al., 2007]. Linezolid comprises four chemical moieties, namely 
three aromatic rings (ring A, B and C) and an acetamidomethyl tail (C5 tail) (Figure 22). 
 
 
Figure 22. Structure of Linezolid [Palumbo Piccionello A. et al., 2012] 
 
Linezolid binds at the PTC within a pocket composed of universally conserved residues 
and is located such that ring C orients toward the intersubunit interface, whereas ring 
A as well as the C5 tails head in the general direction of the ribosomal tunnel. Within 
the pocket, the oxazolidinone ring stacks on U2504, and the C5-tail extends toward 
A2503. Ring-B is sandwiched between A2451 and U2506 [Wilson D.N. et al., 2008] 
(Figure 23). 
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Figure 23. The binding site of oxazolidinones [Leach K.L et al., 2007] 
 
Not surprisingly, genetic polymorphism in domain V of bacterial 23S rRNA have been 
associated with Linezolid resistance even if they are not located in the binding site of 
Linezolid [Leach K.L. et al., 2007; Palenzula L. et al., 2005]. 
Given the similarities between the conserved domains of rRNAs in bacterial and 
human mitoribosomes, Linezolid can bind to similar position in mitoribosomes causing 
mitochondrial toxicity by inhibiting protein synthesis. Furthermore, human mtDNA 
variation in the mitochondrial 16S rRNA gene may confer genetic susceptibility to 
Linezolid toxicity. Indeed some individuals treated with Lin developed 
myelosuppression, lactic acidosis and optic and peripheral neuropathy as a result of 
inhibition of mitochondrial protein synthesis. Sequencing the mitochondrial 12S and 
16S rRNA gene in all individual, it was revealed a homoplasmic A2706G and G3010A 
polymorphism in the mitochondrial 16S rRNA gene [Palenzula L. et al., 2005]. 
Replacement of guanine by adenine, and vice versa, at base pairs 2706 and 3010 in 16S 
rRNA gene, have been suggested to increase the susceptibility of certain individuals to 
the toxic effect of Linezolid through inhibition of mitochondrial protein synthesis and 
activity of the mitochondrial respiratory complexes , especially CIV [Velez J.C. Q et al., 
2010; Pacheu-Grau D. et al., 2013]. 
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4.5 Drugs targeting mitochondrial respiratory chain 
Substances may impair MRC via direct inhibition of any of the 4 protein complexes or 
via acceptance of electrons instead of natural acceptors like CoQ10 or cyt c [Scatena R 
et al., 2007; Olszewska A. et al., 2013]. Specific inhibitors are rotenone (ROT), 
antimycin A, cyanide and carbone monoxide (CO). Some of these compounds are used 
routinely in laboratories in general mitochondrial pharmacology [Olszewska A. et al., 
2013] such as ROT, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and its active 
metabolite MPP+ that have been shown to inhibit mitochondrial CI directly in assays 
involving isolated mitochondria [Bové J., 2012; Martinez T.N et al., 2012; Parker W.D. 
Jr, 1989]. They have been used in a variety of cell-based and animal models to 
investigate their role in the pathogenic mechanism of parkinsonianism [Cannon J.R et 
al., 2011; Gorell J. M. et al., 1998; Dranka B.P et al., 2012; Rodriguez-Pallares J. et al., 
2007; Bové J., 2012; Martinez T.N. et al., 2012]. 
Among medicines, papaverine, meperidine, cinnarizine, amytal, haloperidol, 
ketoconazole, fibrates (e.g. clofibric acid, bezafibrate, gemfibrozil) and their derivates 
thiazolidinediones (e.g. ciglitazone, troglitazione, pioglitazione) share a common 
structural motif: a cyclic head and a hydrophobic tail by which they inhibit CI. [Filser M. 
et al., 1988; Morikawa N. et al., 1996; Subramanyam B. et al., 1990; Veitch K. et al., 
1994; Degli Esposti M, 1998; Duchen M.R, 2004; Miyoshi H, 1998]. 
Artificial electron acceptors, including methylene blu, phanazine methosulfate, 2-6-
indophenol, tetramethyl-p-phenylenediamine, ferricyanide, doxorubicina, menadione 
and paraquat, are capable of interfering with MRC acting as alternative electron 
acceptors by extracting electron from intermediates in the chain [Scatena R. et al., 
2007; Meyer J.N. et al., 2013]. In recent years the investigation of the herbicide PQ has 
suggested that it might be another environmental factor contributing to human PD 
[Dinis-Oliveira R.J. et al., 2006; Rodriguez-Pallares J. et al., 2007]. These compounds 
convert O2 to O
-.
2 by auto-oxidation that can combine with two protons to form H2O2 
or can form via the Fenton reaction the OH. in the presence of ferrous iron (Fe2+) 
damaging DNA, lipid membrane and proteins [Cohen B.H, 2010]. Hexachlorobutadiene, 
4-thiaalkanoates and valproic acid are also capable of inducing ROS generation without 
directly deranging the MRC [Scatena R et al., 2007]. 
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Apart from the common CII inhibitors (e.g. malonate, carboxin, 3-nitropropionic acid), 
cis-crotonalide fungicides, diazoxide, fluoroquinolones, chloramphenicol succinate and 
anthracycline are also studied [Szewczyk A. et al., 2002; Wallace K.B. et al., 2000]. 
There are a large number of CIII inhibitors, including myxothiazol and antimycin A, 
acting at different levels [Szewczyk A. et al., 2002; Walker U.A. et al., 2003] and 
resulting in the generation of ROS [Scatena R. 2012; 2007]. 
Effects on CIV are the most severe because this is the step where O2 is reduced to H20. 
[Scatena R. 2012; 2007]. Cyanide azide and carbon monoxide (CO) are common CIV 
inhibitor. Also NO interact at physiological levels with CIV, leading to a competitive and 
reversible inhibition [Brown G.C. et al., 2004], promoting alterations in the 
electrochemical gradient that could affect Ca2+ uptake and regulating processes such 
as MTP opening and release of proapoptotic proteins [Ho W.P. et al., 2005].  
Oligomycin and drugs such as propanolol and diethylstilbestrol may interfere with 
OXPHOS by direct inhibition of ATP synthesis (CV) [Scatena R. et al., 2007]. 
Finally non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, diclorofenac 
and nimesulide, antitumor, antipsychotic, hypolipidemic and antimycotic compounds 
may lead to uncoupling of OXPHOS dissipating the proton gradient. It can result in the 
generation of heat and, in extreme condition, a malignant hyperthermia syndrome can 
occur [Duchen M.R. et al., 2004; Ernster L., 1984]. These compounds can act as direct 
protonophores, shutting hydrogen ions into the matrix or as ionophores, exchancing 
hydrogen ions for other mono-or divalent cations or may increase the permeability of 
IMM. For all these molecules, the main structure-activity relationship is based on a 
lipophilic weak acid group [Fleischer S., 1979; Moreno-Sanchez R. et al., 1999; Wallace 
K.B. et al., 2000; Scatena R. et al., 2007]. 
Amiodarone and perhexiline, protonated in the acidic IMS, enter the MM where they 
uncouple OXPHOS and inhibit CI and CII, resulting in a reduction of mtDNA level and an 
impairment of fatty acid β-oxidation [Olszewska A. et al., 2013]. 
On the whole, tissue that rely on OXPHOS, are also targets of mitochondrial toxins and 
drugs. For this reason there are numerous common syndrome associated with 
mitochondrial toxicity including lactis acidosis, cardic and skeletal myopathy, 
peripheral, central and optic neuropathy, retinopathy, ototoxicity, enteropathy, 
pancreatitis, diabetes, hepatic steatosis and hematotoxicity [Scatena R et al., 2007]. 
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 Mitochondrial neurotoxicity due to CI inhibitors 
Rotenone MPP+ and paraquat are popular toxicant agents that have been shown to 
inhibit CI, either directly or indirectly, in assays involving isolated mitochondria from a 
variety of cell-based and animal models to investigate their role in the pathogenic 
mechanism of parkinsonianism [Swerdlow R.H. et al., 2012; Cannon J.R et al., 2011; 
Bové J., 2012; Martinez T.N et al., 2012; Parker W.D. Jr, 1989¸ Betarbet R. et al.,2000; 
Richardson J.R. et al., 2005]. The specific interactions of rotenone and MPP+ with CI 
were confirmed bypassing CI, in human neuroblastoma cells, by expressing the single-
subunit NADH dehydrogenase from Saccharomyces Cerevisiae. The introduction 
substitution of this neurotoxic-insensitive CI attenuated the rotenone and MPP+ toxic 
effects [Shere T.B. et al., 2003; Richardson J.R. et al., 2007]. Paraquat’s neurotoxicity 
action is not the results of CI specific inhibition but it is essentially due to its redox 
cycle [Dinis-Oliveira R.J. et al, 2006; Richardson J.R. et al., 2005]. Overall, these 
compounds are known as inhibitor of the ETC, and the ECT is both a target and a 
source of ROS so that the common mechanism proposed for toxicity in all these 
pharmacological models of PD centers around two major pathways: inhibition of 
mitochondrial function, and increased ROS generation [Dranka B.P et al., 2012] (Figure 
24). 
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Figure 24. Mitochondrial dysfunction, ATP energy crisis and oxidative stress model of dopamine neuron 
cell death. Within DA neurons, MPP
+
 and rotenone inhibit CI decreasing ATP levels and endogenous 
antioxidants and generating oxidative stress from CI and CIII which leads to oxidation of 
macromolecules. Additionally, cyt c is released from the IMS, activating caspase signaling and 
subsequent apoptotic cell death. PQ accepts electrons CI and functions as a redox cycler to generate 
oxidative stress and subsequent mitochondrial dysfunction leading to DA neuron death in a manner 
similar to MPP
+
 and rotenone. [Martinez T.N et al., 2012]. 
 
As a result both mitochondrial dysfunction and oxidative stress are attractive targets 
for clinical intervention [Schapira A.H., 2012]. Nevertheless the lack of a direct 
connection between these events is also increasingly being recognized [Fukui H. et al., 
2008; Surmeirer D.J. et al., 2010]: for example despite ROS increase in PD has been 
well documented, clinical trials using antioxidants have not been proven efficacious 
[Dranka B.P et al., 2012].  
Furthermore tobacco smoking has been proposed as an environmental trigger of visual 
loss in LHON due to the impairment of OXPHOS through a direct effect on CI activity 
[Yu-Wai-Man P. et al., 2011]. It has been known that cigarette smoke contains many 
lipophilic compounds (phenols, aldehydes, and aromatic hydrocarbons, etc) that are 
able to accumulate in mitochondria and affect mitochondrial respiratory chain, by 
altering membrane potential (Δψ), oxygen consumption and ATP production, thus 
leading to oxidative stress, mtDNA damage and cellular death [van der Toorn M. et al., 
2007]. 
 
 Rotenone 
The lipophilic pesticide rotenone (2R,6aS,12aS)-1,2,6,6a,12,12a- hexahydro-2-
isopropenyl-8,9- dimethoxychromeno[3,4-b] furo(2,3-h)chromen-6-one), a plant 
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derivate, has been considered an organic pesticide and was commonly used as a 
household insecticide in home gardening and agriculture and kills fish for the past 50–
150 years. The ubiquitous use of rotenone in both work and home settings suggests 
that many people have been exposed [Tanner C.M. et al., 2011]. It is believed to have a 
relatively short environmental half-life and limited bioavailability so that a relationship 
to human disease has been questioned [Hatcher J.M. et al., 2008] (Figure 25). 
 
 
Figure 25. Structure of rotenone 
 
Recent work in rodent models indicated that a temporally limited exposure to this 
pesticide later caused progressive functional and pathologic changes, mimicking 
changes found in human PD [Drechsel A.D. et al., 2008]. Chronic intravenous infusion 
of rotenone in rats caused a 75% reduction in CI activity and selective degeneration of 
nigrostriatal DA neurons that are associated behaviorally with hypokinesia and rigidity 
and for the first time fibrillar cytoplasmic a-synuclein and ubiquitin immunoreactive 
inclusions were accumulated in surviving neurons within the SN and striatum [Betarbet 
R et al., 2000; Lopez-Gallardo E. et al., 2011]. Because it is extremely hydrophobic, 
rotenone crosses the blood-brain barrier (BBB) and biological membranes easily, 
independent of a receptor or transporter and accumulates in subcellular organelles 
including the mitochondria where therefore is well-suited to produce a systemic 
inhibition of electron flow through CI [Drechsel A.D. et al., 2008; Sherer T.B. et al. 
2007]. Particularly rotenone inhibits CI which shuts off the supply of electron to CIII 
[Change B. et al., 1963; Sherer T.B. et al. 2007] blocking one of the eight iron/sulfur 
clusters in CI [Dranka B.P et al., 2012]. Consequently, electrons remains in the matrix 
site for a longer period of time than normal and O2 can react via a one electron 
reduction to produce O2•_ [Drechsel A.D. et al., 2008]. All in all the consequences of 
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inhibition of mitochondrial CI by rotenone are multifarious. It decreases ATP levels, 
which may lead to compromised function of the ubiquitin proteasome system (UPS) 
and mediates bioenergetics crisis within DA neurons, culminating in cells death. 
Moreover it can sensitize DA neurons to an N-methyl-D-aspartate receptor (NMDA) 
receptor and cav1.3 L-type Ca2+ channel increasing a glutamate and a cytoplasmic 
influx of Ca2+ that culminate in excitotoxic cell death [Martinez T.N et al., 2012]. Lastly 
rotenone has been shown to impinge on mitochondrial dynamics by inducing 
mitochondrial fission [Arnold B. et al., 2011].  
 
 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MPTP was first recognized as a neurotoxin when a group of intravenous heroin users 
developed an acute version of Parkinsonism that was symptomatically 
indistinguishable from idiopathic PD [Langston J.W. et al., 1983]. It was discovered to 
be an impurity in the illicit drug synthesis of a narcotic meperidine analogue. Basically 
after it was recognized to function as a DA neurotoxicant, animal models were quickly 
developed providing the first effective nonhuman primate model of Parkinsonism 
[Burns R.S. et al., 1983]. MPTP exhibits the major symptoms of human PD (with the 
exception of tremor) even if it is not progressive, does not affect other brain regions 
that are affected in human PD patients, and Lewy bodies are not observed [Jenner P., 
2009; 2008; Langston J.W. et al., 1999; Martinez T.N. et al., 2012]. Following systemic 
injection, MPTP, that is highly lipophilic, readily crosses BBB [Drechsel A.D. et al., 
2008]. It was shown that neurotoxicity depends on oxidation of MPTP by monoamino 
oxidase (MAO) in brain tissue to the dihydropyridinum form (MPDP+) which is further 
deprotonated (likely due to spontaneous oxidation) to the active neurotoxin N-mehyl-
4-pyridinium (MPP+) [Ramsay R.R. et al 1986; Martinez T.N. et al., 2012]. Both the A 
and B types of MAO process MPTP relatively rapidly, particularly the B type, which is 
enriched in endothelial cells of the BBB microvasculature and in glial cells [Martinez 
T.N. et al., 2012]. The actively toxic species MPP+ diffuses from astrocytes into the 
extracellular milieu where it is selectively bound to the dopamine uptake system (DAT) 
in the synapses and transported to the stroma of dopaminergic neurons [Ramsay R.R. 
et al., 1986; Tolwani R. J. et al., 1999; Martinez T.N. et al., 2012] (Figure 26). 
 
Introduction 
60 
 
Figure 26. . Structure of the proto-toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) and its 
metabolic activation to MPP
+
 [Matusch A. et al., 2010] 
 
Once inside the neuron and during the acute phase of MPTP-induced death, there are 
a few routes that MPP+ can take: it can enter the vesicular pathway, binds to vesicular 
monoamine transporters and translocates into synaptosomal vesicles [Liu Y. et al., 
1992]. It can remain in the cytosol and interact with various cytosolic enzymes 
[Klaidman L.K. et al., 1993] or it can be concentrated within mitochondria via a 
mechanism dependent on mitochondrial transmembrane potential [Ramsay R.R. et al., 
1986; Rossetti Z.L. et al., 1988]. Within the mitochondria, MPP+ binds to CI, uncoupling 
the oxidation of NADH-linked substrates and consequently disrupting the flow of 
electrons along the ETC, resulting in acute ATP deficiency and increased generation of 
ROS, particularly O2
•− [Drechsel A.D. et al., 2008; Richardson J.R. et al., 2007; Nicklas 
W.J. et al., 1985]. Excessive oxidative stress resulting from MPP+ inhibition of CI is one 
proposed mechanism of DA neurotoxicity. Support for this hypothesis is provided by 
the observation that the reduction in ATP levels is not likely to be a severe enough to 
be the primary cause of DA neuron death [Chan P. et al., 1991; Davey G.P. et al., 1996]. 
Furthermore MPTP has been suggested to inhibit mitochondrial CIII and IV (but not II) 
in vitro [Desai V.G., et al, 1996].  
 
 Paraquat  
Paraquat was first recognized as a potential DAergic toxicant based on its structural 
similarity with MPP+. Paraquat treatment elicits a selective and dose-dependent loss of 
nigral DA neurons with associated modest decreases in striatal dopamine nerve 
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terminal density and mildly decreased motor behavior [Brooks A.I.et al., 1999; 
McCormack A.L et al., 2002]. Long-term, systemic paraquat administration in rats 
produces slowly progressive degeneration of nigrostriatal neurons and reduced 
number of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra, 
leading to delayed deficits in dopaminergic transmission that resemble early 
presymptomatic stage of PD [Ossowska K., et al., 2005]. Despite the striking 
resemblance, MPP+ and paraquat exert their deleterious cellular effect via different 
mechanism, although induction of oxidative stress is shared property [Richardson J.R. 
et al., 2005]. The mechanism by which the herbicide kills dopaminergic neurons is not 
clear because the neurotoxicity actions are not the results of transport by the DAT or 
CI specific inhibition but it is essentially due to its redox cycle [Dinis-Oliveira R.J. et al, 
2006; Richardson J.R. et al., 2005]. However paraquat is a potent redox cycler. It is 
reduced, mainly by the mitochondrial CI [Fukushima T et al., 1993; Yamada K et al., 
1993] and by the mitochondrial CIII [Castello P.R et al., 2007] to form a moncation free 
radical (PQ•+). It is then rapidly reoxidized in the presence of O2 generating the 
superoxide radical (02•-) [Brush A.E. et al., 1998; Dicker E. et al., 1991; Jones G.M. et 
al., 2000; Yumino K. et al., 2002] (Figure 27). 
 
 
Figure 27. The redox cycling mechanism of paraquat [Martinez T.N et al., 2012].  
 
This then set off the well-known cascade of reaction leading to the generation of other 
ROS that is a primary cause of paraquat-induced toxicity as evidenced by protection 
from adverse PQ effects by overexpression of SOD [Thiruchelvam M. et al., 2005] or via 
administration of SOD mimetics [Mollace V. et al., 2003]. Another important feature of 
paraquat toxicity is related to its ability to permeate the BBB into the CNS. This 
herbicide is a charged molecule, with a hydrophilic structure, and does not readily 
cross membranes [Dinis-Oliveira R.J. et al, 2006]. Paraquat might be specifically 
transported into the brain by a neutral aminoacid transporter, most likely the system L 
Introduction 
62 
Carrier (LAT-1) [Shimizu K. et al., 2001; Richardson J.R. et al., 2005; Martinez T.N., 
2012]. However, in a new recent study, it was demonstrated that PQ, in high doses, 
employs the organic cationic trasporter-3 (OCT-3) and DAT [Rappold et al., 2011]. 
 
 Tobacco smoking 
Cigarettes, made from dried tobacco leaves, are a complex mixture of chemicals such 
as nicotine, cyanide, benzene, formaldehyde, methanol (wood alcohol), acetylene (the 
fuel used in welding torches), and ammonia - including over 60 carcinogens - produced 
by the burning of tobacco and its additives. Some of these substances cause heart and 
lung diseases, and all of them can be deadly. They also contain tar and the poison 
gases carbon monoxide and nitrogen oxide. The tobacco leaves used in making 
cigarettes also contain radioactive materials, whose amount depends on the soil the 
plants were grown in and fertilizers used (Figure 28). 
 
 
Figure 28. Chemicals inside a cigarette 
 
Thus cigarettes contain small amounts of radioactive material which smokers take into 
their lungs as they inhale [www.cancer.org].  
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AIM 
 
Adverse reactions associated with marketed drugs and xenobiotics are estimated to be 
between the fourth and sixth leading cause of death in the USA and an important 
reason for hospitalization, leading to increased health care costs 
[http://ghr.nlm.nih.gov/]. As a result many studies have just exanimated the role of 
nDNA variability in the toxicity or efficacy of xenobiotics and drugs among individuals. 
However, there is a lack of knowledge on the possible correlation between mtDNA 
variability and the different susceptibility to xenobiotics and drugs has been 
considered in research. Indeed mitochondria are not merely the center for energy 
metabolism, but are also the headquarters for various catabolic and anabolic 
processes, calcium fluxes, and various signaling pathways. In this context, the 
interaction of pharmacological agents with mitochondria make them a valuable target 
due to the special properties of these organelles which are characterized by a unique 
milieu, with an alkaline and negatively charged interior (pH value 8) and a series of 
specific channels and carrier proteins. In any case, identification of mitochondria as 
primary or secondary targets of drugs/xenobiotics may facilitate a better 
understanding of their mechanism of action and open new perspectives on itheir 
application. 
The first aim of this research project was to understand whether the genetic 
polymorphisms within the mtDNA genome may act as susceptibility factors and/or 
influence the citotoxicity of CI inhibitors such as rotenone, MPP+, paraquat and 
tobacco smoking, reflecting on the pathogenic mechanism leading to PD and LHON 
disease, both disorder being linked CI dysfunction and increased ROS production 
[Schapira A.H., 2008; Carelli V. et al., 2009]. Rotenone and MPP+ inhibit CI directly, 
leading to increased O2•_, whereas paraquat neurotoxicity is essentially due indirectly 
through its redox cycle by interfering with MRC and increasing ROS production. 
Tobacco smoking has been proposed to impair OXPHOS and increase ROS, possibly 
through direct effect on CI [Yu-Wai-Man P. et al., 2011] 
Moreover, it is accepted that mtDNA variation contributes to both PD and LHON 
pathogenic mechanism [Carelli, V. et al., 2006; Hudson G. et al., 2007; Ghezzi D. et al, 
2005; Ross O.A. et al., 2003; Schon E.A et al., 2012; Wallace D.C., 2013b]. This variation 
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may be influential also on sensitivity to rotenone, MPP+ and paraquat as well as to the 
deleterious effect of tobacco smoking, by this impinging on the complex relationship 
among genetic variation, its interaction with environmental factors and ultimately the 
pathogenic mechanism leading to both PD and LHON.This intricate relationship is the 
object of this aim. 
The second aim is to understand whether the genetic variation of mtDNA may 
influence the neurotoxicity of Linezolid and CisPt, respectively. Linezolid is an 
antibacterial drug inhibiting bacterial protein synthesis which may interfere with 
mitochondrial function leading to severe side such as myelosuppression, lactic acidosis 
and optic and peripheral neuropathy - phenotypes frequently found in 
mitochondriopathies – [Leach K.L. et al., 2007; Palenzula L. et al., 2005]. CisPt, a drug 
used to treat solid tumor, inhibits mtDNA replication and may lead to ototoxicity, 
nephrotoxicity and neurotoxicity limiting the dose than can be administered to patient 
[Qian W. et al., 2005; Podratz J.L et al., 2011].  
Overall, we investigated the impact of population-specific mtDNA common variation 
on mitochondrial function, and its relevance to interaction with environmental toxic 
agents and drugs by using the cell model of transmitochondrial cytoplasmic hybrids 
(cybrids), in which common mtDNA haplogroups have been transferred.  
 
Materials and methods 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
67 
MATERIALS AND METHODS 
 
5.1 Cellular Lines and Culture Protocols 
Transmitochondrial cytoplasmic hybrids (cybrids) were constructed from fibroblasts 
obtained, after informed consent, from skin biopsies of unrelated healthy subjects and 
LHON patients as previously reported [King M.P. et al., 1996]. Fibroblasts, grown in 
DMEM supplemented with 10% fetal calf serum, were then enucleated and fused with 
osteosarcoma (143.TK-)-derived 206 cell line as acceptor ρ0 cell line. In the most 
common approach for making ρ0 cells, a transformed cell line (143B) that is deficient in 
thymidine kinase activity (TK–) is exposed to ethidium bromide (EtBr), which is an 
inhibitor of mtDNA replication because mitochondria have a high membrane potential 
and take up EtBr, as it is ionizable. The ρ0 line is auxotrophic for uridine and pyruvate 
(U–, P–). The ρ0 cells are repopulated by forming hybrids with cytoplasts from unrelated 
controls that lack nuclei but still contain mitochondria. Fibroblasts were enucleated by 
exposing to cytochalasine B followed by centrifugation. After fusion with polyethylene 
glycol (PEG), cells are plated in media containing bromodeoxyuridine (+BrdU) and 
lacking either pyruvate or uridine (U– or P–), which permits only the growth of ρ0 cells 
that have fused with cytoplasts containing mitochondria by fibroblasts owing to TK+ 
fibroblasts are not able to grow in the presence of BrdU. After selection, several cybrid 
clones were isolated and expanded (Figure 29). 
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Figure 29. Generation of cybrids (modified by Schon A.E. et al., 2012). 
 
Cybrid cell lines were grown in Dulbecco’s modificed Eagle’s medium (DMEM-high 
glucose) supplemented with 10% foetal bovine serum (FBS), 25mM glucose, 5mM 
pyruvate, 2mM L-glutammina, 10mg/mL penicillin-streptomycin, in an incubator with a 
humidified atmosphere of 5% CO2 at 37 C.  
 
5.2 The mitochondrial DNA sequencing and haplogroup affilation 
The mtDNA sequence variation and haplogroup affiliation of cybrids except those 
already characterized [Pello R. et al., 2008; La Morgia C. et al., 2008; Ghelli A. et al., 
2009] was determined by sequencing their entire mtDNA and their mtDNA non-coding 
region (D-loop). The complete mtDNA sequencing was carried out on DNA samples 
extracted from venous blood, in the Laboratory of Genetics, Dipartimento di Genetica 
e Microbiologia, Università di Pavia (Prof. Antonio Torroni), as previously described 
[Achilli A. et al., 2004] 
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D-loop region was determined by DNA extraction using the standard technique of 
extraction with phenol-chloroform [Chomczynski P. et al, 1987] and polymerase chain 
reaction (PCR) method by a GeneAmp PCR System 2700 (Applied Biosystems) thermal 
cycler. The PCR mixture contained 50-100ng of DNA, 1U Taq DNA Polimerase 5U/ul 
(Eppendorf), 1X Buffer Advanced 10X (Eppendorf), 100µM PCR nucleotide Mix (Roche), 
100µM each Primer 2µM (Invitrogen), in a final volume of 50µL. Primers sequences 
and PCR conditions are reported in Table 1.  
 
Table 1. Primers sequences and PCR conditions 
mtDNA polymorphism D-loop 
Fw: CAAATGGGCCTCTCCTTGTA Rv: GGAGTGGGAGGGGAAAATAA 
1 cycle 30 cycles 1 cycle 
95°C x 5’ 95°C x 30’’ 
55°C x 30’’ 
72°C x 1’ 
72°C x 7’ 
 
Sequence analysis requires the amplification of the fragment of interest using labeled 
nucleotides The reaction mixture is composed of 0.5μl of DMSO (dimethylsulfoxide), 
1.5 L of 5X Sequencing Buffer, 1μl of primer, 1μl of 1.1 ABI PRISM BigDye Terminator 
Cycle Sequencing Kit (Applied Biosystems), in a final volume of 10μl. The sequences of 
the primers and amplification condition used are shown in Table 2.  
 
Table 2. Primers sequences and sequence analysis conditions 
mtDNA D-loop Sequence Analysis 
Fw: 
CAAATGGGCCTGTCCTTGTA 
CAGTCAAATCCCTTCTCGTC 
CTTTGATTCCTGCCTCATCC 
Rv: 
AGGGTGGGTAGGTTTGTTGG 
GGAACGTGTGGGCTATTTAGG 
ACAGATACTGCGACATAGGG 
TGGCTGTGCAGACATTCAAT 
25 cycles 
96°C x 10’’ 
50°C x 5’’ 
60°C x 4’ 
 
After sequence reaction, the mixture was purified with PERFORMA ® DTR Gel Filtration 
Cartridges (EdgeBio) according to the manufacturer's instructions and a volume of 
Formamide was added. It was denatured for 5’ at 95 °C, cooled to 4 °C in ice to avoid 
the re-annealing of the filaments, and loaded onto automated sequencer ABI Prism 
310 Genetic Analyzer (Applied Biosystem). The sequence analysis of D-loop was 
performed using Sequencing Analysis 5.2 software, while the search of nucleotide 
substitutions was made with Sequencher 4.8 Demo. All D-loop sequences are 
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compared to the revised Cambridge reference sequence (rRCS) to reveal the 
haplogroup. 
 
5.3 Cellular Viability  
Cell viability was determined using the colorimetric sulforhodamine B (SRB) assay as 
previously described [Bonora E. et al., 2006]. Cells were seeded 30.000 cells/well in 
DMEM-high glucose into 24-well plates and after 24h were washed twice with PBS and 
incubated in DMEM glucose-free medium or complete medium supplemented with 
5nmoli/L galactose, 5nmoli/L Na-pyruvate and 5% FBS (DMEM galactose) in presence 
or absence of environmental factors, including rotenone, MPP+, paraquat and tobacco 
smoking, and drugs such as Linezolid and CisPt at different concentration. Briefly, at 
the end of incubation time, cells were fixed with 50% trichloroacetic acid (TCA) for 1 h 
at 4°C, washed five times with H20 and dried for 1h at room temperature. Cell were 
then stained for 30 min with SRB dye 0.4% diluted in acetic acid 1%, washed four time 
with 1% acetic acid, and solubilized in Tris Buffer 10mM pH 9.8. Absorbance was 
measured at 540 nm by using a microplate reader [VICTOR3 Multilabel Plate Counter 
(PerkinElmer Life and Analytical Sciences, Zaventem Belgium)]. The SRB absorbance 
value in absence of rotenone corresponds to 100% viable cells. 
 
5.4 ATP synthesis 
The assay of mitochondrial ATP synthesis driven by CI or CII substrates was determined 
in digitonin-permeabilized cybrid cell lines, exactly as previously described in 
luciferin/luciferase assay [Manfredi G. et al. 2002], with minor modifications [Giorgio 
V. et al. 2012] by a Bio Orbit 1250 Luminometer. Briefly, after trypsinization, cells were 
resuspended (10x106/mL) in buffer A [150mM KCl, 25mM Tris-HCl, 2mM EDTA, 10mM 
potassium phosphate (KH2PO4), 0.1mM MgCl2 (pH 7.4)] and aliquot was taken to 
measure protein content [Bradford M.M., 1976]. Then they were incubated with 
50µg/mL digitonin for 1’ at room temperature in slight agitation. After centrifugation, 
the cells pellet was resuspended in buffer B [10mM KCl, 25mM Tris-HCl, 2mM EDTA, 
0.1% bovine serum albumin (BSA), 10mM potassium phosphate, 0.1mM MgCl2 (pH 
7.4)] and aliquots were taken to measure ATP synthesis and citrate synthase (CS) 
activity [Trounce I.A et al., 1996]. Aliquots of cell were incubated in a tube assay 
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containing buffer B, 1mM malate plus 1mM piruvate (CI substrates) or with 5mM 
succinate (CII substrate) plus 5µM rotenone for CII to avoid reoxidation of CoH2 from CI 
by RET 
The reaction was started by addition of 0.1mM ADP in the presence of 
luciferine/luciferase kit (Sigma-Aldrich), as detailed by the manufacturer's instructions, 
and chemiluminescence was determined as a function of time with a luminometer. 
After addition of 1µM oligomycin, the chemiluminescence signal was calibrated with 
an internal ATP standard 10µM. The residual activity of ATP synthesis was normalized 
to protein content, and expressed as a ratio of CS activity and as percentage of the 
activity of untreated cells. 
 
CS activity was measured at 412 nm (30°C) with UV-Vis spectrophotometer (V550 
Jasco) in a buffer containing 125mM Tris-HCl (pH 8), 0,1% Triton X100, DTNB 100μM, 
Acetyl CoA 300μM. The reaction was started by addition of oxaloacetate 500μM. 
[Trounce I.A et al., 1996] 
 
5.5 Respiratory chain complexes activity 
Spectophotometric assays for OXPHOS complexes were performed using a dual-
wavelength UV-Vis spectrophotometer (Jasco V550 Europa, Italy), under stirring and 
controlled temperature as previously described [Janssen A.J. et al., 2007]. Respiratory 
chain complexes activity (CI+III, CIII and CIV) were evaluated in mitochondrial-enriched 
fraction isolated from cybrid cell lines grown in DMEM-high glucose in presence or 
absence of Lin. Cells, resuspended in Sucrose-Mannitol buffer (Sucrose 70mM, D-
Mannitol 200mM, EGTA 1mM, HEPES 10mM, in MilliQ pH 7.6 with protease inhibitor 
cocktail), were mechanically homogenized each with 80 strokes using a glass-Teflon 
potter. Homogenates were low centrifuged at 3000 rpm for 10 min at 4 °C discarding 
the cellular debris pellet. Gently collected supernatants (containing the dirty 
mitochondrial fraction) were centrifuged at 13000 rpm for 20 min at 4°C. These pellets 
were then resuspended in Sucrose-Mannitol buffer and stored at - 80 °C. 
CI+CIII activity was performed at double wavelength (540 nm-550 nm) at 37°C in 
agitation and follows the reduction of oxidized bovine heart cyt c exogenous. Kinetics 
was calculated using the cyt c molar extinction coefficient (19,1 mM-1cm-1). The activity 
Materials and methods 
72 
was performed in 50mM potassium phosphate buffer (KPi) (pH 7.6), 0,35% BSA, 
0,3mM KCN, 20μM oxidized cyt c exogenous. The reaction was started by addition of 
150μM NADH. In a separate assay, 1μM rotenone (CI inhibitor) and 1µM Antimycin 
(CIII inhibitor) were added at the beginning of the reaction to measure the non-specific 
activity. 
Complex III activity was analyzed at 540 nm-550 nm wavelength at 37°C in agitation 
and follows the oxidation of reduced quinol:decylbenzoquinol (DBH2) and the 
reduction of oxidized cyt c exogenous. Kinetics was calculated using the cyt c molar 
extinction coefficient (19,1 mM-1cm-1). The activity were performed in 50mM KPi (pH 
7.6), 0,35% BSA, 0,3mM KCN, 20μM oxidized cyt c, 1μM rotenone (CI inhibitor), 5mM 
Malonate (CII inhibitor). The reaction was started by addition of 50μM reduced DBH2. 
In a separate assay, 1µM Antimycin (CIII inhibitor) was added at the beginning of the 
reaction to measure the non-specific activity. 
CIV activity follows the oxidation of reduced cyt c exogenous. It was performed at 540 
nm-550 nm wavelength at 37°C in agitation and kinetics was calculated using cyt c 
molar extinction coefficient (19,1 mM-1cm-1). Buffer contained 50mM KPi (pH 7.6), 
1mM EDTA, 1μM Antimycin (CIII inhibitor). The reaction was started by addition of 
20μM reduced cyt c. The nonspecific activity measurement was performed in a 
separate assay, adding 300μM KCN at the beginning of the reaction. 
The rates were normalized to CS activity and protein content. 
 
5.6 Reactive Oxygen Species Production 
ROS production was determined using 2',7'-dichlorodihydrofluorescein diacetate 
(H2DCFDA) as previously described [Porcelli A.M. et al., 2010]. Cells were seeded 
40.000 cells/well and incubated in Hepes Ringer Solution Medium [NaCl 125mM, KCl 
5mM, MgS04 1mM, KH2P04 1mM, Hepes 20mM, CaCl2 1,3mM, Galactose 5mM (pH 
7,4)] at 37°C in an incubator with a humidified atmosphere of 5% CO2. The medium is 
supplemented with Calcein AM 100µM and H2DCFDA 2µM. After 30 min, cells were 
incubated with environmental factors including rotenone, MPP+, paraquat and CSE for 
2h and 4h. Briefly upon cleavage of the acetate groups by intracellular esterases and 
oxidation, the non-fluorescent H2DCFDA is converted to the highly fluorescent 2',7'-
dichlorofluorescein (DCF). Fluorescence was determined at 485 nm (excitation 
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wavelength) and 535 nm (emission wavelength) using a multilabel plate reader 
[VICTOR3 and Analytical Sciences, Zaventem Belgium)]. 
 
5.7 The mitochondrial DNA copy number/cell quantification  
Absolute quantification of mtDNA relative to nuclear DNA (nDNA) was perfomed by 
real-time PCR using a LightCycler® 480 (Roche Applied Science, Penzberg, BY, DE) as 
previously described [Mussini C et al., 2005] . This method is a multiplex assay based 
on hydrolysis probe chemistry: 10-50ng of DNA extracted from cells was adeguate. 
Briefly, a mitochondrial DNA fragment (MTND2 gene) and a nuclear DNA fragment 
(FASLG gene) were extracted from cybrids and were co-amplified by multiplex PCR and 
concentrations were determined by absolute quantification. 
In the first reaction, mtDNA was measured using a mix of 1x PCR buffer (Promega, 
Madison, Wisconsin, USA), 3mmol (L magnesium chloride, 400pmol primers for 
mtDNA, 0,2mmol/L dNTP and 2U Taq polymerase (Promega). The TaqMan probe used 
for mtDNA was included in the reaction mixture throughout PCR as a real-time 
detector for the amplified product. One cycle of denaturation (95°C for 6’) was 
performed, followed by 45 cycles of amplification (94°C for 30’, 60°C for 60’). The same 
approach was used to quantify nDNA, which was required to obtain the number of 
copies of mtDNA per cell. In this case, primers, designed on the gene sequence FasL, 
wew used. The TaaMan probe Genprobe was included in the reaction mixture 
throughtout PCR ads a real-time detector for the amplified product. 
An mtDNA fragment (MTND2 gene) and an nDNA fragment (FASLG gene) were cloned 
tale to tale in a vector (pGEM-11Z; Promega) and serial dilutions were used to 
construct a standard curve, obtaining a ratio of 1:1 of the reference molecules. From 
the standard curve, the relative copy number of both mtDNA and nDNA was 
determined. The measured values for mtDNA and nuclear DNA were always within the 
range of the standard curve and the correlation coefficient was always > 0.995. 
Absolute values for the copies of mtDNA per cell were then simply obtained from the 
ratio between the relative values of mtDNA and nDNA (obtained versus the same 
vector), multiplied by 2 (as two copies of the nuclear gene are present in a cell). 
Primers, probes and conditions are shown in Table 3. 
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Table 3. Primers, probes and conditions for RT-PCR assay 
RT-PCR assay 
mtDir: CACAGAAGCTGCCATCAAGTA mtRev:CCGGAGAGTATATTGTTGAAGAG 
GenDir: GGCTCTGTGAGGGATATAAAGACA GenRev: AAACCACCCGAGCAACTAATCT 
TaqMan probe(mtDNA): 5’-FAM-CCGGAGAGTATATTGTTGAAGAG-BlackHole Quencer 1-3’ 
TaqMan probe (GenProbe): 5’-Texasred-CTGTTCCGTTTCCTGCCGGTGC-BlackHole Quencer 2-3’ 
1 cycle 
95°C x 6’ 
45 cycles 
94°C x 30’’ 
60°C x 60’’ 
 
 
5.8 Cigarette smoking extract production 
One Marlboro red cigarette was smoked via vacuum pump as previously described 
[Facchinetti F. et al., 2007]. Just before the experiments, the filter was cut from the 
cigarette and cigarette smoke was bubbled through 25 ml of cell growth medium 
without phenol to obtain the cigarette smoking extraxt (CSE). The absorbance (Abs) of 
this extract was measured at 320 nm. 
 
5.9 Statistical analysis 
All statistical analyses were performed using Sigma Stat software package ver 3.5, 
choosing the most appropriate test. Statistical significance was declared at p ≤ 0.05. 
We performed the analysis using comparison between each haplogroups via Anova 
One Way followed by post-hoc Bonferroni Test or via Anova on Ranks followed by 
post-hoc Dunn’s Test when the values from the sample were not normally distributed 
or don’t have the same variance. For correlation between untreated and treated cells 
with Lin is used Student t. Data are presented as means ± SEM.  
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RESULTS 
 
6.1 The mitochondrial DNA sequencing of control cybrids 
In this study we analyzed 11 control (wild type) cybrid cell lines constructed from 
healthy subjects belonging to European haplogroups N1b, H, J, T, U, and K, initially 
genotyped by sequence analysis of the D-loop region. To estabilish the full 
genotype/phenotype correlation of our functional studies we then sequenced the 
entire mtDNA molecules. The raw data of mtDNA sequencing are reported in Appendix 
A and the list of specific non-synonymous nucleotide changes (SNPs) is reported in 
table 4. 
 
Table 4.Specific SNPs found in mtDNA of our cybrids with relative single amino acid substitutions (SAP) 
according to rCRS. SNPs ans SAPs in ND subunits (CI) are shown in black bold 
Wild-type 
cybrids 
SNPs 
SAPs Haplogroup 
Gene bank  
ID 
References 
Position Region 
H28705 C4960T ND2 Ala164Val N1b   
HAD T9592C COIII Val129Ala H1   
HF16W    H1   
HQB 
G5460A 
T7407C 
G8557A 
T13879C 
ND2 
COI 
ATPase6 
ND5 
Ala331Thr 
Tyr502His 
Ala11Thr 
Ser515Pro 
J1b1a2b JQ797764.1 
Pala M. et al. Am. J. Hum. Genet. (2012) 
90(5):915-924 
HGA 
A13681G 
T14798C 
ND5 
Cytb 
Thr449Ala 
Phe18Leu 
J1c GQ304740.1 
Ghelli A. et al. PLoS ONE (2009) 
4(11):e7922 
HFG G15257A Cytb Asp171Asn J2a2c JQ797930.1 
Pala M. et al. Am. J. Hum. Genet. (2012) 
90(5):915-924 
H42 
A5451G 
G7853A 
ND2 
COII 
Thr328Ala 
Val90Ile 
T1a JQ798014.1 
Pala M. et al. Am. J. Hum. Genet. (2012) 
90(5):915-924 
HPS G6261A COI Ala120Thr T2c1c1 JQ798099.1 
Pala M. et al. Am. J. Hum. Genet. (2012) 
90(5):915-924 
HGDA    U1 JN872374.1 
Perli E. et al. Hum Mol Genet (2012) 
21(1): 85-100 
HF01M/10 
T14757C 
T15635C 
Cytb 
Cytb 
Met4Thr 
Ser297Pro 
K1c AY882394.1 
Achilli A. et al. Am. J. Hum. Genet. (2005) 
76(5): 883-886 
HP27 
A4024T 
T11025C 
ND1 
ND4 
Thr240Ser 
Leu89Pro 
K1a2 EU915473.1 
Pello,R. Hum. Mol. Genet. (2008) 
17(24): 4001-4011 
 
Figure30 shows the tree encompassing the data shown in table 5 of cell lines studied. 
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Figure 30. Tree encompassing the complete mtDNA sequences of wt cybrids compared to rCRS. SNPs in 
ND subunits (CI) are shown on the branches in black bold. 
 
All mtDNA sequences were compared to the rRCS, to assign haplogroup affiliation, 
because this is a commonly used reference human mtDNA sequence belonging to a 
European H2a2a1 haplogroup, published in 1981 [Anderson S. et al., 1981] and revised 
by Andrews R. et al in 1999 and Bandelt H.J. et al in 2013 
[http://www.mitomap.org/bin/view.pl/MITOMAP/MitoSeqs]. Recently a “Copernican” 
reassessment of human mtDNA phylogeny has been proposed, switching to a 
Reconstructed Sapiens Reference Sequence (RSRS) as a valid reference derived from 
more than 8000 complete mtDNA sequences. This is assumed to be the root of the 
modern human mtDNA phylogeny [Behar D.M. et al., 2012] (Figure 31).  
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Figure 31. Schematic representation of modern human mtDNA phylogeny. The position of rCRS and 
RSRS are shown [modified by Behar D.M. et al., 2012] 
 
A comparison of rRCS to RSRS and the corresponding nucleotide differences is 
reported in Appendix B. We also compared mtDNA sequences of our cybrids to the 
RSRS. As expected, specific non-synonymous variants (shown in black bold) are 
essentially the same with the exception of the SNP 10398 in ND3 gene. This is shown 
as the substitution of adenine (A) to guanine (G) in rCRS, whereas in RSRS the 
nucleotide G is converted to A. (Figure 32). 
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Figure32. Tree encompassing the complete mtDNA sequences of wt cybrids compared to RSRS. SNPs in 
ND subunits (CI) are shown on the branches in black bold. 
 
The raw data of mtDNA sequencing compared to RSRS are reported in Appendix C  
 
6.2 The mitochondrial DNA sequence aligment and conservation analysis 
The complete mitochondrial sequences of 60 mammalians species, according to mtSAP 
(single amino acid polymorphism) Evaluation, were aligned with UniProtKB. By this 
mean we compared the SNPs of cybrids with both reference sequences and identified 
the percentage of amino acid conservation for specif position in the query alignment 
(Table 5). The analysis reveals that only SNPs of haplogroup K1 - A4042T in ND1 and 
T11025C in ND4 corresponding to SAPs T240A and L89P respectively - are not 
conserved, whereas SAP Y304H in ND1 (SNP T4216C) of haplogroup J/T is the most 
conserved (63,3%) between mammalians. 
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Table 5. SNPs, SAPs and the amino acid conservation analysis in mammalians. 
Specifi SNPs and SAPs in ND1 subunits are shown in red bold and red italics 
SNP SAP Haplogroup Mammalians (n=60) 
Position Region rCRS wt cybrids RSRS Position rCRS wt cybrids RSRS  Position AA 
% of AA 
conservation 
4769 ND2 A G G 100 Met Lys Lys 
 
100 Lys (n=0) 0 
8860 ATPase6 A G G 112 Thr Ala Ala 112 Ala (n=19) 31,67 
15326 Cytb A G G 194 Thr Ala Ala 194 Ala (n=7) 11,67 
14766 Cytb C T T 7 Thr Ile Ile 7 Ile (n=1) 3,33 
7146 COI A A G 58 Thr Thr Ala 58 Ala (n=16) 26,67 
8701 ATPase6 A A G 59 Thr Thr Ala 59 Thr (n=18) 30 
13105 ND5 A A G 257 Ile Ile Val 257 Ile (n=27) 45 
13276 ND5 A A G 314 Met Val Met 314 Met (n=48) 80 
4960 ND2 C T C 164 Ala Val Ala 
N1b 
164 Val (n=21) 35 
8472 ATPase8 C T C 36 Pro Leu Pro 36 Leu (n=2) 3,33 
8836 ATPase6 A G A 104 Met Val Met 104 Val (n=0) 0 
9592 COIII T C T 129 Val Ala Val H1 129 Ala (n=0) 0 
4216 ND1 T C T 304 Tyr His Tyr 
J/T 
304 His (n=38) 63.33 
15454 Cytb C A C 236 Leu Ile Leu 236 Ile (n=26) 43,33 
10398 ND3 A G G 114 Thr Ala Ala J/K 114 Ala (n=17) 28,33 
13708 ND5 G A G 458 Ala Thr Ala J 458 Thr(n=7) 11,67 
5460 ND2 G A G 331 Ala Thr Ala 
J1b 
331 Thr (n=11) 18,64 
13879 ND5 T C T 515 Ser Pro Ser 515 Pro (n=5) 8,47 
7407 COI T C T 502 Tyr His Tyr 502 His (n=3) 5 
8557 ATPase6 G A G 11 Ala Thr Ala 11 Thr (n=48) 80 
13681 ND5 A G A 449 Thr Ala Thr 
J1c 
449 Ala (n=3) 5 
14798 Cytb T C T 18 Phe Leu Phe 18 Leu (n=9) 13,56 
15257 Cytb G A G 171 Asp Asn Asp J2a 171 Asn (n=3) 5 
4917 ND2 A G A 150 Asn Asp Asn T 150 Asp (n=5) 8,33 
5451 ND2 A G A 328 Thr Ala Thr 
T1a 
328 Ala (n=2) 1,67 
7853 COII G A G 90 Val Ile Val 90 Ile (n=53) 88,33 
6261 COI G A G 120 Ala Thr Ala T2c 120 Thr (n=0) 0 
9055 ATPase6 G A G 177 Ala Thr Ala 
K 
177 Thr (n=4) 6,67 
14798 Cytb T C T 18 Phe Leu Phe 18 Leu (n=9) 14,75 
4024 ND1 A T A 240 Thr Ala Thr K1a 240 Ala (n=0) 0 
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11025 ND4 T C T 89 Leu Pro Leu 89 Pro (n=12) 0 
14757 Cytb T C T 4 Met Thr Met 
K1c 
4 Thr(n=4) 20 
15635 Cytb T C T 29 Ser Pro Ser 29 Pro (n=0) 6,67 
 
6.3 The mitochondrial DNA haplogroups sensitivity to the pesticide rotenone 
In order to establish the citotoxicity of rotenone we carried out a cell viability assay in 
a medium devoid of glucose and supplemented with galactose (stress medium). This 
assay detects the mitochondrial energetic efficiency, since galactose reduces the 
glycolytic rate and cells are forced to rely on the ATP produced almost exclusively 
through OXPHOS. We first measured the concentration-dependent effect of rotenone 
(10 to 40nM) in our cybrid cell lines collection (N1b, H1, J, T, U1 and K1 haplogroups). 
Thus after 24h incubation, viability of haplogroup J incubated with rotenone 10 and 
20nM was markedly reduced compared to haplogroup K1 (Figure 33). Haplogroup J 
cybrids group included three different subhplogroups carrying SNPs defining the J1b, 
J1c and J2a (Table 4). In particular, the viability of J1 was significantly reduced in the 
presence of rotenone 10 and 20nM compared to K1, which in turn was the average of 
K1a and K1c (not shown). 
 
 
Figure33. Effect of rotenone on cybrids viability of different mtDNA haplogroups (N1b, H1, J, T, U1 and 
K1). Cells were incubated in galactose with rotenone for 24h. Data are reported as mean ±SEM 
(**p≤0,001) 
 
To better define the bioenergetic set up of our cybrids, the rate of ATP synthesis driven 
by CI (malate and pyruvate) and CII substrates (succinate) was measured in cells 
incubated with rotenone 10nM in galactose medium for 24h, and digitonin-
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permeabilized. As reported in figure 34, the rate of ATP synthesis driven by CI was 
consistently more reduced by rotenone in cybrids with haplogroup J1 (74%) compared 
to K1 (52%). Conversely, we did not observe significant differences in reduction by 
rotenone of CII-driven ATP synthesis rate among mtDNA haplogroups J1, J2, H1 and K1. 
 
 
Figure 34. Effect of rotetenone on ATP synthesis driven by CI and CII substrates in cybrids of different 
mtDNA haplogroups (H1, J1, J2 and K1). Cells were incubated with rotenone 10nM and galactose for 24h 
and then were digitonin-permeabilized. ATP synthesis rate was normalized for CS activity. Data are 
reported as mean ±SEM (p≤0,05) 
 
The assays of mitochondrial ATP synthesis and viabilty in galactose medium represent 
a combination of outcome measures that evaluate the energetic state of cybrids 
incubated with or without rotenone. These results clearly indicated a selective 
impairment in CI of cybrids carrying variants defining mitochondrial haplogroup J1 in 
the presence of this pesticid. In addition, we also measured the direct effect of 
rotenone on ATP synthesis driven by CI substrates adding rotenone in the assay tube. 
Under this experimental condition, CI-driven ATP synthesis was reduced in a dose-
dependent manner in all cybrid cell lines (H1, J1, J2 and K1 haplogroups), yet in 
presence of rotenone 20nM mitochondria belonging to haplogroup J1 had a 
significantly more reduced ATP synthesis compared to K1 (Figure 35). 
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Figure 35. Effect of rotenone on ATP synthesis driven by CI substrates in cybrids of different mtDNA 
haplogroups (H1, J1, J2 and K1). Cells were incubated in glucose. Rotenone was added to digitonin-
permeabilized cells directly in the assay tube. The rate of ATP synthesis was normalized for CS activity. 
Data are are reported as mean±SEM (p<0,05 ) 
 
These results are in agreement with previous studies suggesting a CI-dependent 
impairment of OXPHOS efficiency in haplogroup J [Ghezzi D. et al., 2005; Ross O.A. et 
al., 2003] that our experiments highlight to enhances the sensitivity to rotenone 
exposure. 
Moreover, it has been reported that after rotenone exposure there is a CI-induced 
increase in ROS production [Dranka B.P. et al., 2012; Drechsel A.D. et al., 2008]. Hence, 
we measured the production of H2O2 in our cybrids incubated in galactose medium at 
incremental concentration of rotenone. After exposure for 2-4h, no differences in H2O2 
levels between aplogroups H1, J1, J2 and K1 were observed (not shown). Thereafter, 
the effect of rotenone on H2O2 levels was investigated, limiting our analysis to the 
mitochondrial macro-haplogroups J and K, as the more divergent to rotenone toxicity 
as shown by the previous experiments. The shift from glucose to galactose medium 
increased H2O2 production as expected [Floreani M.et al., 2006], and haplogroup J 
cybrids had a slight but significant overproduction of ROS compared to K1. The 
addition of rotenone failed to further enhance ROS production, even if haplogroup J 
presented again a limited but significant higher production of ROS compared to K1, as 
shown in figure 36. Thus, we conclude that the poorly performing CI displayed by 
haplogroup J cybrids, as shown by the ATP synthesis assay, is also reflected in a slightly 
higher ROS production. 
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Figura 36. Effect of rotenone on H2O2 levels in cybrids of macro-haplogroup J and K. Cells are incubated 
in galactose (Hepes Ringer Solution Medium) with rotenone for 2 and 4 hours. Data are are reported as 
mean±SEM (p<0,05) 
 
As final experiment we also tested the effect of rotenone pesticid on mitochondrial 
biogenesis. The mtDNA copy number/cell was evaluated in cybrids (H1, J1, J2 and K1 
haplogroups) treated with rotenone 10nM in galactose for 24h. As shown in figure 37, 
there was no significant difference in mtDNA content among different haplogroups 
induced by galactose only, but the mtDNA copy number in cells with haplogroup J1 
was markedly reduced by rotenone 10nM compared to K1. 
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Figure 37. Effect of rotenone on the mtDNA quantification in cybrids of different mtDNA haplogroups 
(H1, J1, J2 and K1). The mtDNA copy number/cell was evaluated in wt cells treated with rotenone 10nM 
in galactose for 24h. Data are reported as mean ±SEM (p≤0,05)  
 
6.4 The mitochondrial DNA haplogroups sensitivity to the MPP+ drug 
Initially, we determinated the concentration-dependent effect on cell viability of MPP+ 
in our cybrids (N1b, H1, J1, J2, T1, T2 and K1 haplogroups). Figure 38 shows the cell 
viability in a galactose medium supplemented with MPP+ at concentration of 0,1 and 
0,2mM. After 24h incubation, cell viability of cybrids with haplogroup J1 was markedly 
reduced compared to both haplogroup T (T1 and T2) and K1. 
 
 
Figure 38. Effect of MPP
+
 on cybrids viability of different mtDNA haplogroups N1b, H1, J1, J2, T1, T2 and 
K1. Cells were incubated in galactose with MPP
+
 for 24h. Data are reported as mean ±SEM (*p≤0,05) 
 
In figure 39, we show the rate of ATP synthesis driven by CI substrates titrating 
increasing concentration of MPP+ directly in the assay tube going up to 0,35mM and 
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0,5mM MPP+ concentrations. Under these conditions, CI-driven ATP synthesis was 
incrementally reduced in a dose-dependent manner, but no significant difference was 
apparent between mtDNA haplogroups J1 and K1. 
 
 
Figure 39. Effect of MPP+ on ATP synthesis driven by CI substrates in cybrids of mtDNA haplogroups J1 
and K1 Cells were incubated in glucose. MPP
+
 was added to digitonin-permeabilized cells directly in the 
assayntube. The rate of ATP synthesis was normalized for CS activity.Data are are reported as 
mean±SEM 
 
Based on the previous results, the CI inhibition occurs at high concentrations of MPP+. 
Thus, we also tested the effect of MPP+ on H2O2 production in our cybrids (J1 and K1 
haplogroups) incubated in galactose 0.2-0.35-0.5 mM MPP+ for 2-4h. At high 
concentration of MPP+ (0,35mM and 0,5mM), haplogroup J1 diverged displaying 
reduced ROS production as compared with haplogroup K1 (figure 40). 
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Figure 40. Effect of MPP
+
 on H2O2 levels in cybrids of mtDNA haplogroups J1 and K1. Cells are incubated 
in galactose (Hepes Ringer Solution Medium) with MPP
+
 for 2 and 4 hours. Data are are reported as 
mean±SEM (*p≤0,05) 
 
6.5 The mitochondrial DNA haplogroups sensitivity to the herbicide paraquat 
 
Figure 41 shows the cell viability in galactose medium with paraquat supplemented at 
different concentrations (0,5 mM and 1mM). T2 subhaplogroup was the most sensitive 
to this herbicide together with H1, whose viability also declined rapidly at incremental 
concentration of paraquat. Strikingly, a significant resistance to paraquat was shown 
by the T1 haplogroup. 
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Figure 41 Effect of paraquat on wt cybrids vabiality of different mtDNA haplogroups (N1b, H1, T1, T2 
and K1). Cells were incubated in galactose with paraquat for 24h. Data are reported as mean ±SEM 
(*p≤0,05)  
 
The rate of ATP synthesis driven by CI substrates adding paraquat directly in the assay 
tube was not reduced by incremental concentrations of this herbicide, and no 
differences among mtDNA haplogroups J1, T2 and K1 were observed (figure 42). We 
also measured the rate of the rate of ATP synthesis driven by CI and CII substrates in 
cells incubated in galactose and paraquat 0,75mM, and digitonin-permeabilized. 
Preliminary results showed that T2 cybrids were most sensitive to inhibition of 
paraquat on ATP synthesis driven by CII, and most consistently by CI (not shown). 
 
 
Figure 42. Effect of paraquat on ATP synthesis driven by CI substrates in cybrids of different mtDNA 
haplogroups (J1,T2 and K1). Cells were incubated in glucose. Paraquat was added to digitonin-
permeabilized cells. The rate of ATP synthesis was normalized for CS activity.Data are are reported as 
mean±SEM 
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According to literature, the mechanism by which paraquat kills dopaminergic neurons 
is essentially due to its redox cycle that interfers with MRC and increases ROS 
production [Dinis-Oliveira R.J. et al, 2006; Richardson J.R. et al., 2005]. Hence, we 
measured the production of H2O2 in our cybrids (J1, T1, T2 and K1 haplogroups) 
incubated in galactose and paraquat 1mM. After exposure of 2-4h no differences in 
H2O2 levels were detected (figure 43) in contrast with previous reports [Dinis-Oliveira 
R.J. et al, 2006; Richardson J.R. et al., 2005].  
 
 
Figure 43. Effect of paraquat on H2O2 levels in cybrids of different mtDNA haplogroups (J1, T1, T2 and 
K1). Cells are incubated in galactose (Hepes Ringer Solution Medium) with paraquat 1mM for 2 and 4 
hours. Data are are reported as mean±SEM 
 
Finally we evaluated the mtDNA copy number/cell in cybrids (J1, T1, T2 and K1 
haplogroups) in galactose for 24h and after addition of paraquat 0,75mM. As shown in 
figure 44, no significant difference was detected on mtDNA content in galactose, but 
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both haplogroup J1 and K1 displayed an increased mtDNA copy number after addiction 
of paraquat. 
 
 
Figure 44 Effect of paraquat on the mtDNA quantification in cybrids of different mtDNA haplogroups (J1, 
T1, T2 and K1). The mtDNA copy number/cell was evaluated in wt cells treated with paraquat 0,75mM in 
galactose for 24h. Data are reported as mean ±SEM (*p≤0,05) 
 
6.6 The mitochondrial DNA haplogroups and mtDNA LHON mutations sensitivity 
to cigarette smoking extract 
We studied the effect of cigarette smoking extract (CSE) on cell viability of our cybrids 
generated from control subject. After 24h of incubation, we did not observe 
differences in cell growth among the macrohaplogroup investigated (N1b, H1, J1, J2, 
T1, T2, U1 and K1) (data not shown). Nevertheless, when we considered the 
subhaplogroup affiliation of all eleven cybrids, the cell viability of J1c and J2a 
subhaplogroups was markedly reduced (Figure 45)  
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Figure 45. Effect of CSE on cybrids viability of different mtDNA haplogroups (N1b, H1, J1b, J1c, J2a, T1, 
T2, U1, K1a and K1c). Cells were incubated in glucose with CSE for 24h. Data are reported as mean ±SEM 
(**p≤0,001) 
 
Tobacco smoking has been proposed to impair OXPHOS and increase ROS, possibly 
through a direct effect on CI [Yu-Wai-Man P. et al., 2011]. Nevertheless exposure of 
cybrids to CSE did not reduce ATP synthesis driven by CI in a dose-dependent manner 
and we did not observe differences between haplogroups in H2O2 levels (data not 
shown). 
It has been previously described that haplogroups J1c and J2b increase penetrance of 
the 11778/ND4 and 14484/ND6 mutations associated with LHON [Carelli, V. et al., 
2006; Hudson G. et al., 2007]. Furthermore, besides haplogroups it has been shown 
that also environmental factors such as tobacco smoking may trigger optic neuropathy 
in LHON [Yu-Wai-Man P. et al., 2011]. Therefore, given our results of a specific 
sensitivity of J subhaplogroup to CSE, we also investigated CSE effect on LHON cybrids. 
We first classified the haplogroup affiliation of LHON cybrids by sequencing the D-loop 
region and we further refined the haplotype by sequencing the entire mtDNA. The raw 
data are reported in Appendix D and the list of specific non-synonymous nucleotide 
changes is reported in table 6. 
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Table 8. SNPs found in mtDNA from LHON patients with relative SAPs compared to rCRS. Pathogenic 
point mutation are reported in red bold 
LHON cybrids 
SNP 
SAP Haplogroup  Gene bank ID  References 
Position Region 
HPE 
G11778A 
T12083G  
ND4 
ND4) 
Arg340His 
Ser442Ala 
J1c EU915476.1 
Pello R. et al. Hum. Mol. Genet. (2008) 
17(24):4001-11 
HL180 
T7042C 
T14484C 
T14798C 
COI 
ND6 
Cytb) 
Val380Ala 
Met64Val  
Phe18Leu 
J1c EU915479.1 
Pello R. et al. Hum. Mol. Genet. (2008) 
17(24):4001-11 
HFF 
G9477A 
A9667G 
G11778A 
A14793G 
COIII 
COIII 
ND4 
Cytb 
Val91Ile 
Asn154Ser 
Arg340His 
His16Arg 
U5a1 EU915477.1 
Pello R. et al. Hum. Mol. Genet. (2008) 
17(24):4001-11 
RJ206 G3460A ND1 Ala52Thr  T1a GQ304742.1 Ghelli A. et al. PLoS ONE (2009) 4(11):e7922 
HMM12 G3460A  ND1 Ala52Thr  H12 EU915475.1 
Pello R. et al. Hum. Mol. Genet. (2008) 
17(24):4001-11 
 
Figure 42 shows the cell viability of LHON cybrids response to different CSE 
preparation (0,14-0,18-0,2 Abs unit). After 24h incubation, the viability of LHON 
G3460A/ND1 cybrids (H12 and T1a haplogroups) was strikingly reduced compared to 
LHON G1778A/ND4 cybrids (haplogroup U). The 14484/ND6 cybrids displayed an 
intermediate behaviour (Figure 46). 
 
 
Figure 46. Effect of CSE on LHON cybrids viability of different mtDNA haplogroups. Cells were incubated 
in glucose with CSE for 24h. Data are reported as mean ±SEM (*p≤0,05; **p≤0,001) 
 
Moreover, we matched LHON cybrids with control cybrids ccording to their mtDNA 
haplogroups affiliation. As a result, cell viability of LHON G3460A/ND1 cells with 
haplogroup H12 and T1a showed a marked reduction also compared to their 
haplogroup-matched control cybrids (figure 47). 
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Figure 47. Effect of CSE on LHON and control cybrids variability marched for mtDNA haplogroups. Cells 
were incubated in glucose with CSE for 24h. Data are reported as mean ±SEM (*p≤0,05; **p≤0,001) 
 
6.7 The mitochondrial DNA polymorphisms sensitivity to antibiotic Linezolid 
To evaluate the effect of the antibiotic Linezolid on mitochondrial function, we studied 
nine cybrids belonging to European mtDNA haplogroups N1b, H, J and T. As reported in 
table 9, cybrids were classified according to the different combinations of the two 
frequent SNPs at position 2706 and 3010 affecting the 16S rRNA in the sequence 
region predicted to be very close to the PTC. The list of specific non-synonimous 
nucleotide changes characterizing European mtDNA haplogroups is reported in table 5. 
We grouped the different combinations of the two variants in 2706G/3010G 
(haplogroups N1b, T1, T2 and J2 cosidered as control), 2706G/3010A (haplogroup J1 
considered as single mutant), 2706A/3010G (haplogroup H5 considered as alternative 
single mutant) and 2706A/3010A (haplogroup H1 considered as “double mutant”). 
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Table 9. SNP variants at position 2706 and 3010 in 16SrRNAin cybrids 
Cybrids Haplogroup 
2704G/3010G in rRNA 16S 
H28705  N1b  
HFG5 J2a 
H42  T1a  
HPS11 T2c  
2706G/3010A in rRNA 16S 
HQB17  J1b  
HGA  J1c  
2706A/3010G in rRNA 16S 
HPC7  H5 
2706A/3010A in rRNA 16S 
HAD H1  
HF16W.1 H1 
 
The first tested the viability of all cybrid clones after five days of exposure to increasing 
concentration of Linezolid (5-20μg/mL). Figure 48 shows that, despite a lack of 
statistical significance, the “double mutant“ 2706A/3010A was the more susceptible to 
Linezolid. In a further analysis of the same assay we considered separately the 
subhaplogroup affiliation of our control group cybrids i.e. haplogroup N1b (at the root 
of all European haplogroups), haplogroup T and haplogroup J2. Haplogroup N1b was 
less susceptible to Linezolid compared to the other 2706G/3010G J2/T controls, 
whereas the double mutant 2706A/3010A H1 was constantly the worst (not shown). 
 
 
Figure 48. Effect of Linezolid on cybrids viability. Cells were incubated in glucose with CSE for five days. 
Data are reported as mean ±SEM 
 
Next, the rate of ATP synthesis, after 24h exposure to 20μg/mL Linezolid in glucose 
medium, was evaluated on the different genetic combinations for 2706 and 3010 
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variants. As reported in figure 49 the differential ATP synthesis with and without 
Linezolid exposure was greater for the double mutant 2706A/3010A H1 cybrid clone. 
 
 
Figure 49. Effect of Linezolid on ATP synthesis driven by CI substrates in cybrids. Cells were incubated in 
glucose and Linezolid 20μg/mL for 24h and then were digitonin-permeabilized. ATP synthesis rate was 
normalized for CS activity. Data are reported as mean ±SEM (p≤0,05) 
 
Finally, the specific activity of OXPHOS complexes was measured in presence or 
absence of Linezolid 20 μg/mL in mitochondrial-enriched fraction isolated from cybrid 
cell lines. Figure 50 shows that the “double mutant” 2706A/3010A H1 cybrid clone 
displayed a significant reduction in CI+CIII and CIV specific activity compared to 
untreated cells, whereas no difference were detected in CIII activity. CI+III activity is 
function of CI activity that is known to be limiting compared to CIII activity, and solves 
the problems of reproducibility of the CI isolated assay. 
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Figure 50. Effect of Linezolid on OXPHOS activities in cybrids. Cells were incubated with Linezolid 
20μg/mL and glucose for 24h and then mitochondrial-enriched fraction was separated. OXPHOS activity 
was normalized for CS activity. Data are reported as mean ±SEM (*p≤0,05) 
 
Overall these results indicate that the increased susceptibility to Linezolid of the 
2706A/3010A combination of polymorphisms, already observed for cell viability and 
mitochondrial ATP synthesis experiments, is also reflected in functional activity of 
OXPHOS complexes (CI and CIV). 
 
6.8 The mitochondrial DNA haplogroups sensitivity to chemioterapic cisplatin 
Finally, we started to examinate the effects of CisPt on mitochondrial function by 
testing the viability of our cybrids (N1b, H1, J, T2 and K1 haplogroups) after exposure 
to CisPt 5 and 10μM. It has been previously demonstrated that this chemioterapic 
agent induces hearing loss in patients with haplogroup J. [Peter U. et al., 2003]. Our 
preliminary results shows that despite cell viability was only slightly reduced, 
haplogroup J was more susceptible compared to K1a (Figure 51). 
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Figure 51. Effect of CisPt on cybrids viability of different mtDNA haplogroups (N1b, H1, J, T2 and K1). 
Cells were incubated in glucose with CisPt for 24h. Data are reported as mean ±SEM (**p≤0,001 all 
pairwise 
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DISCUSSION 
 
It is well known that medicines and other chemicals can interfere at various levels with 
mitochondrial function and frequently they cause mitochondrial dysfunction 
(mitotoxicity), affecting mtDNA maintenance and stability, protein synthesis of the 13 
subunits encoded by mtDNA, MRC function, and other mitochondrial metabolic 
processes, channels and transporters. In this study we investigated the impact of 
mtDNA genetic variations on susceptibility to environmental agents and drugs 
previously implicated in predisposition to neurodegenerative disorders, or other kinds 
of neurotoxicity. To this end we selected compounds on a collection of 
transmitochondrial cytoplasmic hybrids (cybrids) constructed to carry mtDNAs from 
different human haplogroups and mtDNA mutations (G3460A/ND1, G11778A/ND4 and 
G14484A/ND6) affecting CI, pathogenic for LHON, a neurodegenerative disorder for 
which a modifying effect of mtDNA haplogroups has already been documented, as well 
as the influence of environmental factors (tobacco smoking) [Carelli, V. et al., 2006; 
Hudson G. et al., 2007; Yu-Wai-Man P. et al., 2011].  
The cybrids cell lines generated for this study carried the most relevant mtDNA 
haplogroups of European populations (N1b, H, J, T, U, and K). This standard haplogroup 
affiliation of mtDNA sequence is normally obtained by comparison to the reference 
sequence known as rCRS that belongs to H2a2a1 haplogroup [Andrews R.M. et al., 
1999; Bandelt H.J. et al., 2013]. However recently Behar et al. proposed a new 
reference sequence denominated RSRS based on the assumption that all modern 
mtDNA sequences should be referred to an ancestral common root as best reference 
[Behar D.M. et al., 2012]. Therefore, we philogenetically related all our mtDNA 
sequence with both rCRS and RSRS. As expected specific non-synonymous variants that 
define mtDNA haplogroups are essentially the same in both reference sequences with 
the exception of the SNP 10398 in ND3 gene. This is shown as the substitution of A to 
G in rCRS, whereas in RSRS the nucleotide G is converted to A. The SNP A10398G, 
obtained by comparison of our mtDNA sequences to rCRS, is a common variant for 
European macrohaplogroups J and K. The SNP G10398A, obtained by comparison to 
the RSRS, is a common variant for all European macrohaplogroups (H, T and U) expect 
for N1b, J and K. Furthermore, to establish the conservation pattern of the amino acid 
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positions affected by haplogroup-specific SNPs (most conserved amino acid changes or 
SAPs) we analyzed 60 mammalians species, according to mtSAP Evaluation. Our 
analysis revealed that SAPs T240A in ND1 (SNP A4024T) and L89P in ND4 (SNP 
T11025C) of haplogroup K1a are not conserved, whereas SAP Y304H in ND1 (SNP 
T4216C) of haplogroups J/T is the most conserved (63,3%). Thus, different 
combinations of SNPs in different haplogroup backgrounds may exert both protective 
and/or predisposing roles, by interacting with environmental exposure to toxicants or 
drugs. 
 
We first investigated a set of environmental agents, chosen because commonly 
implicated in PD such as rotenone, MPP+ and paraquat. These are all toxic agent that 
have been shown to inhibit CI, either directly or indirectly. CI is also a target and a 
source of ROS, thus the common mechanism proposed for toxicity in all these 
pharmacological models of PD centres around two major pathways: inhibition of 
mitochondrial function (CI), and increased ROS generation [Dranka B.P et al., 2012]. 
Although neither maternal transmission nor specific mtDNA mutations have been 
associated with idiopathic PD, Ghezzi D. et al suggested that the European mtDNA 
haplogroups J and K exert a protective role, lowering the risk of PD, possibly through 
the SNP A10398G in the ND3 gene [Ghezzi D. et al, 2005]. On the contrary, the root 
lineage originating both haplogroups J and T, defined by the T4216C SNP in the ND1 
gene, seems to be more frequent among PD patients, thus exerting a predisposing role 
[Ross O.A. et al., 2003]. 
Our set of experiments with the pesticide rotenone revealed that cybrids carrying SNPs 
belonging to haplogroup J1 were most sensitive to the reduction of cell viability. This 
matched the impairment of OXPHOS through CI inhibition, as documented by the ATP 
synthesis assay with CI-dependent substrates. Furthermore, a slight chronic increase of 
ROS production was also evident, as predicted. However haplogroup J1 cybrids did not 
activate mitochondrial biogenesis efficiently, as a compensatory effect to the low 
OXPHOS efficiency. These results strikingly contrasted with in the performance of 
haplogroup K1 cybdrids challenge with rotenone toxicity, supporting the indication 
that the genetic variation of this mtDNA haplogroup exerts a protective effect on PD, 
as indicated by population genetic studies [Ghezzi D. et al, 2005; Ross O.A. et al., 
Discussion 
101 
2003]. Hence it is possible that SAPs T240A of haplogroup K1a and Y304H in ND1 of 
haplogroups J/T can act as protective and risk factor in PD disease respectively. 
As second well-known toxin inducing Parkinsonism in humans we tested MPP+. Again 
haplogroup J1 was the most sensitive to MPP+ exposure in term of cell viability, and 
incremental amounts of MPP+ progressively inhibited CI-driven ATP synthesis in both J 
and K haplogroup cybrids. These results are in agreement with previous reports 
[Richardson J.R. et al., 2007; Nicklas W.J. et al., 1985] even though haplogroup J 
displayed reduced ROS production at high concentrations of MPP+ as compared to K 
haplogroup cells. These results confirm that MPP+ is toxic to mitochondrial OXPHOS 
through CI inhibition, however even if haplogroup J seemed the most sensitive, there 
was no clear cut difference with haplogroup K cybrids. A first comment is that the 
inhibitory mechanism of MPP+ is presumably different from that of rotenone, for 
which is known an interaction with the ND1 subunit that enters in the composition of 
the CoQ pocket/binding site of CI. Indeed the polymorphic variant in ND1 associated 
with haplogroups J/T may well play a modifying role in rotenone sensitivity/toxicity, as 
shown by our results. This does not apply to MPP+. Furthermore, rotenone is assumed 
to be a toxin widely present in the environment, thus reflected into the genetic 
epidemiology of PD patients for whom the protective role of haplogroup K was 
documented and here confirmed on a functional ground by our in vitro experiments. 
At difference, MPP+ is not present in the environment, being a contaminant of a 
recreational drug, thus limited to drug users with no epidemiological impact. In fact, 
our in vitro results do not suggest a relevant haplogroup-dependent protection from 
MPP+ of haplogroup K. However, haplogroup J remains the choke-point mtDNA 
background when environmental interaction with toxins comes into play. 
The third toxin considered as risk factor for PD is the herbicide paraquat. Despite the 
drastic effect of paraquat on haplogroup T2c cell viability, its neurotoxicity does not 
result from a direct inhibition on CI, as shown by the CI-driven ATP synthesis 
experiments. Furthermore, in our hands, ROS production did not differ among 
haplogroups. Preliminary results on the rate of ATP synthesis driven by CI and CII 
substrates revealed that T2c cell lines, incubated in galactose and paraquat 0,75mM 
for 24h, were the most sensitive to its inhibition, corroborating the cell viability results. 
Moreover, haplogroup T also presented a lower mtDNA copy number, possibly 
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explaining the peculiar sensitivity of this haplogroup to 0.75mM paraquat, whereas J1 
and most strikingly haplogroup K1 increased mtDNA copy number. This may be again 
relevant to the proposed protective effect of haplogroup K1. These experiments do not 
clearly indicate a major role for oxidative stress in paraquat toxicity. This may depend 
on the experimental cell model used, given that cybrids may be lacking paraquat 
transporters such as LAT-1 [Shimizu K. et al., 2001; Richardson J.R. et al., 2005; 
Martinez T.N., 2012], OCT-3 and DAT [Rappold et al., 2011], thus paraquat would need 
more time to diffuse within these cells to exert its toxicity.  
In conclusion, this turn of experiments provides for the first time a functional basis for 
the proposed modifying role of mtDNA haplogroups in predisposition/protection 
to/from PD, and we show that this effect may be deeply dependent on a differential 
sensitivity of mtDNA haplogroups to the interaction with environmental factors 
relevant to PD pathogenesis, such as the pesticide/herbicide/toxins we here 
investigated. 
 
In a second set of experiments, we have investigated the mitochondrial toxicity of 
tobacco smoking (CSE), the most common and relevant environmental toxic exposure 
for a large set of individuals, which has been proposed to impair OXPHOS and increase 
ROS, possibly through a direct effect on CI [Yu-Wai-Man P. et al., 2011]. Among many 
roles played by tobacco smoking in predisposing to cancer and other conditions, it is 
now well recognized its role in contributing to neurodegeneration in LHON patients, 
triggering RGCs cell death and visual loss. Moreover, the pathogenic potential of LHON 
mutations is modified by the mtDNA haplogroup, being haplogroups J1c and J2b well 
established as backgrounds that increase LHON penetrance  
Thus we tested the effect of CSE on mitochondrial function, analyzing cells viability of 
control cybrids in presence of incremental CSE Abs unit in glucose medium. 
Haplogroups J1c and J2a viability was markedly reduced. However, despite the effect 
on cell viability of haplogroups J1c and J2b, there was nor haplogroup-dependent 
difference in CI-driven ATP synthesis, nor in ROS production. Therefore, we switched 
with the same experiment on five cybrids generated from LHON patient fibroblasts 
belonging to European mtDNA haplogroups J1c, H12, T1a and U. Cell viability was 
strikingly depressed by CSE in LHON 3460/ND1 cells (H12 and T1a haplogroups) 
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compared to LHON 11778/ND4 and 14484/ND6 cybrids (haplogroups J1c and U) and 
matched control cell lines (H and T haplogroup). Paradoxically, the 11778/ND4 and 
14484/ND6 LHON cybrids exposed to CSE had better viability to their haplogroup-
matched control cybrids. Thus, one conclusion is that smoking is particularly relevant 
as LHON trigger for patients with the 3460/ND1 mutations, whereas the relationship 
between LHON mutations and mtDNA background needs to be elucidated for the 
11778/ND4 and 14484/ND6 mutations. Notably, these two mutations only are 
associated with haplogroup J, and do not affect CI activity. Thus, their pathogenic 
mechanism is recognized as different from the 3460/ND1 mutations that is not 
associated with haplogroup J and sharply decreases the CI activity. 
 
The last set of experiments investigated two drugs for which there is documented 
mitochondrial toxicity and neurotoxic effect, namely the antibiotic Linezolid and the 
chemioterapic CisPt, respectively inhibiting mitochondrial protein translation and 
mtDNA replication.  
Patients under prolonged Linezolid treatment develop myelosuppression, lactic 
acidosis and optic neuropathy indistinguishable from LHON, as a result of OXPHOS 
impairment. Sequencing the mitochondrial 16S rRNA gene in these patients, suggested 
that the combination of the A2706G and G3010A polymorphisms in the region that 
binds Linexolid may modulate the susceptibility to Linezolid [Velez J.C. Q et al., 2010; 
Pacheu-Grau D. et al., 2013]. 
We studied nine cybrid cell lines harboring the European mtDNA haplogroups N1b, H, J 
and T. For this particular study we classified these cybrids according to the different 
combinations of the two mtDNA SNPs at position 2706 and 3010 in the 16S rRNA gene 
in the sequence region predicted to be very close to the PTC. For clarity we arbitrarily 
defined as “wild-type” the combination of 2706G/3010G (haplogroups N1b, J2a, T1a 
and T2c) and as “pathological” the following polymorphic combinations: single mutant 
2706A/3010G (Haplogroup H5), alternative single mutant 2706G/3010A (haplogroup 
J1) and double mutant 2706G/3010G (haplogroup H1). In the human mtDNA, the 
haplogroup H is defined by the polymorphism G2706A (alternative single mutant as 
H5) and subhaplogroups H1 is characterized by SNP G3010A (“double mutant). This 
SNP also defines subhaplogroup J1 (single mutant). 
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Our results demonstrate that the 2706A/3010A combination (haplogroup H1) 
enhances cell sensitivity to Linezolid toxicity as shown by inhibition of CI-driven ATP 
synthesis and specific activity of OXPHOS complexes (CI and CIV), in agreement with 
what recently reported by Velez J.C. Q et al., 2010 and Pacheu-Grau D. et al., 2013.  
These results establish the possibility to test in advance the patients as eligible for 
Linezolid treatment or at risk for suffering the severe side effects, proposing a 
personalized medicine approach to circumvent or be aware of the intrinsic risk of using 
this antibiotic. 
Concerning CisPt, this forms a preferential covalent binding to DNA (CisPt-DNA adduct) 
inhibiting mtDNA replication, disrupting mtDNA transcription, generating ROS 
production, impairing mitochondrial respiratory chain and inducing apoptosis [Sawyer 
D.E et al., 1999; Reedii JK J et al., 1985; Olivero O.A. et al., 1997]. We preliminarily 
examined the effect of CisPt on mitochondria, showing that haplogroup J seems to 
enhance cell sensitivity to CisPt toxicity, in agreement with what recently proposed by 
Peter U. et al., 2003. 
 
Overall, the studies carried out in this thesis highlight a proof of principle on how 
complex the interaction could be between mtDNA sequence variation, as exemplified 
by the haploytpe definition through complete mtDNA sequencing, and sensitivity to 
environmental factors. We have chosen specific toxins or drugs previously involved in 
neurodegeneration and/or neurotoxicity and tested the haplogroup-sensitivity to their 
mitochondrial toxicity. The results for Parkinson-related toxins broadly agree with the 
predictions generated by the population-based genetic epidemiology of mtDNA 
haplogroups, validating on the functional ground these predictions. The results on CSE 
influence on LHON disclosed some unexpected differences due to the different LHON 
pathogenic mutations. Also testing the two drugs Linezolid and CisPt indicated the 
possibility to apply a personalized approach in administering them to patients.  
One observation stands out from all these experiments. The haplogroup J and some 
specific subhaplogroups belonging to this affiliation display invariably a special 
sensitivity to compounds interfering with mitochondrial function, in particular with 
OXPHOS efficiency. This haplogroup is characterized for an accumulation by descent of 
multiple non-synonymous variants, which in particular generate variability in ND 
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subunits of CI and in the cyt b gene. Others and we have previously proposed that this 
genetic variability may affect partially the interaction between CI and CIII in the 
contest of supercomplex assemblage. This peculiar feature of haplogroup J on the 
biochemical ground probably resulted from adaptative selection, as proposed by 
Wallace and colleagues [Wallace D.C., 2013a; 2013b]. The adaptative advantages 
derived from selecting this cluster of slightly functional variants reflects on the 
interaction with toxins and more in general with the predisposing/protective role that 
may occur under different conditions. The studies carried out here using cybrids may 
benefit of a higher throughput approach, as now provided by cutting edge techniques. 
The field of mitochondrial pharmacology is just at the beginning, but holds a lot of 
promises for personalized medicine and for new drugs development. 
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CONCLUSIONS 
 
Pharmacogenomics is the study of how genes affect the individual response to drugs to 
develop medications tailored to a person’s genetic makeup because the efficacy/safety 
profile is not the same for everyone. 
It has been well demonstrated that medicines and other chemicals can cause 
mitochondrial dysfunction (mitotoxicity), causing alteration of mtDNA, protein 
synthesis, MRC, metabolic processes, channels and transporters.  
The results here reported demonstrated that mitochondrial genetic variability may 
influence individual susceptibility to drugs or environmental factors toxicity 
highlighting interesting associations between specific haplogroups, mitochondrial 
functional alterations, and toxic agents. More in details: 1) haplogroups K1 was found 
to play a protective role against rotenone toxicity whereas haplogroup J1 was more 
susceptible to the action of both rotenone and MPP+ even if the latter affinity to CI is 
less marked; 2) haplogroup T seems to be more susceptible to the action of paraquat; 
3) haplogroups H12 and T1 in association with the LHON mutation 3460/ND1 and 
haplogroups J1c J2A all increase the susceptibility to mitochondrial damage after CSE 
exposure. Moreover, haplogroup H1, characterized by SNPs 2706A/3010A in 16SrRNA 
is the most sensitive to Linezolid toxicity and haplogroup J appears to act as risk factor 
in CisPt toxicity. 
Though future studies will be necessary to better understand the mechanism of action 
of some of these molecules, the study of associations between mitochondrial 
haplogroups and toxicity of drugs and chemicals is extremely useful to prevent toxicity 
in predisposed subjects.  
Ultimately, to increase drugs safety, pharmaceutical companies have started to assay 
the mitochondrial toxicity early in the drug-development process because severe in 
vitro mitochondrial impairment might be sufficient to withdraw a development 
program.  
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APPENDIX A – Raw data from complete mtDNA sequencing compared to the rRCS 
 
H28705 – Haplogroup N1b 
Position CRS Mutation Region AA Change 
73 A G D-loop  
152 T C D-loop  
263 A G D-loop  
309+C : C  D-loop  
315+C : C  D-loop  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
1598 G A 12S_rRNA  
1703 C T 16S_rRNA  
1719 G A 16S_rRNA  
2639 C T 16S_rRNA  
2706 A G 16S_rRNA  
3921 C A  ND1 Ser205Ser 
4769 A G ND2 
Met100Met/ 
Met100Lys 
 4960 C T ND2 Ala164Val 
4967 T C ND2  
5471 G A ND2  
7028 C T COI  
8251 G A COII  
8472 C T ATPase8 Pro36Leu 
8836 A G ATPase6 Met104Val 
8860 A G ATPase6 Thr112Ala 
9335 C T COIII  
10238 T C ND3  
11362 A G ND4  
11719 G A ND4  
12007 G A ND4  
12501 G A ND5  
12705 C T ND5  
12822 A G ND5  
14766 C T Cyt b Ile7Thr 
15326 A G Cyt b Thr194Ala 
16145 G A D-loop  
16176G C G  D-loop  
16209 T C D-loop  
16223 C T D-loop  
16390 G A D-loop  
16519 T C D-loop  
 
 
HAD – Haplogroup H1 
Position rCRS Mutation Region AA change 
63 A G D-loop  
315+C : C  D-loop  
374 A G D-loop  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
3010 G A 16S_rRNA  
4769 A G ND2 
Met100Met/ 
Met100Lys 
8860 A G ATPase6 Thr112Ala 
9592 T C COIII Val129Ala 
15326 A G Cytb Thr194Ala 
16357 T C D-loop  
16519 T C D-loop  
 
 
 
 
 
HF16W – Haplogroup H1 
Position rCRS Mutation Region AA change 
263 A G D-loop  
309.1 : C  D-loop  
315.1 : C  D-loop  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
3010 G A 16S_rRNA  
4769 A G ND2 
Met100Met/ 
Met100Lys 
8860 A G ATPase6 Thr112Ala 
9015 C T ATPase6  
15326 A G Cytb Thr194Ala 
16129 G A D-loop  
16240 A G D-loop  
16468 T C D-loop  
16519 T C D-loop  
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HQB – Haplogroups J1b 
Position rCRS Mutation Region AA change 
73 A G D-loop  
199 T C D-loop  
242 C T D-loop  
263 A G D-loop  
295 C T D-loop  
315.1 : C  D-loop  
462 C T D-loop  
489 T C D-loop  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
2158 T C 16S_rRNA  
2706 A G 16S_rRNA  
3010 G A 16S_rRNA  
4216 T C ND1 Tyr304His 
4769 A G ND2 
Met100Met/ 
Met100Lys 
4772 T C ND2  
5460 G A ND2 Ala331Thr 
5964 T C COI  
7028 C T COI  
7407 T C COI Tyr502His 
8269 G A COII  
8557 G A 
ATPase6 Ala11Thr 
ATPase8 Leu64Leu 
8860 A G ATPase6 Thr112Ala 
9968 C T COIII  
10398 A G ND3 Thr114Ala 
11251 A G ND4  
11719 G A ND4  
12007 G A ND4  
12396 T C ND5  
12612 A G ND5  
13308 A G ND5  
13708 G A ND5 Ala458Thr 
13879 T C ND5 Ser515Pro 
14766 C T Cytb Ile7Thr 
15326 A G Cytb Thr194Ala 
15452A C A  Cytb Leu236Ile 
16069 C T D-loop  
16126 T C D-loop  
16145 G A D-loop  
16261 C T D-loop  
16468 T C D-loop  
 
HGA – Haplogroup J1c 
Position rCRS Mutation Region AA Change 
73 A G D-loop  
146 T C D-loop  
185 G A D-loop  
228 G A D-loop  
263 A G D-loop  
295 C T D-loop  
315.1 : C D-loop  
462 C T D-loop  
489 T C D-loop  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
2706 A G 16S_rRNA  
3010 G A 16S_rRNA  
4216 T C ND1 Tyr304His 
4769 A G ND2 
Met100Met/ 
Met100Lys 
6464A C A  COI  
6554 C T COI  
7028 C T COI  
8860 A G ATPase6 Thr112Ala 
10398 A G ND3 Thr114Ala 
11251 A G ND4  
11719 G A ND4  
12127 G A ND4  
12612 A G ND5  
13681 A G ND5 Thr449Ala 
13708 G A ND5 Ala458Thr 
14766 C T Cytb Ile7Thr 
14798 T C Cytb Phe18Leu 
15326 A G Cytb Thr194Ala 
15452A C A  Cytb Leu236Ile 
16069 C T D-loop  
16092 T C D-loop  
16126 T C D-loop  
16261 C T D-loop  
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HFG – Haplogroup J2c 
Position rCRS Mutations Region AA Change 
73 A G D-loop  
150 C T D-loop  
195 T C D-loop  
263 A G D-loop  
295 C T D-loop  
309.1 : C  D-loop  
309.2 : C  D-loop  
315.1 : C  D-loop  
489 T C D-loop  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
2706 A G 16S_rRNA  
4216 T C ND1 Tyr304His 
4769 A G ND2 
Met100Met/ 
Met100Lys 
6671 T C COI  
7028 C T COI  
7476 C T tRNA_Ser(1)  
8860 A G ATPase6 Thr112Ala 
10398 A G ND3 Thr114Ala 
10499 A G ND4L  
11002 A G ND4  
11149 G A ND4  
11251 A G ND4  
11377 G A ND4  
11719 G A ND4  
12570 A G ND5  
12612 A G ND5  
13708 G A ND5 Ala458Thr 
14766 C T Cytb Ile7Thr 
15257 G A Cytb Asp171Asn 
15326 A G Cytb Thr194Ala 
15452A C A  Cytb Leu236Ile 
15679 A G Cytb  
16069 C T D-loop  
16126 T C D-loop  
16231 T C D-loop  
16319 G A D-loop  
 
 
H42 – Gaplogroup T1a 
Position rCRS Mutation Region AA Change 
73 A G D-loop  
152 T C D-loop  
263 A G D-loop  
315.1 : C  D-loop  
471 T C D-loop  
709 G A 12S_rRNA  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
1888 G A 16S_rRNA  
2706 A G 16S_rRNA  
4216 T C ND1 Tyr304His 
4769 A G ND2 
Met100Lys 
Met100Lys 
4917 A G ND2 Asn150Asp 
5451 A G ND2 Thr328Ala 
7028 C T COI  
7853 G A COII Val90Ile 
8697 G A ATPase6  
8860 A G ATPase6 Thr112Ala 
10463 T C tRNA_Arg - 
11251 A G ND4 - 
11719 G A ND4 - 
12633 C T ND5 - 
12927 C T ND5 - 
13368 G A ND5 - 
14766 C T Cytb Ile7Thr 
14905 G A Cytb - 
15326 A G Cytb Thr194Ala 
15452A C A  Cytb Leu236Ile 
15607 A G Cytb - 
15721 T C Cytb - 
15928 G A tRNA_Thr - 
16126 T C D-loop - 
16163 A G D-loop - 
16186 C T D-loop - 
16189 T C D-loop - 
16294 C T D-loop - 
16311 T C D-loop - 
16519 T C D-loop - 
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HPS – Haplogroup T2c 
Position rCRS Mutation Region AA Change 
73 A G D-loop  
150 C T D-loop  
263 A G D-loop  
315+C : C Insertion D-loop  
709 G A D-loop  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
1888 G A 16S_rRNA  
2706 A G 16S_rRNA  
3834 G A ND1  
3915 G A ND1  
4216 T C ND1 Tyr304His 
4769 A G ND2 
Met100Lys  
Met 100Met 
4823 T C ND2  
4841 G A ND2  
4917 A G ND2 Asn150Asp 
6261 G A COI Ala120Thr 
7028 C T COI  
7301 A G COI  
8697 G A ATPase6  
8860 A G ATPase6 Thr112Ala 
10463 T C tRNA Arg - 
10822 C T ND4 - 
11251 A G ND4 - 
11719 G A ND4 - 
11812 A G ND4 - 
12378 C T ND5 - 
13368 G A ND5 - 
14233 A G ND6 - 
14413 C T ND6 - 
14766 C T Cytb Thr7Ile 
14905 G A Cytb - 
15326 A G Cytb Thr194Ala 
15452 C A Cytb Leu236Ile 
15454 T C Cytb - 
15601 T C Cytb - 
15607 A G Cytb - 
15928 G A tRNa Thr - 
16126 T C D-loop - 
16146 A G D-loop - 
16292 C T D-loop - 
16294 C T D-loop - 
16519 T C D-loop - 
 
 
HGDA – Haplogroup U1 
Position rCRS Mutations Region AA change 
73 A G D-loop  
195 T C D-loop  
263 A G D-loop  
663 A G 12S_rRNA  
750 A G 12S_rRNA  
1438 A G 12S_rRNA  
1861 T C 16S_rRNA  
2218 C T 16S_rRNA  
2706 A G 16S_rRNA  
4769 A G ND2 
Met100Met/ 
Met100Lys 
4991 G A ND2  
6026 G A COI  
7028 C T COI  
7403 A G COI  
7581 T C COII  
8860 A G ATPase6 Thr 112 Ala 
11116 T C ND4  
11467 A G ND4  
11719 G A ND4  
12308 A G tRNA-Leu  
12372 G A ND5  
13656 T C ND5  
14070 A G ND5  
14364 G A ND6  
14766 C T Cytb Ile 7 Thr 
15115 T C Cytb  
15148 G A Cytb  
15217 G A Cytb  
15326 A G Cytb Thr 194 Ala 
15954 A C Cytb  
16189 T C   
16249 T C D-loop  
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HP27 – Haplogroup K1a 
Position rCRS Mutations Region AA change 
73 A G D-loop  
263 A G D-loop  
310 : C  D-loop  
317 : C D-loop  
750 A G 12s-rRNA  
1189 T C 12s-rRNA  
1438 A G 12s-rRNA  
1719 G A 16s-rRNA  
1811 A G 16s-rRNA  
2706 A G 16s-rRNA  
3107d   16s-rRNA  
3480 A G ND1  
4024 A T ND1 Thr240Ser 
4769 A G ND2 
Met100Met/ 
Met100Lys 
5773 G A tRNA-Cys  
7028 C T COI  
8468 T C ATPase8  
8860 A G ATPase6 Thr112Ala 
9055 G A ATPase6 Ala177Thr 
9698 T C COIII  
10398 A G ND3 Thr114Ala 
10550 A G ND4L  
11025 T C ND4 Leu89Pro 
11299 T C ND4  
11467 A G ND4  
11719 G A ND4  
12308 A G tRNA-Leu  
12372 G A ND5  
14167 C T ND6  
14766 C T Cytb Thr7Ile 
14798 T C Cytb Phe18Leu 
15326 A G Cytb Thr194Ala 
16145 G A D-loop  
16224 T C D-loop  
16244 T C D-loop  
16311 T C D-loop  
16497 A G D-loop  
16519 T C D-loop  
 
 
HF01M/10 – Haplogroup K1c 
Position rCRS Mutations Region AA change 
73 A G D-loop  
146 T C D-loop  
152 T C D-loop  
263 A G D-loop  
316 : C D-loop  
498 C : D-loop  
750 A G 12S rRNA  
1189 T C 12S rRNA  
1438 A G 12S rRNA  
1811 A G 16S rRNA  
2706 A G 16S rRNA  
3107   16S rRNA  
3480 A G ND1  
4769 A G ND2 
Met100Met/ 
Met100Lys 
7028 C T COI  
7082 C T COI  
8860 A G ATPase6 Thr112Ala 
9055 G A ATPase6 Ala177Thr 
9093 A G ATPase6  
9698 T C COIII  
10398 A G ND3 Thr114Ala 
10550 A G ND4L  
11299 T C ND4  
11377 G A ND4  
11467 A G ND4  
11719 G A ND4  
12308 A G tRNA-Leu  
12372 G A ND5  
14167 C T ND6  
14757 T C Cytb Met4Thr 
14766 C T Cytb Thr7Ile 
14798 T C Cytb Phe18Leu 
15326 A G Cytb Thr194Ala 
15635 T C Cytb Ser297Pro 
16224 T C D-loop   
16301 C T D-loop  
16311 T C D-loop  
16519 T C D-loop  
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APPENDIX B - Raw data from complete mtDNA sequencing of the rCRS compared to 
the RSRS and the corresponding nucleotide differences  
 
Position rCRS  RSRS Region AA Change 
73 A G D-loop  
146 T C D-loop  
152 T C D-loop  
195 T C D-loop  
247 G A D-loop  
263 A G D-loop  
750  A G 12S rRNA  
769 G A 12S rRNA  
825 T A 12S rRNA  
1018 G A 12S rRNA  
1438 A G 12S rRNA  
2706 A G 16S rRNA  
2758 G A 16S rRNA  
2885 C T 16S rRNA  
3594 C T ND1  
4104 A G ND1  
4312 C T tRNA-Ile  
4769 
A 
G ND2 
Met100Lys 
G Met100Met 
7028 C T COI  
7146 A G COI Thr 415Ala 
7256 C T COI  
7521 G A tRNA-Asp  
8468 C T ATPase8  
8655 C T ATPase6  
8701 A G ATPase6 Thr 59Ala 
8860 A G ATPase6 Thr112Ala 
9540 T C COIII  
10398 A G ND3 Thr114Ala 
10664 C T ND4L  
10688 G A ND4L  
10810 T C ND4  
10873 T C ND4  
10915 T C ND4  
11719 G A ND4  
11914 G A ND4  
12705 C T ND5  
13105 A G ND5 Ile257Val 
13276 A G ND5 Met314Val 
13506 C T ND5  
13650 C T ND5  
14766 C T Cytb Tht7Ile 
15326 A G Cytb Thr194Ala 
16129 G A D-loop  
16187 C T D-loop  
16189 T C D-loop  
16223 C T D-loop  
16230 A G D-loop  
16278 C T D-loop  
16311 T C D-loop  
16519 T C D-loop  
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APPENDIX C - Raw data from complete mtDNA sequencing compared to the RSRS 
 
 
H28705 – Haplogroup N1b 
Position RSRS Mutations Region AA change 
146 C T D-loop  
195 C T D-loop  
247 A G D-loop  
309.1 : C D-loop  
315.1 : C D-loop  
769 A G 12S rRNA  
825 A T 12S rRNA  
1018 A G 12S rRNA  
1598 G A 12S_rRNA  
1703 C T 16S_rRNA  
1719 G A 16S_rRNA  
2639 C T 16S_rRNA  
2758 A G 16S_rRNA  
2885 T C 16S_rRNA  
3594 T C ND1  
3921 C A ND1  
4104 G A ND1  
4312 T C tRNA-Ile  
4960 C T ND2 Ala164Val 
4967 T C ND2  
5471 G A ND2  
7146 G A COI Ala415Thr 
7256 T C COI  
7521 G A tRNA-Asp  
8251 G A COII  
8468 T C ATPase8  
8472 C T ATPase8 Pro36Leu 
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
8836 A G ATPase6 Met104Val 
9335 C T COIII  
9540 C T COIII  
10238 T C ND3  
10398 G A ND3 Ala114Thr 
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11362 A G ND4  
11914 A G ND4  
12007 G A ND4  
12501 G A ND5  
12822 A G ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 T C ND5  
16129 A G D-loop  
16145 G A D-loop  
16176 C G T D-loop  
16187 T C D-loop  
16189 C T D-loop  
16209 T C D-loop  
16230 G A D-loop  
16278 T C D-loop  
16311 C T D-loop  
16390 G A D-loop  
 
 
HAD – Haplogroup H1 
Position RSRS Mutations Region AA Change 
73 G A D-loop  
146 C T D-loop  
152 C T D-loop  
195 C T D-loop  
247 A G D-loop  
315+C : C  D-loop  
374 A G D-loop  
769 A G 12S_rRNA  
825 A T 12S_rRNA  
1018 A G 12S_rRNA  
2706 G A 16S_rRNA  
2758 A G 16S_rRNA  
2885 T C 16S_rRNA  
3010 G A 16S_rRNA  
3594 T C ND1  
4104 G A ND1  
4312 T C tRNA-Ile  
7028 T C COI  
7146 G A COI Ala415Thr 
7256 T C COI  
7521 A G tRNA-Asp  
8468 T C ATPase8  
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9540 C T COIII  
9592 T C COIII Val129Ala 
10398 G A ND3 Ala114Thr 
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11719 A G ND4  
11914 A G ND4  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 T C ND5  
13650 T C ND5  
14766 T C Cytb Ile7Thr 
16129 A G D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16230 G A D-loop  
16278 T C D-loop  
16311 C T D-loop  
16357 T C D-loop  
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HF16W – Haplogroup H1 
Position RSRS Mutations Region AA Change 
73 G A D-loop  
146 C T D-loop  
152 C T D-loop  
195 C T D-loop  
247 A G D-loop  
309.1 : C    
315+C : C  D-loop  
769 A G 12S_rRNA  
825 A T 12S_rRNA  
1018 A G 12S_rRNA  
2706 G A 16S_rRNA  
2758 A G 16S_rRNA  
2885 T C 16S_rRNA  
3010 G A 16S_rRNA  
3594 T C ND1  
4104 G A ND1  
4312 T C tRNA-Ile  
7028 T C COI  
7146 G A COI Ala415Thr 
7256 T C COI  
7521 A G tRNA-Asp  
8468 T C ATPase8  
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9015 C T ATPase6  
9540 C T COIII  
10398 G A ND3 Ala114Thr 
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11719 A G ND4  
11914 A G ND4  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 C T ND5  
13650 T C ND5  
14766 C T ND5 Ile7Thr 
16129 A G D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16230 G A D-loop  
16240 A G D-loop  
16278 T C D-loop  
16311 C T D-loop  
16468 T C D-loop  
 
 
HQB – Haplogroup J1b 
Position RSRS Mutations Region AA Change 
146 C T D-loop  
152 C T D-loop  
195 C T D-loop  
199 T C D-loop  
242 C T D-loop  
247 A G D-loop  
295 C T D-loop  
315.1 : C  D-loop  
462 C T D-loop  
489 T C D-loop  
769 A G 12S_Rrna  
825 A T 12S_Rrna  
1018 A G 12S_Rrna  
2158 T C 16S_rRNA  
2758 A G 16S_Rrna  
2885 C T 16S_Rrna  
3010 G A 16S_Rrna  
3594 T C ND1  
4104 G A ND1  
4216 T C ND1 Tyr304His 
4312 T C Trna-Ile  
4772 T C ND2  
5460 G A ND2 Ala331Thr 
5964 T C COI  
7146 G A COI Ala415Thr 
7256 T C COI  
7407 T C COI Tyr502His 
7521 A G tRNA-Asp  
8269 G A COII term 
8468 T C ATPase8  
8557 G A 
ATPase6 Ala11Thr 
ATPase8 Leu64Leu 
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9540 C T COIII  
9968 C T COIII  
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11251 A G ND4  
11914 A G ND4  
12007 G A ND4  
12396 T C ND5  
12612 A G ND5  
12705 T C ND5  
13107 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13308 A G ND5  
13506 T C ND5  
13650 T C ND5  
13708 G A ND5 Ala458Thr 
13879 T C ND5 Ser515Pro 
15452A C A Cytb Leu236Ile 
16069 C T D-loop  
16126 T C D-loop  
16129 A G D-loop  
16145 G A D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16230 G A D-loop  
16261 C T D-loop  
16278 T C D-loop  
16310 C T D-loop  
16468 T C D-loop  
16519 C T D-loop  
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HGA – Haplogroup J1c 
Position RSRS Mutations Region AA Change 
152 C T D-loop  
185 G A D-loop  
195 C T D-loop  
228 G A D-loop  
247 A G D-loop  
295 C T D-loop  
315.1 : C D-loop  
462 C T D-loop  
489 T C D-loop  
769 A G 12S_ rRNA  
825 A T 12S_ rRNA  
1018 A G 12S_ rRNA  
2758 A G 16S_rRNA  
2885 C T 16S_rRNA  
3010 G A 16S_Rrna  
3594 T C ND1  
4104 G A ND1  
4216 T C ND1 Tyr304His 
4312 T C tRNA-Ile  
6464 C A  COI  
6554 C T COI  
7146 G A COI Ala415Thr 
7256 T C COI  
7521 A G Trna-Asp  
8468 T C ATPase6  
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9540 C T COIII  
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11251 A G ND4  
11914 A G ND4  
12127 G A ND4  
12612 A G ND5  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 T C ND5  
13650 T C ND5  
13681 A G ND5 Thr449Ala 
13708 G A ND5 Ala->Thr 
14798 T C Cytb Phe18Leu 
15452 C A  Cytb Leu->Ile 
16069 C T D-loop  
16092 T C D-loop  
16126 T C D-loop  
16129 A G D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16230 G A D-loop  
16261 C T D-loop  
16278 T C D-loop  
 
 
HFG – Haplo J2a 
Position RSRS Mutations Region AA Change 
146 C T D-loop  
150 C T D-loop  
152 C T D-loop  
247 A G D-loop  
295 C T D-loop  
309.1 : C  D-loop  
309.2 : C  D-loop  
315.1 : C  D-loop  
489 T C D-loop  
769 A G 12S_rRNA  
825 A T 12S_rRNA  
1018 A G 12S_rRNA  
2758 A G 16S_Rrna  
2885 C T 16S_Rrna  
3594 T C ND1  
4104 G A ND1  
4216 T C ND1 Tyr304His 
4312 T C Trna-Ile  
6671 T C COI  
7146 C A COI Ala415Thr 
7256 T C COI  
7476 C T tRNA_Ser  
7521 A G tRNA_Asp  
8468 T C ATPase8  
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9540 C T COIII  
10499 A G ND4L  
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11002 A G ND4  
11149 G A ND4  
11251 A G ND4  
11377 G A ND4  
11719 A A ND4  
11914 A G ND4  
12570 A G ND5  
12612 A G ND5  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 T A ND5  
13650 T C ND5  
13708 G A ND5 Ala458Thr 
15257 G A Cytb Asp->Asn 
15452A C A  Cytb Leu236Ile 
15679 A G Cytb  
16069 C T D-loop  
16126 T C D-loop  
16129 A G D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16230 G A D-loop  
16231 T C D-loop  
16278 T C D-loop  
16311 C T D-loop  
16319 G A D-loop  
16519 C T D-loop  
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H42 – Haplogroup T1a 
Position RSRS Mutations Region AA Change 
146 C T D-loop  
165 C T D-loop  
247 A G D-loop  
315.1  C insertion D-loop  
471 T C D-loop  
709 G A 12S_rRNA  
769 A G 12S_Rrna  
825 A T 12S_Rrna  
1018 A G 12S_Rrna  
1888 G A 16S_rRNA  
2758 A G 16S_rRNA  
2885 T C 16S_rRNA  
3594 T C ND1  
4104 G A ND1  
4216 T C ND1 Tyr340His 
4312 T C tRNA-Ile  
4917 A G ND2 Asn150Asp 
5451 A G ND2 Thr328Ala 
7146 G A COI Ala415Thr 
7256 T C COI  
7521 A G tRNA-Asp  
7853 G A COII Val90Ile 
8468 T C ATPase8  
8655 T C ATPase6  
8697 G A ATPase6  
8701 G A ATPase6 Ala59Thr 
9540 C T COIII  
10398 G A ND3 Ala114Thr 
10463 T C Trna_Arg  
10644 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11251 A G ND4  
11914 A G ND4  
12633 C T ND5  
12705 T C ND5  
12927 C T ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13368 G A ND5  
13506 T C ND5  
14905 G A Cytb  
15452A C A transversion Cytb Leu236Ile 
15607 A G Cytb  
15721 T C Cytb  
15928 G A tRNA_Thr  
16126 T C D-loop  
16129 T C   
16163 A G D-loop  
16186 C T D-loop  
13187 T C   
16223 T C   
16230 G A   
16278 T C   
16294 C T D-loop  
 
 
HPS – Haplogroup T2c 
Map position RSRS Mutations Region AA Change 
146 C T D-loop  
150 C T D-loop  
152 C T D-loop  
195 C T D-loop  
247 A G D-loop  
315+C : C  D-loop  
709 G A D-loop  
769 A G 12S_rRNA  
825 A T 12S_rRNA  
1018 A G 12S_rRNA  
1888 G A 16S_rRNA  
2758 A G 16S_rRNA  
2885 C T 16S_rRNA  
3564 T C ND1  
3834 G A ND1  
3915 G A ND1  
4104 G A ND1  
4216 T C ND1 Tyr340His 
4312 T C tRNA-Ile  
4823 T C ND2  
4841 G A ND2  
4917 A G ND2 Asn150Asp 
6261 G A COI Ala120Thr 
7146 G A COI Ala415Thr 
7256 T C COI  
7301 A G COI  
7521 A G tRNA-Asp  
8468 T C ATPase6  
8568 T C ATPase6  
8697 G A ATPase6  
8701 G A ATPase6 Ala59Thr 
9540 C T COIII  
10398 G A ND3 Ala114Thr 
10463 T C tRNA Arg  
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10822 C T ND4  
10873 C T ND4  
10915 C T ND4  
11251 A G ND4  
11812 A G ND4  
11914 A G ND4  
12378 C T ND5  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13278 G A ND5  
13368 G A ND5  
13506 T C ND5  
13650 T C ND5  
14233 A G ND6  
14413 C T ND6  
14905 G A Cytb  
15452A C A Cytb Leu236Ile 
15454 T C Cytb  
15601 T C Cytb  
15607 A G Cytb  
15928 G A tRNa Thr  
16126 T C D-loop  
16129 A G D-loop  
16146 A G D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16230 G A D-loop  
16278 T C D-loop  
16292 C T D-loop  
16294 C T D-loop  
16311 C T D-loop  
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HGDA – Haplogroup U1 
Position RSRS Mutations Region AA change 
146 C T D-loop  
152 C T D-loop  
247 A G D-loop  
663 A G 12S_rRNA  
769 A G 12S_Rrna  
825 A T 12S_rRNA  
1018 A G 12S_rRNA  
1861 T C 16S_rRNA  
2218 C T 16S_rRNA  
2758 A G 16S_rRNA  
2885 C T 16S_rRNA  
3594 T C ND1  
4104 G A ND1  
4312 T C tRNA-Ile  
4991 G A ND2  
6026 G A COI  
7146 G A COI Ala415Thr 
7256 T C COI  
7403 A G COI  
7521 A G tRNA-Asp  
7581 T C COII  
8468 T C ATPase8  
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9540 C T COIII  
10398 G A ND3 Ala114Thr 
10664 T C ND4L  
10688 A G ND4l  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11116 T C ND4  
11467 A G ND4  
11914 A G ND4  
12308 A G tRNA-Leu  
12372 G A ND5  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 T C ND5  
13650 T C ND5  
13656 T C ND5  
14070 A G ND5  
14364 G A ND6  
15115 T C Cytb  
15148 G A Cytb  
15217 G A Cytb  
15954 A C Cytb  
16129 A G D-loop  
16145 G A D-loop  
16187 T C D-loop  
16223 T C D-loop  
16230 G A D-loop  
16249 T C D-loop  
16278 T C D-loop  
16311 C T D-loop  
16519 C T D-loop  
 
 
 
 
HP27 – Haplogroup K1a 
Position RSRS Mutations Region AA change 
146 C T D-loop  
150 C T D-loop  
195 C T D-loop  
247 A G D-loop  
310 : C  D-loop  
317 : C D-loop  
497 C T D-loop  
769 A G 12s rRNA  
825 A T 12s rRNA  
1018 A G 12s rRNA  
1189 T C 12s-rRNA  
1719 G A 16s-rRNA  
1811 A G 16s-rRNA  
2758 A G 16s-rRNA  
2885 C T 16s-rRNA  
3107d N : 16s-rRNA  
3480 A G ND1  
3594 T C ND1  
4024 A T ND1 Thr240Ser 
4104 G A ND1  
4312 T C tRNA-Ile  
5773 G A tRNA-Cys  
7146 G A COI Ala415Thr 
7256 T C COI  
7521 A G trNA-Asp  
8468 T C ATPase8  
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9055 G A ATPase6 Ala177Thr 
9540 C T COIII  
9698 T C COIII  
10550 A G ND4L  
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11025 T C ND4 Leu89Pro 
11299 T C ND4  
11467 A G ND4  
11914 A G ND4  
12308 A G tRNA-Leu  
12372 G A ND5  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 T C ND5  
13650 T C ND5  
14167 C T ND6  
14798 T C Cytb Phe18Leu 
16129 A G D-loop  
16145 G A D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16224 T C D-loop  
16230 G A   
16278 T C   
16497 A G D-loop  
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HF01M/10 – Haplogroup K1c 
Position RSRS Mutations Region AA change 
195 C T D-loop  
247 A G D-loop  
316 : C D-loop  
498 C : D-loop  
769 A G 12S rRNA  
825 A T 12S rRNA  
1018 A G 12S rRNA  
1189 T C 12S rRNA  
1811 A G 16S rRNA  
2758 A G 16S rRNA  
2885 C T 16S rRNA  
3480 A G ND1  
3595 T C ND1  
4104 G A ND1  
4312 T C tRNA-Ile  
7082 C T COI  
7146 G A COI Ala415Thr 
7256 T C COI  
7521 A G tRNA-Asp  
8468 T C ATPase8  
8655 T C ATPase6  
8701 G A ATPase6 Ala59Thr 
9055 G A ATPase6 Ala177Thr 
9093 A G ATPase6  
9540 C T COIII  
9698 T C COIII  
10550 A G ND4L  
10664 T C ND4L  
10688 A G ND4L  
10810 C T ND4  
10873 C T ND4  
10915 C T ND4  
11299 T C ND4  
11377 G A ND4  
11467 A G ND4  
11914 A G ND4  
12308 A G tRNA-Leu  
12372 G A ND5  
12705 T C ND5  
13105 G A ND5 Val 257Ile 
13276 G A ND5 Val 314Met 
13506 T C ND5  
13650 T C ND5  
14167 C T ND6  
14757 T C Cytb Met4Thr 
14798 T C Cytb Phe18Leu 
15635 T C Cytb Ser297Pro 
16129 A G D-loop  
16187 T C D-loop  
16189 C T D-loop  
16223 T C D-loop  
16224 T C D-loop D5  
16230 G A D-loop  
16278 T C D-loop  
16301 C T D-loop  
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APPENDIX D - Raw data from complete mtDNA sequencing of LHON patients 
compared to the RSRS and rCRS 
 
HMM12 - LHON 3460/ND1 – Haplogrpu H12 
Positions RSRS Mutations rCRS Region AA Change 
73 G A A D-loop  
146 C T T D-loop  
152 C T T D-loop  
195 C C T D-loop  
247 A G G D-loop  
263 G G A D-loop  
750 G G A 12S_rRNA  
769 A G G 12S_rRNA  
825 A T T 12S_rRNA  
1018 A G G 12S_rRNA  
1438 G G A 12S_rRNA  
2706 G A A 16S_rRNA  
2758 A G G 16S_rRNA  
2885 C T T 16S_rRNA  
3460 G A G ND1 Ala52Thr 
3594 T C C ND1  
3936 C T C ND1  
4104 G A A ND1  
4312 T C C tRNA-Ile  
4769 G G A ND2  
7028 T C C COI  
7146 G A A COI Ala415Thr 
7256 T C C COI  
7521 A G G tRNA-Asp  
8468 T C C ATPase8  
8655 T C C ATPase6  
8701 G A A ATPase6  
8860 G G A ATPase6 Thr112Ala 
9540 C T T COIII  
10398 G A A ND3 Ala114Thr 
10664 T C C ND4L  
10688 A G G ND4L  
10810 C T T ND4  
10873 C T T ND4  
10915 C T T ND4  
11719 A G G ND4  
11914 A G G ND4  
12705 T C C ND5  
13105 G A A ND5 Val 257Ile 
13276 G A A ND5 Val 314Met 
13506 T C C ND5  
13650 T C C ND5  
14552 A G A ND6 Val41Ala 
14766 T C C ND5 Ile7Thr 
15326 G G A Cytb Thr->Ala 
16129 A G G D-loop  
16187 T C C D-loop  
16189 C T T D-loop  
16223 T C C D-loop  
16230 G A A D-loop  
16274 G A G D-loop  
16278 T C C D-loop  
16311 C T T D-loop  
16519 C C T D-loop  
 
 
 
HL180 – LHON 1448/ND6 – Haplogroup J1c 
Position RSRS Mutations rCRS Region AA change 
73 G G A D-loop  
146 C T T D-loop  
152 C T T D-loop  
185 G A G D-loop  
188 A G A D-loop  
195 C T T D-loop  
247 A G G D-loop  
263 G G A D-loop  
295 C T C D-loop  
310+C : C  : D-loop  
317 +C : C  : D-loop  
462 C T C D-loop  
489 T C T D-loop  
750 G G A 12S_rRNA  
769 A G G 12S_rRNA  
825 A T T 12S_rRNA  
1018 A G G 12S_rRNA  
1438 G G A 12S_rRNA  
2706 G G A 16S_rRNA  
2758 A G G 16S_rRNA  
2885 C T T 16S_rRNA  
3010 G A G 16S_rRNA  
3594 T C C ND1  
4104 G A A ND1  
4216 T C T ND1 Tyr 304 His 
4312 T C C tRNA-Ile  
4769 G G A ND2  
7028 T T C COI  
7042 T C T COI Val 380 Ala 
7146 G A A COI Ala415Thr 
7256 T C C COI  
7521 A G G tRNA-Asp  
8468 T C C ATPase8  
8655 T C C ATPase6  
8701 G A A ATPase6  
8727 C T C ATPase6  
8860 G G A ATPase6 Thr 112 Ala 
9540 C T T COIII  
10398 G G A ND3 Thr 114 Ala 
10664 T C C ND4L  
10688 A G G ND4L  
10810 C T T ND4  
10873 C T T ND4  
10915 C T T ND4  
11251 A G A ND4  
11719 A A G ND4  
11914 A G G ND4  
12612 A G A ND5  
12705 T C C ND5  
13105 G A A ND5 Val 257Ile 
13276 G A A ND5 Val 314Met 
13506 T C C ND5  
13650 T C C ND5  
13708 G A G ND5 Ala458Thr 
14279 G A G ND6 Ser 132 Leu 
14484 T C T ND6 Met 64 Val 
14766 T T C Cytb Ile 7 Thr 
14798 T C T Cytb Phe 18 Leu 
15326 G G A Cytb Thr 194 Ala 
15452A C A C Cytb Leu 236 Ile 
16069 C T C D-loop  
16126 T C T D-loop  
16129 A G G D-loop  
16187 T C C D-loop  
16189 C T T D-loop  
16223 T C C D-loop  
16230 G A A D-loop  
16278 T C C D-loop  
16311 C T T D-loop  
16362 T C T D-loop  
16390 G A G D-loop  
16519 C T T D-loop  
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HPE9 – LHON 11778/ND4 – Haplogrpuo J1c 
Position RSRS Mutations rCRS Region AA change 
73 G G A D-loop  
146 C T T D-loop  
152 C T T D-loop  
185 G A G D-loop  
195 C T T D-loop  
228 G A G D-loop  
247 A G G D-loop  
263 G G A D-loop  
295 C T C D-loop  
310+C : C  : D-loop  
317 +C : C  : D-loop  
462 C T C D-loop  
489 T C T D-loop  
750 G G A 12S_rRNA  
769 A G G 12S_rRNA  
825 A T T 12S_rRNA  
1018 A G G 12S_rRNA  
1438 G G A 12S_rRNA  
2706 G G A 16S_rRNA  
2758 A G G 16S_rRNA  
2885 C T T 16S_rRNA  
3010 G A G 16S_rRNA  
3594 T C C ND1  
4104 G A A ND1  
4216 T C T ND1 Tyr 304 His 
4312 T C C tRNA-Ile  
4769 G G A ND2  
7028 T T C COI  
7146 G A A COI Ala415Thr 
7256 T C C COI  
7521 A G G tRNA-Asp  
8468 T C C ATPase8  
8655 T C C ATPase6  
8701 G A A ATPase6  
8860 G G A ATPase6 Thr 112 Ala 
9540 C T T COIII  
9632 A G A COIII  
10398 G G A ND3 Ala 114 Thr 
10664 T C C ND4L  
10688 A G G ND4L  
10810 C T T ND4  
10873 C T T ND4  
10915 C T T ND4  
11251 A G A ND4  
11719 A A G ND4  
11778 G A G ND4 Arg340His  
11914 A A G ND4  
12083 T G T ND4 Ser442Ala 
12612 A G A ND5  
12705 T C C ND5  
13105 G A A ND5 Val257Ile 
13276 G A A ND5 Val314Met 
13506 T C C ND5  
13650 T C C ND5  
13708 G A G ND5 Ala 458 Thr 
14766 T T C Cytb Ile 7 Thr 
14798 T C T Cytb Phe 18 Leu 
15326 G G A Cytb Thr 194 Ala 
15452A C A C Cytb Leu 236 Ile 
16069 C T C D-loop  
16126 T C T D-loop  
16129 A G G D-loop  
16187 T C C D-loop  
16189 C T T D-loop  
16223 T C C D-loop  
16230 G A A D-loop  
16278 T C C D-loop  
16311 C T T D-loop  
16519 C T T D-loop  
 
 
HFF3 – LHON 11778/ND4 – Haplogroup U5a1 
Position RSRS Mutations rCRS Region AA change 
73 G G A D-loop  
146 C T T D-loop  
152 C T T D-loop  
195 C T T D-loop  
247 A G G D-loop  
263 G G A D-loop  
316 +C : C : D-loop  
358 +C : C  : D-loop  
750 G G A 12S_rRNA  
769 A G G 12S_rRNA  
825 A T T 12S_rRNA  
1018 A G G 12S_rRNA  
1438 G G A 12S_rRNA  
2706 G G A 16S_rRNA  
2758 A G G 16S_rRNA  
2885 C T T 16S_rRNA  
2906 C T C 16S rRNA  
3197 T C T 16S rRNA  
3594 T C C ND1  
4014 G A A ND1  
4312 T C C tRNA-Ile  
4553 T C T ND2  
4655 G A G ND2  
4769 G G A ND2  
4914 C T C ND2  
7028 T T C COI  
7146 G A A COI Ala415Thr 
7256 T C C COI  
7521 A G G tRNA-Asp  
8468 T C C ATPase8  
8655 T C C ATPase6  
8701 G A A ATPase6  
8860 G G A ATPase6 Thr 112 Ala 
9477 G A G COIII Val91Ile 
9540 C T T COIII  
9667 A G A COIII Asn154Ser 
10398 G A A ND3 Ala 114 Thr 
10664 T C C ND4L  
10688 A G G ND4L  
10810 C T T ND4  
10873 C T T ND4  
10915 C T T ND4  
11467 A G A ND4  
11719 A A G ND4  
11778 G A G ND4 Arg340His 
11914 A G G ND4  
12308 A G A tRNA-Leu  
12372 G A G ND5  
12705 T C C ND5  
13105 G A A ND5  
13276 G A A ND5  
13506 T C C ND5  
13617 T C T ND5  
13650 T C C ND5  
14766 T T C Cytb Ile 7 Thr 
14793 A G A Cytb His16Arg 
15326 G G A Cytb Thr 194 Ala 
16129 A G G D-loop  
16186 T C C D-loop  
16189 C T T D-loop  
16192 C T C D-loop  
16223 T C C D-loop  
16230 G A A D-loop  
16256 C T C D-loop  
163270 C T C D-loop  
16278 T C C D-loop  
16291 C T C D-loop  
16311 G T T D-loop  
16399 A G A D-loop  
16519 C T T D-loop  
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RJ206 – LHON 3460/ND1 – Haplogroup T1a 
Position RSRS Mutations rCRS Region AA Change 
73 G G A D-loop  
146 C T T D-loop  
152 C C T D-loop  
195 C T T D-loop  
247 A G G D-loop  
263 G G A D-loop  
310+C : C : D-loop  
317+C : C : D-loop  
709 G A G 12S_rRNA  
750 G G A 12S_rRNA  
769 A G G 12S_rRNA  
825 A T T 12S_rRNA  
1018 A G G 12S_rRNA  
1438 G G A 12S_rRNA  
1888 G A G 16S_rRNA  
2706 G G A 16S_rRNA  
2758 A G G 16S_rRNA  
2885 c t t 16S_rRNA  
3460  A G ND1 Ala52Thr 
3594 T C C ND1  
4104 G A A ND1  
4216 T C T ND1 Tyr304His 
4312 T C C tRNA-Ile  
4769 G G A ND2  
4917 A G A ND2 Asn150Asp 
7028 T T C COI  
7146 G A A COI Ala415Thr 
7256 T C C COI  
7521 A G G tRNA-Asp  
8468 T C C ATPase8  
8655 T C C ATPase6  
8697 G A G ATPase6  
8701 G A A ATPase6  
8860 G G A ATPase6 Thr112Ala 
9540 C T C COIII  
9899 T C T COIII  
10398 G A A ND3 Ala114Thr 
10463 T C T tRNA-Arg  
10664 T C C ND4L  
10688 A G G ND4L  
10180 C T T ND4  
10873 C T T ND4  
10915 C T T ND4  
11251 A G A ND4  
11719 A A G ND4  
11914 A G G ND4  
12633  T C ND5  
12705    ND5  
13105 G A A ND5 Val257Ile 
13276 G A A ND5 Val314Met 
13368 G A G ND5  
13506 T C C ND5  
13650 T C C ND5  
14766 T T C Cytb Ile7Thr 
14905 G A G Cytb  
15326 G G A Cytb Thr194Ala 
15452A C A C Cytb Leu236Ile 
15607 A G A Cytb  
15928 G A G tRNA_Thr  
16126 T C T D-loop  
16129 A G G D-loop  
16163 A G A D-loop  
16186  T C D-loop  
16187 T C C D-loop  
16189 C C T D-loop  
16223 T C C   
16230 G A A   
16278 T C C   
16294 C T C D-loop  
16311 C T T   
16519 C C T D-loop  
 
